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 i 
Abstract 
 
Neuroinflammation is the local reaction of the brain to infection, trauma, toxic 
molecules or protein aggregates. The brain resident macrophages, microglia, are able to 
trigger an appropriate response involving secretion of cytokines and chemokines, resulting 
in the activation of astrocytes and recruitment of peripheral immune cells. The activated 
astrocytes also produce pro-inflammatory molecules that can lead to a vicious inflammatory 
circle in the brain. This toxic environment produced by both cell types seems to be one of 
the causes of neuronal death in neurodegenerative diseases. IL-1 plays an important role 
in this response; yet its expression and mode of action in the brain are not fully understood 
and its precise implication in neurodegenerative diseases needs further characterization.  
Therefore, the aim of this study was to obtain a better understanding of the role of the 
inflammasome-dependent IL-1 signalling within the brain as well as its possible 
implication in neurodegenerative diseases. The main objectives were i) to profile the 
expression and regulation of inflammasome in microglia and astrocytes, ii) to test the 
reactivity of inflammasome to compounds-related to neurodegenerative diseases iii) to 
investigate the implication of inflammasome in Parkinson’s disease (PD). 
Our results indicate that the capacity to form a functional NLRP3 inflammasome and 
to secrete IL-1 is limited to the microglial compartment in the mouse brain. Indeed, we 
were not able to observe IL-1 secretion from astrocytes, nor do they express all NLRP3 
inflammasome components. The capacity of these cells to express others inflammasome 
complexes also seems compromised, contrarily to microglia which exhibit the potentiality to 
express AIM2, NLRC4 or non-canonical inflammasome. 
In addition to IL-1, microglia were able to secrete IL-18, IL-1 and HMGB1 in an 
NLRP3 inflammasome-dependent way and through mechanisms similar to those observed 
in macrophages. Moreover, microglia stimulation with neurodegeneration-related 
compounds, such as amyloid-β peptide, rotenone or ATP resulted in the inflammasome 
activation and IL-1 release, suggesting that the microglial inflammasome can play a role in 
the neuroinflammation observed during neurodegenerative disease. Finally, if NLRP3 is 
linked to Alzheimer’s pathogenesis, our preliminary results tend to indicate that genetic 
ablation of NLRP3 do not exert any significant impact on the neurodegenerative processes 
occurring in an in vivo model of Parkinson’s disease. However, deeper investigations will 
be needed to better define the role of the inflammasome and its targets in PD. 
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Part I: The Central Nervous System 
 
The nervous system is divided into two parts: the Central Nervous System (CNS) 
and the Peripheral Nervous System (PNS). The CNS includes the brain and the spinal 
cord. It integrates the information and coordinates the activity of all parts of the body. The 
PNS includes ganglia (spinal and autonomic) and nerves. It is in charge of the 
communication between the brain and the sensory organs, the muscles, the glands and 
the blood vessels. In this introduction, we will focus our attention on the CNS. 
 
1. Development of the CNS 
 
In mammals, the CNS development begins at the end of the gastrula stage with the 
induction of the neuroectoderm and the neural plate formation. This structure is arising 
from a layer of primary progenitors known as neural stem cells (NSCs). During the CNS 
development, NSCs undergo cellular differentiation which restricts the potentiality of 
progenitor cells to finally give rise to mature neurons, astrocytes and oligodendrocytes    
(Fig. 1; Paridaen & Huttner, 2014). 
 
Two important steps drive CNS development: the neurogenesis and the gliogenesis. 
At the onset of neurogenesis, around embryonic day 12 (E12) in mice, the NSC switches 
from a symmetric to an asymmetric division mode, giving rise to a NSC daughter cell in 
addition to an immature neuron (Miller & Gauthier, 2007). Interestingly, during this phase, 
NSCs also undergo a phenotypic change to become Radial Glial cells (RGCs) which 
support the migration of the neurons (Götz & Huttner, 2005). Once their final location 
reached, the immature neurons integrate the complex neuronal network by developing 
their projections and their neurotransmitter secretion capacity. 
The switch from neurogenesis to gliogenesis occurs around E16-18 (in mice cortex) 
and is controlled by both extrinsic and intrinsic signals. Most of these embryonic 
developmental signals include bone morphogenetic proteins (BMPs), JAK (Janus kinase)/ 
STAT (Signal Transducer and Activator of Transcription), Notch, Noggin and Sonic 
hedgehog signalling pathways (Jiang & Nardelli, 2015). During gliogenesis, NSCs 
successively give rise to astrocyte progenitor (APCs) and oligodendrocyte progenitor cells 
(OPCs ; Xing et al, 2014). As with the development of any cell lineage, astrocyte and 
oligodendrocyte differentiation requires a sequential series of events that result in the 
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generation of a mature cell population that actively participates in CNS physiology, as 
presented hereafter.  
 
 
Fig. 1: Simplistic view of brain cell development. 
Neurons and macroglia derive from a common progenitor, the neural stem cell (NSC), and differentiate trough two 
successive steps: neurogenesis and gliogenesis. RGC = Radial Glial Cell, N= immature neuron, APC = Astrocyte Progenitor 
Cell, OPC = Oligodendrocyte Progenitor Cell. Adapted from (Xing et al, 2014)  
 
2. Cell populations 
 
In the adult brain, three major cell populations compose the CNS: Neurons, 
Macroglia (Oligodendrocytes and Astrocytes) and Microglia. Nowadays, their numerical 
repartition in the adult brain is always debated. A widespread belief is that glia makes up 
more than 80% of the cells in the human brain. However, recent reports suggest that, at 
least in the human brain, this ratio is much closer to 1:1(Lent et al, 2012). In any case, all 
brain cell types deserve attention considering their important roles and specificities. 
 
 
 
Fig. 2: The different cells of the CNS. 
The brain is composed of neurons and glial 
cells. Glia can be divided into two classes: 
macroglia and microglia. The macroglial cells 
comprise astrocytes and oligodendrocytes. 
Astrocytes make the connection between blood 
vessels and neurons, participate to the neuronal 
synaptic communication and contribute to the 
blood brain barrier. Oligodendrocytes form the 
myelin sheath around the axon to speed the 
neuronal signal transmission. Microglia are 
responsible for the monitoring of the brain for 
damage or infections. They are also implicated 
in neuronal development and neural 
connectivity.  
Adapted from (Felten, 2006). 
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2.1. Neurons 
 
Neurons are about 100 billion in the human adult brain (Lent et al, 2012). They are 
the excitable cells that process and transmit the information across the body.  
Neurons represent a heterogeneous cell population. They can differ by their size, by their 
shape (bipolar, multipolar or unipolar) or by their functions. However, all mature neurons 
share common characteristics. They possess a cellular body (or soma), representing the 
metabolic centre, from which extend two different types of processes: dendrites and axons 
(Fig. 2). The dendrites collect and transport the afferent information to the cellular body by 
a modification of the cell membrane polarization. The stimuli, which have traveled down 
the dendrites, converge at the axon hillock where they are summed to determine the 
neuronal response. If the sum of the stimuli reaches a certain voltage, known as the 
threshold potential, depolarization will be transmitted to the axon. Most of the axons are 
insulated at regular intervals by the myelin sheaths produced by oligodendrocytes (see 
below) in view to accelerate signal transmission (Zoupi et al, 2011).  
Each neuron is connected to another one by a structural cleft called synapse. A 
synapse includes the pre-synaptic neuron membrane, the post-synaptic neuron/organ/cell 
membrane and the intercellular space between them. The information exchange taking 
place in the synapse is called neurotransmission (or synapse signalling). It aims to 
propagate information. The neurotransmission can be electrical or chemical. The electrical 
one transmits directly the impulse via gap junctions established between both neurons. 
On the other hand, in the chemical synapse, the pre-synaptic neurons are in charge of the 
release of neurotransmitters into the cleft to spread the information. The neurotransmitters 
will interact with post-synaptic membrane receptors to initiate the membrane 
depolarization and are quickly removed from the synaptic space to avoid excessive 
activation (Nelson, 1993). The most common neurotransmitters are γ-aminobutyric acid 
(GABA – inhibitory) and glutamate (excitatory). However, other neurotransmitters exist 
and determine six main neuronal systems: Noradrenaline/Noradrenergic, 
Adrenaline/Adrenergic, Dopamine/Dopaminergic, Serotonine/Serotonergic, 
Acetylcholine/Cholinergic and Histamine/Histaminergic neurons (Pradhan et al, 2014). 
 
2.2. Oligodendrocytes 
 
Oligodendrocytes are the myelinating glial cells of the CNS: they electrically insulate 
the axons by forming myelin sheaths around them. This myelinisation process is a 
remarkably specialized cellular interaction specific to vertebrates. It enables the saltatory 
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conduction, in which a neuronal action potential is propagated between myelin sheet gaps 
(nodes of Ranvier) to increase both the speed and energy efficiency of nerve conduction. 
A single oligodendrocyte is able to myelinate up to 60 segments of different axons 
(Scholze & Barres, 2012). In addition to the electrically insulation of axons, 
oligodendrocytes also provide them trophic support and promote the neuron viability via a 
metabolic coupling, where oligodendrocytes provide lactate to axons as an energy source 
(Lee et al, 2012). 
 
2.3. Astrocytes 
 
Astrocytes are the major glial cell type in the brain. They represent a heterogeneous 
population of cells that exhibit different structural, functional, chemical and molecular 
characteristics. 
 
2.3.1. Astrocytes: a heterogeneous population 
 
Classically, astrocytes are classified into two major types: the protoplasmic 
astrocytes and the fibrous astrocytes. Protoplasmic astrocytes, found in the grey matter, 
are spongiform and possess a lot of extensive fine branching. They particularly ensure the 
blood-brain barrier (BBB), the homeostatic and the metabolic astrocytic functions (see 
below). The fibrous astrocytes are located in the white matter and are characterized by 
fewer long processes which form an axonal support network. However, over the years, 
studies have revealed that astrocytes are much more heterogeneous than the classical 
and simple distinction between fibrous and protoplasmic astrocytes (Bribian et al, 2015). 
Indeed, the astrocytic population encloses different groups of cells which differ in their 
morphology, developmental, origin, gene expression profile, electrophysiological 
properties, function and response to injury and disease (Zhang & Barres, 2010; Oberheim 
et al, 2012).  
Currently, astrocytes are defined by a the expression of different markers such as 
Glial Fibrillary Acidic Protein (GFAP), the glutamate transporters GLAST/EATT1 and 
GLT-1/EAAT2 or the calcium binding protein S100β among others (Schitine et al, 2015). 
However, the expression of these markers depends on the considered brain structure, 
varies over time and is also observed in others cells, without clear evidence if they are 
astrocytes or not (e.g. radial glial cells, retinal Muller cells or Bergmann glia ; Khakh & 
Sofroniew, 2015; Rossi, 2015). Therefore, deeper investigations are needed to better 
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define the astrocyte notion, especially by the characterization of type-specific markers 
(Bayraktar et al. 2015; A. V. Molofsky et al. 2012).  
 
2.3.2. Astrocyte functions 
 
Consistent with their heterogeneity, astrocytes ensure a large variety of functions in 
order to preserve the brain homeostasis. 
 
The Blood Brain Barrier (BBB). An important characteristic of the brain parenchyma is that 
its communication with the circulatory system is tightly regulated. The BBB, a physical and 
functional separation between the CNS and the peripheral blood circulation, plays this role 
by preventing the diffusion of harmful elements into the brain (Abbott et al, 2006). The 
main members of BBB are the endothelial cells, the pericytes, the astrocytes and the 
extracellular matrix (Obermeier et al, 2013). Astrocytes possess specialized endfeets that 
cover about 99% of the abluminal surface of cerebral vessels. Their role is to surround the 
endothelial cells by providing a structural support (Prat et al, 2001; Abbott et al, 2006). 
Astrocytes also release morphogens and growth factors, such as fibroblast growth factor 
(FGF) 2 and 5, that modulate pathways involved in the regulation of BBB integrity by 
maintaining the endothelial tight junctions (Reuss et al, 2003; Obermeier et al, 2013).  
 
The neurovascular unit is the functional association of neurons and blood vessels by the 
intermediate of astrocytes. Astrocytes are responsible for the energy supply of neurons. 
When neurons increase their energy need, they release some factors sensed by 
astrocytes (such as glutamate). These signals lead astrocytes to modify the blood stream 
in order to upregulate the glucose uptake. Astrocytes can convert this glucose to glycogen 
for storage (major brain energy store) or can transform glucose into lactate which will in 
turn be delivered to neurons to satisfy their increased metabolic demands (Tsacopoulos & 
Magistretti, 1996). 
 
Tripartite synapse. Astrocytes play a fundamental role in the homeostasis of synapses by 
enwrapping the pre- and post-synaptic cleft to form a tripartite system. The main role of 
this organization is to control the water quantity as well as the concentration of 
metabolites and neurotransmitters in the synapse. They ensure, for example, the 
clearance of potassium or glutamate, two substances becoming neurotoxic if present in 
excess (Oliveira Da Cruz et al. 2015; Sibille, Pannash, and Rouach 2013). Astrocytes are 
also able to sense the synaptic activity through the stimulation of their ion channels, 
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neurotransmitter transporters and receptors. Once stimulated, calcium signalling takes 
place in astrocytes with a subsequent uptake or release of gliotransmitters such as 
glutamate, ATP, and D-serine or adenosine. These transmitters can directly act on post-
synaptic neurons or can modulate the release of neurotransmitters by pre-synaptic 
neurons (Halassa et al, 2007; Perea et al, 2014). In addition, astrocytes also play a role in 
synapse maintenance and neurite outgrowth (Allen, 2014; Rossi, 2015). 
 
Reactive astrogliosis. Astrocytes respond to all forms of CNS insult such as infection, 
trauma, ischemia and neurodegeneration by a process called “reactive astrogliosis” 
(Burda & Sofroniew, 2014). The major roles of reactive astrogliosis are to protect the brain 
parenchyma, seal off damaged areas, reconstruct the BBB and promote the correct 
remodelling of the neural circuitry. This aspect of the astroglial function will be detailed in 
the second part of this introduction (Part II: “The neuroinflammation”). 
 
2.4. Microglia 
 
Microglia are the resident macrophages of the CNS. In the mature brain, microglia 
are dispersed throughout the whole CNS, although their density can be higher in some 
brain regions such as in the hippocampus and the substantia nigra (Lawson et al, 1990).  
 
2.4.1. Origin 
 
In contrast to the previously mentioned brain cells, microglia do not have an 
ectodermal origin.  
For decades, microglial cells have been described as having a mesodermal origin, 
derived from hematopoietic stem cells in the bone marrow. This dogma has recently been 
rebutted by elegant experiments demonstrating that microglia derive from primitive 
macrophages produced in the Yolk sack (Fig. 3, Ginhoux et al, 2010; Schulz et al, 2012; 
Lourbopoulos et al, 2015). These progenitors infiltrate the brain through blood vessels 
between E8.5 and E9.5 (Ginhoux et al, 2010; Ransohoff et al, 2015), just before the onset 
of neurogenesis and the BBB implementation (Dahlstrand et al, 1995). Then, the isolation 
of microglia from the periphery contribute to the maintenance of their difference from 
circulating immune cells (Schulz et al, 2012; Ginhoux et al, 2013) and to their unique 
transcriptional signature (Butovsky et al, 2014). Thus, even if microglia are classically 
defined as macrophages of the brain, recent evidence suggests that they differ 
considerably from the macrophages residing in other tissues.  
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Fig. 3: Microglial ontogeny. 
A transient early wave of myeloid cell development called primitive hematopoiesis takes place at E7.5–E8.0 in the yolk sac 
in mice. Around E9, the erythromyeloid progenitors (EMPs) populate the brain parenchyma and give rise to the embryogenic 
microglia. These early microglia reside in the brain throughout life. Adapted from (Prinz & Priller, 2014). 
 
The microglial turnover in the healthy adult brain is ensured by their self-renewal 
capacity and is totally independent from the bone-marrow derived macrophages (Elmore 
et al, 2014). The understanding of microglial origin is experiencing a revolution, and many 
aspects of their physiology are being redefined.  
 
2.4.2. Roles of Microglia 
 
Microglia are often described as the macrophages of the brain as they form the first line of 
defence against pathogen invasion, injury or disease. Their implication in immunity is 
indeed well characterized. Phagocytic microglia can detect and quickly remove 
pathogens, damaged or dying cells and clear the debris. 
However, it is now outdated to consider microglia as being only the brain’s immune cells 
(Fig. 4). There is increasing evidence that resting microglia play an important role during 
brain development and the establishment of neuronal connectivity. Microglia participate in 
removing apoptotic neurons during embryogenesis but also in the adult brain (Caldero et 
al, 2009; Sierra et al, 2010). Microglia may also phagocyte unwanted dendrites and 
synapses, thus participating in the axon pruning process (Nimmerjahn et al, 2005; Wake 
et al, 2009; Tremblay et al, 2010). In addition, they are able to secrete brain-derived 
neurotrophic factor (BDNF), which is implicated in the learning-dependent synapse 
formation (Parkhurst et al, 2013). Microglia also promote the neuron survival and axonal 
growth by providing other growth factors to neurons (Ueno et al, 2013). 
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Fig. 4: Functional roles of microglia in healthy brain. 
The population of microglial cells is maintained by self-renewal. Surveillant microglial cells constantly scan the brain 
microenvironment, in order to detect perturbations of CNS homeostasis. Phagocytic microglia can detect and quickly 
remove damaged or dying neurons, preventing the injury of neighbouring cells. The phagocytic capacity of microglia is 
particularly important in development (pruning microglia), when they can contribute to the removal of supernumerary 
synapses in neuronal pathways. Moreover, it has been suggested that microglia can have a direct or indirect modulatory 
role at the synapse, influencing neuronal activity (neuromodulatory microglia ; Gomez-Nicola & Perry, 2015). 
 
3. Neurodegenerative diseases  
 
Dysfunction of the different brain cell types can lead to neurological disorders, in 
particular to neurodegenerative diseases. These disorders characterized by a strong 
neuronal loss in specific brain areas, include Alzheimer’s disease (AD), Parkinson’s 
disease (PD), Huntington’s disease and Amyotrophic Lateral Sclerosis (ALS). In the 
following sections, we will focus our attention on AD and PD. 
 
3.1. Alzheimer’s disease  
 
AD is characterized by memory loss, progressive cognitive impairment, and 
neuropsychiatric disturbances. The histopathological hallmarks of AD comprise 
amyloid-β (Aβ) plaques, formation of neurofibrillary tangles and neuroinflammation. 
Together, they lead to the death of glutaminergic neurons, cholinergic neurons and 
interneurons in cortical and subcortical regions (Rubio-Perez & Morillas-Ruiz, 2012; 
Heneka et al, 2013).  
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The vast majority of AD cases (95%) are sporadic forms while the remaining cases 
(5%) are caused by mutations conferring an hereditary profile to the disease (Calero et al, 
2015). Interestingly, these AD-linked mutations often lead to an Aβ overproduction. 
The Aβ peptide is formed from the sequential proteolysis of the amyloid precursor 
protein (APP) present on the neuronal cell surface. APP can be processed by two 
different mechanisms: the non-amyloidogenic (physiological) and the amyloidogenic 
(pathological) pathways (Fig. 5). The non-amyloidogenic pathway involves a first cleavage 
of APP by a α˗secretase and a second cleavage within the membrane by a γ-secretase. 
The α-secretase cleaves APP in the Aβ domain, inhibiting the production of the Aβ 
peptide. In contrast, the amyloidogenic pathway is directly responsible for the formation of 
the Aβ peptide. In this case, APP is first cleaved by BACE-1 (β-site amyloid precursor 
protein cleavage enzyme-1), which liberates a sAPPβ fragment. This one is further 
processed by the γ-secretase which releases the 40 or 42 amino acids long Aβ peptides 
into the extracellular compartment (Haass et al, 2012).  
 
 
Fig. 5: Aβ processing. 
The processing of the APP can be achieved through two pathways: amyloidogenic and non-amyloidogenic pathways. The 
non-amyloidogenic pathway is accomplished by the successive action of the α-secretase and γ-secretase. The 
amyloidogenic pathway is performed by the action of BACE-1 followed by the γ-secretase. This pathway leads to the 
production of the A and the sAPPβ fragment. Aβ monomers may then go on to form oligomers, protofibrils, fibrils and 
amyloid plaques in case of pathology (Querfurth & LaFerla, 2010). 
 
In the healthy brain, Aβ is released within synapses to dampen excitatory 
transmission and to prevent neuronal hyperactivity (Kamenetz et al, 2003). The imbalance 
between the production and the clearance of Aβ is one of the causes of the aggregation of 
the peptide. Aβ is able to self-associated and form soluble oligomers which can further 
aggregate and give rise to insoluble fibrillary plaques (Querfurth & LaFerla, 2010).  
Once Aβ peptides accumulated, as observed in AD, they can be further 
proteolytically processed, chemically modified, or cross-linked, thereby modifying their 
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relative insolubility, stability, and toxicity. This is why the Aβ peptides identified in amyloid 
plaques  
vary in their amino acid composition, ranging from the full-length Aβ (1-40/42) to shorter 
carboxy-terminal or amino-terminal Aβ peptides (Wiltfang et al, 2002). Among the shorter 
A peptides, the 25-35 fragment is endogenously found in elderly people and has been 
described to be more toxic form (Millucci et al, 2009). Moreover, the Aβ25-35 affects the 
cognitive processes when injected in rat CNS (Stepanichev et al, 2005; Limón et al, 
2009).  
Currently, it is still debated whether Aβ plaques are part of the neurodegenerative 
process itself or whether they are the consequence of neuronal loss. In both cases, the 
accumulation of Aβ peptide is thought to contribute to the development of the pathology at 
least by enhancing inflammation and neuronal disturbances. 
 
3.2. Parkinson’s disease  
 
PD is the second most frequent neurodegenerative disorder. Similar to AD, PD 
affects predominantly older people and its prevalence increases with age from 428 at 60-
69 years to 1,903 per 100,000 in 80 years old people (Pringsheim et al, 2015). PD is 
mainly characterized by a triad of motor impairments, i.e. bradykinesia, resting tremor and 
rigidity but also by non-motor symptoms such as depression, anxiety and dementia. The 
principal neuropathological hallmark of PD is the progressive loss of dopaminergic 
neurons in the Substantia Nigra pars compacta (SNpc) which is responsible for the motor 
dysfunction. Other PD characteristics are the presence of protein inclusions called Lewy 
Bodies and the chronic neuroinflammation (Phani et al, 2012). 
The aetiology of PD is thought to result from an interaction between aging, 
environmental and genetic factors (Herrero et al, 2015). The exposure to pesticides (i.e. 
rotenone), herbicides (i.e. paraquat), air pollutants or metal iron has been identified as a 
key risk factor to develop sporadic PD (Litteljohn et al, 2010). The genetic forms of the 
disease (5%) are linked to rare mutations which increase the susceptibility to develop the 
disease. To this date, mutations associated to PD have been identified in several genes: 
leucine-rich repeat kinase 2 (Lrkk2), glucocerebrosidase (Gba), Park2 and Parkin7 
(coding respectively for Parkin and DJ-1), Pink1, Mapt genes and more importantly Snca 
gene (Xu & Chan, 2015). In human, six point mutations in Snca have been identified and 
are linked to PD. They are listed in table 1 (Xu & Chan, 2015).  
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Table 1: Missense mutations in Snca gene causing autosomal dominant Parkinson’s disease. 
Point mutations  References 
Ala30Pro  A30P (Jensen et al, 1998) 
Ala53Thr  A53T (Farrer et al, 1998) 
Glu46Lys E46K (Zarranz et al, 2004) 
His50Gln  H50Q (Proukakis et al, 2013) 
Gly51Asp  G51D (Kiely et al, 2013) 
Ala53Glu  A53E (Pasanen et al, 2014) 
 
Snca gene encodes for a small protein named α-synuclein (α-syn). α-syn is an 
abundant protein in the brain, and notably in the substantia nigra. Until now, the precise 
role of α-syn remains unknown. However, consistent with its initial description in neuronal 
nuclei and presynaptic terminals (Maroteaux et al, 1988), it has been proposed that α-syn 
associates with vesicular and membranous structures in order to play a role in 
neurotransmitter management (Bendor et al, 2013). α-syn proteins can adopt an altered 
conformation under pathological conditions, leading to the cytotoxic formation of 
oligomers, amyloid fibrils and finally Lewy bodies (Fig. 6 ; Conway et al, 2000; Fujiwara et 
al, 2002).  
 
 
Fig. 6: Hypothetical model of α-syn toxicity in PD. 
Under physiological conditions, α-syn exists in a soluble random coil state. Under pathological conditions, the native protein 
undergoes misfolding into pathogenic α-syn oligomers that further aggregate into amyloid fibrils. Ultimately, these structures 
are the building blocks for the pathological inclusions of α-syn called Lewy bodies. Adapted from (Irwin et al, 2013). 
 
It is still not well understood how these α-syn aggregates harm neurons. 
Nevertheless, different hypotheses have been proposed such as their ability to induce an 
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oxidative stress, to inhibit the protein degradation system or to impair the normal 
dopamine neurotransmission (Xu & Chan, 2015). In addition, α-syn as well as its mutant 
forms, can activate microglia and thus promote the neuroinflammation (Zhang et al, 2005; 
Lee et al, 2010; Roodveldt et al, 2010).  
INTRODUCTION 
 
 14 
Part II: The neuroinflammation 
 
1. The inflammatory response 
 
1.1. Generalities 
 
Inflammation is a normal, immediate and transient response to external aggressions 
compromising the integrity of the body. It is defined by the four cardinal signs of 
inflammation: redness, heat, swelling and pain described over 2,000 years ago by Celsus. 
However, the inflammation process is much more complex and involves specific 
molecular and cellular responses to infection, injury or stress. It aims to defend the body 
against insults, to clean dead and damaged cells and to restore the homeostasis.  
Inflammation is classically viewed as an immediate and transient response of the 
immune system. However, it happens that inflammation becomes chronic when the injury 
or infection persists or during autoimmune diseases. Both acute and chronic inflammation 
differ by the rapidity of their onset (fast / slow), the types of involved immune cells 
(granulocytes / monocytes and lymphocytes), or the resulting tissue injury (Mild / Severe 
and progressive).  
 
1.2. Inflammatory signalling pathways 
 
Inflammation is classically triggered when immune cells detect the presence of 
specific signals by the germ-line encoded receptors also known as Pattern Recognition 
Receptors (PRRs). PRRs specifically recognize either pathogen-associated molecular 
pattern (PAMPs) or sterile danger/damage-associated molecular patterns (DAMPs). 
PAMPs include for example bacterial- and viral-derived carbohydrates, nucleic acids or 
lipoproteins whereas DAMPs comprise molecules such as ATP (Adenosine tri-
phosphate), uric acid, HMGB1 (High mobility group box 1) or heat-shock proteins (Kigerl 
et al, 2014). Under normal, non-inflammatory conditions, DAMPs exhibit cellular 
compartmentalization preventing a physiological interaction with their specific PRRs. 
Under pathological conditions, however, DAMPs are either passively released from 
injured/inflamed tissues, dying cells or actively secreted (Feldman et al, 2015). 
The most common PRRs family is represented by the Toll-like receptors (TLRs). 
Besides, PRRs also include the intracellular Nod-like Receptors (NLRs, described below), 
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Scavenger receptors (SRs), Mannose Receptors (MRs) and complement receptors 
(Farina et al, 2007; Kigerl et al, 2014). Following the recognition of PAMPs/DAMPs, PRRs 
trigger intracellular signalling pathways including NF-κB (Nuclear Factor-κB), MAP 
(Mitogen-Activated Protein) kinase, JAK/STAT and AP1 (Activator Protein 1) pathways. 
These signalling pathways lead to the production of a large variety of pro-inflammatory 
factors that can induce a positive regulatory loop to amplify their inflammatory responses. 
Among these pro-inflammatory products, the most notable are nitric oxide (NO), 
reactive oxygen species (ROS), cytokines and chemokines. An important group of 
inflammatory mediators is the family of cytokines which are small proteins including 
interleukins, interferons, tumor necrosis factor, adipokines and lymphokines. 
Interleukin-1beta (IL-1β) and tumor necrosis factor alpha (TNFα) are two members of 
cytokines which have gained much attention in the literature and play pivotal roles during 
inflammation. 
 
1.3. Sterile inflammation 
 
Inflammation is often considered as the consequence of an infection. However, this 
process can also be trigger in the absence of pathogen and is then called “sterile 
inflammation”. It can be caused by mechanical trauma, ischemia, stress or environmental 
conditions. These damage-related stimuli induce the release of DAMPs which in turn 
activate the PRRs (e.g. TLRs or NLRs) and drive the sterile inflammatory reaction. Sterile 
inflammation is implicated in disease processes such as gout, atherosclerosis, cancer or 
neuroinflammatory diseases including AD and PD (Tsung et al, 2014; Feldman et al, 
2015). 
2. Neuroinflammation 
 
Even if the access of peripheral immune cells to the CNS is restricted and tightly 
regulated, it is now commonly accepted that the CNS is capable of dynamic immune and 
inflammatory responses to a variety of insults (for review: Heneka, Kummer, and Latz 
2014; Lyman et al. 2014; Rivest 2009). 
Astrocytes and microglia represent the key effectors of the neuroinflammatory 
response. However, additional cell types are also implicated in this process: 1) CNS 
intrinsic neural cells (neurons, oligodendrocytes, NG2+ cells, NSCs progenitors), 2) CNS 
intrinsic non neural cells (pericytes or endothelial cells) and 3) CNS extrinsic non neural 
INTRODUCTION 
 
 16 
cells (monocytes, macrophages, eosinophils, natural killer cells, T and B cells, among 
others ; Ransohoff & Brown, 2012).  
2.1. Reactive Microglia  
 
The on/off system. In the healthy brain, microglia exhibit a highly ramified shape and 
are called “resting microglia”. This term is misleading as these cells are not really 
quiescent. Indeed, microglia constantly scan the brain parenchyma with their long and 
motile processes in order to detect any homeostasis perturbation. This “resting” state is, in 
part, actively maintained by surrounding cells, in particular by healthy neurons which 
provide so called “off signals” such as CX3CL1, CD22, various neurotransmitters or 
neurotrophins (Biber et al, 2007). However, these “off signals” can be altered or missing, 
for example after neuronal loss. In addition, microglia can also detect specific “on” signals 
via its PRRs such as the presence of pathogens, cellular debris, critical concentrations of 
physiological molecules (e.g. glutamate, ATP) or presence of misfolded proteins (e.g. Aβ 
or α-syn peptides ; Long-smith et al, 2009). In case of “off” signals disruption and/or “on” 
signals detection, microglia react promptly and shift toward an “activated state”.  
 
Activation state of microglia. This activated state is characterized by an impressive 
change in proliferation and microglia morphology (i.e. the cells are adopting an amoeboid 
shape). Microglia become also highly motile and migrate to the site of injury. There, they 
phagocyte damaged cells or debris and generate a particular environment by secreting a 
large variety of factors: cytokines, chemokines, NO, ROS or growth factors. They also 
release chemoattractant factors to recruit peripheral immune cells (Prinz et al, 2011).  
Until recently, the profile of microglial activation was essentially characterized by two 
extreme phenotypes: the M1 state, which is highly pro-inflammatory, and the M2 state, an 
alternative activation state rather dedicated to the tissue repair. However, this concept has 
recently been reappraised, because these two phenotypes were not sufficient to 
characterise all the activation states of microglia. It is now evident that they have to be 
considered as a large continuous spectrum of phenotypes with a large variety of functions 
(Heppner et al, 2015). The context, the environment and the surrounding cells (especially 
astrocytes and neurons) influence and determine all these specific phenotypes (Hanisch & 
Kettenmann, 2007). 
Short and moderate activating signals direct microglia toward a neuroprotective 
phenotype (Fig. 7). In this context, microglia clear debris by phagocytosis, secrete growth 
factors and support regeneration. In contrast, intensive acute or chronic activation can 
render microglia neurotoxic. In this case, they produce ROS, NO, proteases but also a 
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large plethora of pro-inflammatory cytokines such as IL-1, IL-6 and TNFα. All these factors 
endanger neuronal activity (London et al, 2013).  
 
Fig. 7: Microglial activation. 
Upon recognition of a danger signal, microglia switch to an activated mode, adopt an amoeboid form and migrate to the 
injury site. There, they phagocyte damaged cells or debris, secrete a large variety of factors, recruit circulating immune cells 
and support regeneration. All these events aim to restore the homeostasis in the brain parenchyma. Adapted from (London 
et al, 2013). 
 
2.2. Reactive astrocytes 
 
In case of CNS insults, astrocytes undergo a process of activation called reactive 
astrogliosis, a hallmark of neuroinflammation. Similarly to microglia, astrocytes can sense 
endogenous danger signals via the expression of PRRs. These signals are diverse but 
they mainly result from the microglial response to injury. 
The basic process of reactive astrogliosis involves cellular hypertrophy, changes in 
gene expression and can include astrocyte proliferation after particularly severe insults 
(Sofroniew & Vinters, 2010). Reactive astrocytes are commonly characterized by an 
increased synthesis of GFAP and a re-expression of the progenitor markers, vimentin and 
nestin (Hamby and Sofroniew 2010; Pekny and Nilsson 2005). They also initiate the 
expression and release of several mediators such as cytokines, chemokines, eicosanoids, 
ROS, NO and excitatory amino acid that influence the microglial activation and potentiate 
the recruitment of immune cells to the inflamed sites (Dong & Benveniste, 2001; Lee, 
2015). 
Accumulating evidence indicates that reactive astrogliosis is not a simple all or none 
response but could vary in a context-specific manner which corresponds to the level of 
injury, the astrocyte subtype and the location of the lesion site. Accordingly, the astrocyte 
phenotypes can be classified into a continuum of progressive activation states from mild 
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astrogliosis to severe astrogliosis leading to the formation of a glial scar. These different 
levels are described in figure 8 (Sofroniew and Vinter 2010; Zamanian et al. 2012). 
 
 
Fig. 8: Reactive astrogliosis. 
(a) In healthy CNS tissue, astrocytes occupy a defined domain without overlapping with other cells. (b) In mild to moderate 
reactive astrogliosis, astrocytes are characterized by anti-inflammatory properties and are found at distal regions from brain 
injury. There are involved in brain regeneration. (c) In severe diffuse reactive astrogliosis, astrocyte morphology is highly 
affected. They are located close to the brain injury and release pro-inflammatory cytokines. (d) Further astrocyte activation 
induces a glial scar formation. This barrier protects the healthy brain region from the spread of inflammation and the 
damaged tissue. However, it could restrict the regeneration processes (Sofroniew & Vinters, 2010). 
 
2.3. Neuroinflammation: detrimental or not? 
 
Neuroinflammation aims to facilitate the recovery from injury by reducing the size of 
a lesion, isolating the damaged zone and facilitating wound repair. However, although 
intended to be beneficial and protective, an excessive inflammation can cause or 
contribute to tissue damage and disease pathology. The main actors of this neurotoxicity 
are the pro-inflammatory cytokines and other factors released by both microglia and 
astrocytes. They can lead to the breakdown of the BBB, the impairment of synaptic 
activity, the inhibition of the neurogenesis and neuronal regeneration and to neuronal cell 
death (Lyman et al, 2014).  
Among the neurotoxic pro-inflammatory factors, the IL-1 family members are 
well-described. Dysregulated production of these cytokines can give rise to inflammatory 
diseases and neuronal injury. This is why the production of IL-1 is regulated at multiple 
levels: transcription, translation, cleavage and cellular release (Allan et al, 2005). A key 
player in this regulation is the inflammasome complex which will be described in the 
following section.  
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Part III: The inflammasome 
 
The inflammasome is a large cytosolic multiprotein complex formed upon detection 
of a large spectrum of infection- or stress-associated stimuli. The assembly of the complex 
leads to the activation of caspase-1 which is in charge of numerous inflammatory 
responses, such as the maturation of the cytokines IL-1β and IL-18, the release of 
alarmins or the initiation of pyroptosis, a characteristic form of caspase-1-dependent cell 
death (de Zoete et al, 2014). 
Martinon and collaborators first described the complex in 2002. They reported the 
identification of a caspase-1-activating complex, which they called “inflammasome” in 
order to highlight its similarity to the apoptosome complex as well as its particular 
implication in inflammation (Martinon et al, 2002).  
1. Inflammasome structure  
 
The inflammasome complex is classically formed of a sensor protein, an adaptor 
protein and a specific caspase (Fig. 9). Upon activation, the different components 
assemble through homotypic domain interactions.  
 
 
Fig. 9: Principal inflammasome components and their domain structure. 
To date, the well-described inflammasomes are the NLRP1, NLRP3, NLRC4 and AIM2 inflammasomes. Their names 
derived from the sensor protein involved in the complex. Sensor proteins recruit the two other components of the 
inflammasome, the adaptor protein ASC and the caspase 1/11, by homotypic domain interactions in order to form the 
inflammasome complex. FIIND = Function to find domain; CARD = Caspase activation and recruitment domain; NBD = 
Nucleotide-binding domain; PYD = Pyrin domain; NR100 = Amino-terminal domain of rodent NLRP1 of about 100 amino 
acids; HIN-200 = DNA-binding domain. 
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1.1 The sensor proteins 
 
Two main protein families act as sensor proteins in inflammasome complexes: the 
NLR-family (nucleotide-binding domain and leucine-rich repeat containing receptor, 
previously named NOD-family) and the PYHIN (Pyrin and HIN domain-containing) protein 
family (Fig.9).  
The NLR family consists of 33 genes in mouse and 22 genes in human (Ting et al, 
2008; Ye & Ting, 2008). All NLRs share a common domain structure: an N-terminal 
leucine-rich repeat (LRR) domain, a central nucleotide-binding domain (NBD) and a C-
terminal effector domain in charge of the direct or indirect recruitment of the caspase. This 
effector domain defines the subfamily classes of NLRs: NLRA (A for acidic transactivating 
domain), NLRB (B for BIR domain), NLRC (C for CARD), NLRP (P for pyrin domain) and 
NLRX (X for no significant homology). So far, the capacity to form an inflammasome has 
been mainly demonstrated for NLRP1, NLRP3, NLRC4, but also AIM2. AIM2 (Absent In 
Melanoma 2) is a member of the PYHIN protein family and not of the NLR family. Its 
domain structure is a N-terminal PYD domain coupled to a HIN-200 DNA-binding domain 
in C-terminus (Fernandes-Alnemri et al, 2009).  
 
1.2 The adaptor ASC 
 
The adaptor protein apoptosis-associated speck like protein (ASC) is responsible for 
the connection between the sensor protein and the caspase in inflammasome complex 
(Martinon et al, 2002; Srinivasula et al, 2002). ASC is encoded by the Pycard gene and 
contains two different death-fold domains (Fig. 9): a PYD domain that engages in 
homotypic interactions with the PYD domain of the sensor protein (NLR or AIM2 ; 
Fernandes-Alnemri et al, 2009; Vajjhala et al, 2012) and a CARD domain that is required 
for the recruitment of caspase-1, again through homotypic protein-protein domain 
interactions (Proell et al, 2013). 
Importantly, ASC is dispensable in certain inflammasome complexes such as in 
NLRP1 and NLRC4 inflammasomes that can directly bind the caspase (Faustin et al, 
2007; Broz et al, 2010). However, some studies propose that ASC might still be required 
for optimal activation of these complexes (Faustin et al, 2007; Case, 2011). 
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1.3 The pro-inflammatory caspases 
 
Caspases (cysteine-aspartic proteases) are proteolytic enzymes largely known as 
regulators of cell death and inflammation. This protease family is composed of 12 different 
members that can be grouped in two distinct classes: apoptotic caspases (casp-2, -3, -7, 
-8, -9 and -10) and inflammatory caspases (casp-1, -4, -5 / -11) (Shi et al. 2014). More 
recently, caspases-12 and -14 have been identified but their respective roles are not yet 
totally understood. 
In 1989, a protease responsible for the cleavage of IL-1β into its active form was 
described for the first time. This protease has been named Interleukin-β Convertase 
Enzyme (ICE ; Kostura et al, 1989). It was rapidly identified as a homolog of the already 
known caspase-1 (Yuan et al, 1993). Caspase-1 is the protease classically involved in the 
inflammasome complexes. However, recent publications show that caspase-11 can be 
implicated in a non-canonical inflammasome pathway (Kayagaki et al, 2011). While 
caspase-1 is constitutively expressed in many cell types, the caspase-11 (murine otholog 
of caspase-4/-5) is inducible. However, both caspases are produced as zymogens, thus 
existing under an inactive pro-form that needs to be cleaved to become active.  
Caspase proenzymes contain three domains: an amino-terminal CARD domain, a large 
subunit that contains the active-site cysteine (p20) and a carboxy-terminal small subunit 
(p10 ; Fig. 10). The cleavage of the zymogen generates two subunits, p20 and p10, which 
associate as a hetero-tetramer to form the active caspase-1. This maturation process 
occurs via a close proximity model of auto-activation. Indeed, the pro-peptide is cleaved in 
case of the apposition of more than two monomers of pro-caspase as is the case when 
inflammasome is assembled (Bauernfeind et al, 2011). However, we have to note that 
caspase-1 seems to exist in two activation states, unprocessed and fully processed, 
depending on the composition of the inflammasome (Broz et al, 2010). 
 
 
 
Fig. 10: Caspase 1/11 activation.  
Caspase proenzymes contain an amino-terminal CARD and two carboxy-terminal subunits: p10 and p20. Two cleavage 
events at aspartate (Asp.) residues could occur. The first divides it into large and small caspase subunits, and the second 
removes the N-terminal prodomain. The resulting functional caspase is a tetramer of two large (p20) and two small (p10) 
subunits. 
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2. NLRP3 inflammasome 
 
2.1 Two-step mechanism of inflammasome activation 
 
The NLRP3 inflammasome is the best-characterized inflammasome. It is composed 
of NLRP3, the adaptor protein ASC and caspase-1. NLRP3 inflammasome activation is 
generally described as a two-step mechanism requiring two different signals (Fig. 11).  
 
 Fig. 11: Activation of the NLRP3 inflammasome requires two signals. 
Signal 1 (or priming) is represented by microbial molecules or pro-inflammatory cytokines. They lead to the activation of the 
NF-κB pathway and to the regulation of the synthesis of NLRP3 and pro-IL-1β. Priming also licenses NLRP3 by inducing its 
deubiquitination. Signal 2 is responsible for the activation of NLRP3. It can be trigger by a large array of factors (DAMPs, 
PAMPs, crystals). Once signal 1 and 2 are engaged, the NLRP3 inflammasome is formed which leads to caspase-1 
activation and, among other events, to IL-1β/IL-18 maturation and secretion. Inspired from (Franchi et al, 2012). 
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“Signal 1” (or priming) is a sine qua non condition for inflammasome assembly. It 
aims to upregulate the protein expression level of NLRP3. Priming is triggered by different 
pro-inflammatory molecules, such as bacterial lipopolysaccharide (LPS) or endogenous 
cytokines. These factors lead to the activation of the NF-κB pathway activation and to the 
subsequent upregulation of NLRP3 and pro-IL-1β (Franchi et al, 2009; Bauernfeind et al, 
2010). Additionally, the signal 1 can non-transcriptionally prime NLRP3 by stimulating its 
deubiquitination (Juliana et al, 2012; Py et al, 2013).  
 
“Signal 2” consists in an NLRP3 agonist responsible for complex formation (Fig. 11). 
NLRP3 is a broadly activated sensor protein since it can detect a large array of stimuli. 
The table 2 presents few examples of the NLRP3 activators described. It is not fully 
understood how these structurally diverse molecules activate NLRP3. However, we know 
that their presence induces a change in NLRP3 conformation that allows the recruitment 
of ASC and caspase-1 and ultimately the cleavage of its substrates (Mayor et al, 2007; 
Compan et al, 2012).  
 
Table 2: Diversity of NLRP3 activators. 
NLRP3 activators References 
PAMPs  
Bacterial components (Mariathasan et al, 2006; Duncan et al, 2009; He et al, 2010; Toma 
et al, 2010; Shimada et al, 2011) 
Fungal components (Gross et al, 2009; Joly et al, 2009; Hise et al, 2010) 
Viral components (Allen et al, 2009; Thomas et al, 2009; Ichinohe et al, 2010; Rajan 
et al, 2011) 
DAMPs  
ATP (Mariathasan et al, 2006) 
Uric acid crystals (MSU) (Martinon et al, 2006) 
Aβ peptides (Halle et al, 2008) 
Environmental factors  
Silica (Dostert et al, 2008) 
Abestesos (Eisenbarth et al, 2008) 
 
2.2 Different NLRP3 activation models 
 
Regarding the huge diversity of stimuli, it is unlikely that NLRP3 senses each PAMP 
or DAMP directly. Instead, a common molecular event is probably leading to its activation. 
Three main models have been proposed: the ion flux model, the ROS and mitochondrial 
INTRODUCTION 
 
 24 
impairment model and the lysosomal damage model (Fig. 12). However, so far, none of 
these models totally accounts for inflammasome activation, probably because all these 
events are strongly interrelated (Guicciardi et al, 2004; Muñoz-Planillo et al, 2013).  
 
 
Fig. 12: Models for NLRP3 activation. 
Various PAMPs and DAMPs provide the signal 2 required to assemble and activate the NLRP3 inflammasome. Although 
the precise mechanism leading to NLRP3 activation is still controversial, three models have been proposed: the lysosomal 
damage, the ions fluxes and the mitochondrial damage and associated ROS. However, these cellular events are strongly 
correlated and probably act together. Adapted from (Saxena & Yeretssian, 2014). 
 
2.2.1 Ion flux model  
 
Cellular ion fluxes play an important role in NLRP3 activation, in particular 
potassium (K+) efflux and Calcium (Ca2+) mobilization from intracellular stores.  
Several known inflammasome activators are pore-forming toxins (i.e. Nigericin) and are 
described as cause of K+ efflux. Similarly, ATP activates the ionotropic P2X7 receptor 
which results in the opening of potassium channels and the release of K+ in the 
extracellular space. Incubating cells in KCl-enriched medium inhibits the K+ efflux and 
results in reduced IL-1β and IL-18 release (Pétrilli et al, 2007), demonstrating the 
importance of the potassium flux for inflammasome activation.  
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In addition to K+, Ca2+ fluxes have also been studied in the context of NLRP3 
activation. Several recent reports demonstrate that an increase of intracellular calcium is 
indispensable for NLRP3 activation by ATP, Nigericin, but also lysosomotropic peptides 
(T. Murakami et al. 2012; Rossol et al. 2012; Zhong et al. 2013). However, even if calcium 
mobilization is required for NLRP3 activation, it cannot be sufficient, given that calcium 
signalling is triggered in many settings without coincident inflammasome activation. 
Moreover, a recent study showed that extracellular calcium activates NLRP3 only when a 
K+ efflux is permitted (Muñoz-Planillo et al, 2013). This publication also shows that the 
activation of NLRP3 by Ca2+-enriched media was attributed to the formation of insoluble 
calcium phosphate salts, which was previously linked to K+ efflux and NLRP3 activation 
(Jin et al, 2011). Therefore, the current view is that a drop in cytosolic K+ plays a central 
role in the NLRP3 activation. However, it remains to be clarified how K+ efflux are sensed 
by NLRP3. 
 
2.2.2 Mitochondrial damage and ROS  
 
ROS are chemically reactive compounds (free radicals and molecules) derived from 
the oxygen metabolism. While ROS are a by-product of physiological cell function, 
excessive amounts can cause deleterious effects. 
Most inflammasome activators, such as ATP, Nigericin, Alum or uric acid induce a ROS 
production (Tschopp & Schroder, 2010). Experiments using ROS inhibitors have shown 
that this oxidative stress is important for NLRP3 activation. ROS generated by the NADPH 
oxidase 2 were first considered to be direct inflammasome activator (Cruz et al, 2007; 
Dostert et al, 2008). However, later studies have shown that NOX2-deficient cells exhibit 
normal NLRP3 activation upon stimulation (Bruggen et al, 2010; Latz, 2010; Muñoz-
Planillo et al, 2013). Moreover, a deficiency in superoxide dismutase (SOD-1), increasing 
ROS levels in cells, leads to an unexpected inhibition of caspase-1 activity (Meissner et al, 
2010). Therefore, the discrepant results about the role of ROS and antioxidants on 
inflammasome activation are still matters of discussion (Rubartelli et al, 2011).  
Mitochondria, important cellular organelles, are very sensitive to cellular stress. Its 
damage triggers molecular events such as the production of ROS or modifications in Ca2+ 
signalling, two processes already relied to NLRP3 activation. Zhou and colleagues have 
shown that blocking mitophagy induces NLRP3 activation (Zhou et al, 2010). Furthermore, 
mitochondrial DNA, released in case of injury, can directly bind to and activate NLRP3 
(Nakahira et al, 2011; Shimada et al, 2012) similarly to cardiolipin, a phospholipid 
enclosed in the inner mitochondria membrane (Iyer et al, 2013). On the other hand, the 
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protection of mitochondrial integrity also prevents inflammasome activation (Chang et al, 
2014). In addition to these results, many reports have demonstrated that a large variety of 
NLRP3 activators drive mitochondrial damage and subsequent events (Gurung et al, 
2014). All these findings support the mitochondrial dysfunction as another important 
cellular event leading to NLRP3 inflammasome activation. 
 
2.2.3 Lysosomal damage 
 
Several particles and crystalline molecules, such as Alum, MSU, Silica or Aβ, have 
been shown to activate the NLRP3 inflammasome upon “frustrated” phagocytosis and 
disruption of lysosomal membrane. Proteases, such as cathepsin B that are normally 
sequestered in this organelle, can then be released. Treatment with cathepsin B inhibitors 
induce a reduction of NLRP3 activation (Halle et al, 2008; Hornung et al, 2008; Chu et al, 
2009; Duncan et al, 2009; Codolo et al, 2013). However, cathepsin B-deficient mice show 
no reduction in IL-1β release following particle exposure (Dostert et al, 2009; Orlowski et 
al, 2015). Moreover, a recent publication demonstrates that NLRP3 activation by MSU or 
silica could occur in the absence of phagocytosis but was dependent on K+ efflux (Muñoz-
Planillo et al, 2013; Hari et al, 2014). These results indicate once again the complexity to 
construct a unique NLRP3 activation model.  
 
In conclusion, the mechanisms of NLRP3 activation supported by the most studies 
include potassium efflux, the generation of ROS, mitochondrial damage and the lysosomal 
destabilization. However, not all of these events are induced by all NLRP3 agonists and 
some conflicting results on this topic are published. Therefore, the precise mechanism of 
NLRP3 activation is still debated and need clarification. 
 
3. Other inflammasomes 
 
In addition to NLRP3, other inflammasome complexes have been described. Even if 
each of them is specifically activated by particular stimuli (Fig. 13), their assembly all 
triggers caspase-1 activation and the related cellular events.  
INTRODUCTION 
 
 27 
 
Fig. 13: Distinct stimuli activate different inflammasomes. 
A large variety of stimuli, associated with infection or cellular stress, are able to activate the inflammasomes and 
subsequently the caspase-1. Each of these different triggers preferentially activates one the inflammasome sensor proteins. 
For example, NLRP1 is activated by Anthrax, Bacilllus anthracis or Muramyl dipeptide (MDP) whereas NLRC4 is sensitive to 
fatty acids (palmitate) or different bacterial PAMPs. Moreover, the nature of the stimuli determines the ASC-dependency of 
both NLRP1 and NLRC4 complexes assembly. AIM2 can detect the presence of DNA, either viral, bacterial or self-DNA. 
Inspired from (de Zoete et al, 2014) 
 
3.1. NLRP1 inflammasome 
 
NLRP1 was the first described inflammasome complex. It was defined by the 
spontaneous assembly of NLRP1 protein, ASC and caspase-1 in a cell free system 
(Martinon et al, 2002). Today, we know that ASC is dispensable for NLRP1 inflammasome 
formation even if its presence enhances the complex’s activity (Faustin et al, 2007; Van 
Opdenbosch et al, 2014). Although NLRP1 has been described in both humans and 
mouse, they are encoded by paralog genes. In human, a single genes codes for 
NLRP1whereas in mice three different genes code for NLRP1a, NLRP1b and NLRP1c. 
Accordingly, human and mouse NLRP1 display different structures which might explain 
that they are not sensitive to the same stimuli (Fig. 9). For example, Muramyl dipeptide 
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(MDP), a bacterial proteoglycan fragment, is a natural ligand of human NLRP1 but not of 
murine NLRP1 (Faustin et al, 2007; Kovarova et al, 2012). On the other hand, murine 
NLRP1 seems sensitive to the Bacillus anthracis lethal toxin whereas human NLRP1 is 
not (Fink et al, 2008). More precisely, this sensitivity to anthrax toxin is restricted to 
specific mouse genetic backgrounds such as in the mice strains BALB/c and 129s1 
(Boyden & Dietrich, 2006).  
 
3.2. NLRC4 inflammasome 
 
NLRC4 (formerly called IPAF) is specialized in the detection of bacterial pathogens, such 
as Shigella flexneri (Suzuki & Núñez, 2007), Legionella pneumophila (Amer et al, 2006; 
Lamkanfi et al, 2007) or Salmonella typhimurium (Amer et al, 2006; Miao et al, 2006). 
NLRC4 does not directly recognize these pathogens but indirectly interacts with different 
NLR-family apoptosis-inhibiting proteins (NAIPs) in the cytosol (Kofoed & Vance, 2011). In 
mice, NAIP1 and 2 bind the bacterial type III secretory system (T3SS) whereas both 
NAIP5 and 6 bind bacterial flagellin (Kofoed & Vance, 2011; Rayamajhi et al, 2013). Once 
NAIP proteins bind their ligands, they can oligomerize with NLRC4 and induce the 
recruitment of other NLRC4 inflammasome components. Similar to NLRP1, NLRC4 could 
directly interact with the CARD domain of caspase-1 (Poyet et al, 2001) or indirectly by 
the recruitment of ASC (Broz et al, 2010; Proell et al, 2013). 
 
3.3. AIM2 inflammasome 
 
AIM2 is a member of the PYHIN family and is able to recognize cytosolic viral or 
bacterial double-stranded DNA (Broz et al, 2010; Fernandes-Alnemri et al, 2010; 
Rathinam et al, 2010; Sauer et al, 2010) but also the DNA released by apoptotic cells via 
its HIN200 domain (W. Zhang et al. 2013). The binding to DNA induces a conformational 
change of AIM2 and the oligomerization of AIM2 occurs around this DNA molecule 
allowing the subsequent recruitment of ASC and caspase-1 (Jin et al, 2012, 2013). 
 
3.4. Non-canonical inflammasome pathway 
 
Recently, it was shown that caspase-1-deficient mice are also deficient for caspase-11, 
due to the close proximity of both genes in the mouse genome and the consequent 
difficulty to segregate these genes during homolog recombination (Kuida et al, 1995; 
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Kayagaki et al, 2011). To study the precise role of each caspase, new transgenic mice 
have been designed expressing caspase-11 from a C57BL/6 bacterial artificial 
chromosome transgene. The experiments carried out with these new strains show that 
Casp11-/- cells are still able to process IL-1β and IL-18 in response to ATP or MSU but not 
when infected by some Gram-negative bacteria (Kayagaki et al, 2011). Indeed, further 
investigations have demonstrated that caspase-11 is directly activated after macrophage 
stimulation with Gram-negative bacteria, such as E. coli, Citrobacter rodentium or Vibrio 
cholerae (Fig. 14 ; Kayagaki et al, 2011; Rathinam et al, 2012; Broz & Monack, 2013).  
 
 
Fig. 14. Non-canonical inflammasome pathway. 
Intracellular LPS recognition by caspase-11 triggers its auto-activation. Once activated, caspase-11 triggers pyroptosis and 
HMGB1 secretion, in a caspase-1-independent way. During this process, IL-1β and IL-18 releases are also observed but 
they are dependent on the NLRP3 inflammasome and on the caspase-1 activity. This observation suggests a cross-talk 
between the canonical and non-canonical inflammasome pathways which must be further investigated. 
In fact, caspase-11 can be activated by direct binding to intracellular LPS (Hagar et al, 
2013; Kayagaki et al, 2013; Shi et al, 2014). Once activated, caspase-11 can trigger 
pyroptosis and HMGB1 release in a caspase-1-independent way (Kayagaki et al, 2011) 
but also induce IL-1β and IL-18 releases in a caspase-1-, ASC- and NLRP3-dependent 
way (Kayagaki et al, 2011, 2013). These findings and further investigations have shown 
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that caspase-11 activation is a new way to activate caspase-1 and is therefore called the 
“non-canonical inflammasome”. 
 
3.5. NLRP2, NLRP6, NLRP12, IFI16 and RIG-I inflammasomes 
 
Other sensor proteins have been described to form functional inflammasomes.  
An early study shows that the co-expression of NLRP6 and ASC in fibroblastic cell 
lines triggers caspase-1 activation and IL-1β release (Grenier et al, 2002). Additionally, 
IL-18-deficient mice present an NLRP6-associated alteration of their microbiota, proposing 
a role for NLRP6 in IL-18 release (Elinav et al, 2011).  
NLRP12 closely resembles NLRP6. Its implication in intestinal homeostasis is well 
described (Zaki et al, 2011; Allen et al, 2012) and its co-expression with ASC leads to 
caspase-1 activation and subsequent IL-1β release (Wang et al, 2002). Another study 
showed that Yersinia pestis infection triggers IL-1β and IL-18 release in a 
NLRP12-dependent manner (Vladimer et al, 2012). 
NLRP2, another member of the NLR subfamily, was already known as a potent 
inhibitor of NF-κB pathway via the sequestration of the IKK complexes (Bruey et al, 2004). 
More recently, it has been demonstrated that NLRP2 is able to form a functional 
inflammasome in human astrocytes via assembly with ASC and caspase-1 (Minkiewicz et 
al, 2013). 
Finally, some members of the ALR (AIM2 Like Receptor) family were found to 
colocalize with ASC and generate IL-1β secretion (Brunette et al, 2012). Human 
Interferon-inducible protein 16 (IFI16) has been described to form a functional 
inflammasome in endothelial cells following herpesvirus infection (Singh et al, 2013; 
Monroe et al, 2014). Last but not least, retinoic acid-inducible gene I (RIG-I) seems also 
able to recruit ASC and caspase-1 via the CARDs to form an inflammasome complex 
(Poeck et al, 2010).  
Further studies are needed to validate and complete our knowledge about these 
inflammasome complexes, notably about the assembly-triggering stimuli specific for each 
inflammasome. 
 
4. Inflammasome-mediated cellular events 
 
The main outcome of the different inflammasomes is the activation of caspase-1 
upon assembly of the multimeric complexes. Once activated, this protease will mature the 
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pro-inflammatory cytokines IL-1β and IL-18 and induce of pyroptotic cell death. In addition, 
the inflammasome activation allows the release of alarmins such as IL-1 and HMGB1.  
 
4.1. IL-1β and IL-18 maturation and release  
 
IL-1β and IL-18 are cytokines of the IL-1 family and are expressed as immature 
pro-peptides that have to be cleaved in order to become biologically active.  
 
4.1.1. IL-1β 
 
IL-1β is a powerful pro-inflammatory cytokine primarily produced by cells of the 
myeloid lineage, such as monocytes, macrophages and dendritic cells. It is encoded by 
the Il1b gene and is not expressed under resting conditions. Its transcription must be 
triggered by activation of the NF-κB pathway. Once translated, IL-1β is present in the 
cytoplasm as a 31 kDa inactive pro-form that is subsequently proteolytically processed 
into a 17 kDa active cytokine. This maturation step is mainly performed by caspase-1 
following inflammasome activation. Nevertheless, in 1997, Fantuzzi et al. published the 
first evidence of caspase-1-independent IL-1β maturation (Fantuzzi et al, 1997). 
Subsequent studies have validated that neutrophil- and macrophage-derived proteases 
such as proteinase 3 (Coeshott et al, 1999; Joosten et al, 2009), elastase, chymase 
(Guma et al, 2009), and the two metalloproteinases, Merpin a and Merpin b (Banerjee & 
Bond, 2008; Herzog et al, 2009; Banerjee et al, 2011) are also IL-1β-processing enzymes. 
More recently, caspase-8 has been identified as another enzyme responsible for the IL-1β 
maturation (Bossaller et al. 2012). 
Regardless of the enzymes in charge of the cleavage, the active 17 kDa IL-1β must 
be released from the cell to trigger a strong inflammatory response in surrounding cells. 
Its actual route of secretion is still not entirely clear. The lack of a signal peptide indicates 
however that secretion does not occur via the classical ER-Golgi route (Rubartelli et al, 
1990). Different alternatives have been proposed, from the direct externalization at 
plasma membrane to the implication of vesicles (Piccioli & Rubartelli, 2013). 
Once released, IL-1β acts on other cells by binding to the Interleukin-1 Receptor 
(IL-1R). There are two forms of IL-1R: IL-1R1, which mediates the cellular activation by 
IL-1, and IL-1R2, which regulates the activity of IL-1β. When IL-1β binds IL-1R1, a 
second chain called the IL-1RAcp joins the receptor to form a complex, triggering the 
IL-1β-dependent cellular events: induction of antimicrobial resistance, activation of NF-κB 
and MAPK/JNK pathways or cell polarization into TH17 state (Garlanda et al, 2013). 
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IL-1R2 is a biologically inert receptor that competes IL-1β binding to IL-1R1 to 
negatively regulate cell activation (Hannum et al, 1990). A soluble molecule, called IL-
1Ra, also acts as specific inhibitor of IL-1β pathway. It is structurally very closed to IL-1β 
but a mutation renders it incapable to bind IL-1RAcp, preventing the complex assembly of 
IL-1R1 (Dinarello, 2011). 
The release and activity of IL-1β must be tightly controlled in order to prevent an 
excessive activation of the immune response. 
 
4.1.2. IL-18 
 
IL-18, also called IFNγ-inducing factor, is another cytokine belonging to the IL-1 
family. In opposition to IL-1β, IL-18 is constitutively expressed in myeloid cells, 
keratinocytes and epithelial cells (Puren et al, 1999). It is synthetized as an inactive pro-
peptide of 24 kDa which is further cleaved into 18 kDa and 6 kDa subunits to become 
biologically active. 
Similar to IL-1β, IL-18 is mainly processed by caspase-1 via the inflammasome 
complex. Nevertheless, two other caspases are also able to cleave IL-18: 1) Caspase-3 
but the resulting product seems to be biologically inactive (Akita et al, 1997). 2) caspase-8 
which is able to process IL-1β and IL-18 in macrophages (Bossaller et al, 2012). In 
addition to caspases, other proteases are also competent to cleave IL-18 such as the 
neutrophillic proteinase-3 (Sugawara et al, 2001) , Granzyme b (Omoto et al, 2010) or 
Merpin-b (Banerjee & Bond, 2008). 
The receptor of IL-18 — a heterocomplex of IL-18Ra and b — is formed upon 
bonding of mature IL-18 to IL-18Ra. While most cells express IL-18Ra, IL-18Rb seems 
restricted to T-cells and dendritic cells (Dinarello & Fantuzzi, 2003; Felderhoff-Mueser et 
al, 2005). The IL-18 receptor activation leads to the polarization of T helper cells towards 
a TH1 state and to the induction of IFNγ (Dinarello, 1999).  
As for IL-1β, the downstream effects of IL-18 are strongly controlled by two different 
mechanisms: 1) The IL-18 binding protein (IL18bp) which binds to IL-18 with higher affinity 
than IL-18Ra (Novick et al, 1999; Kim et al, 2000), 2) a truncated form of IL-18Ra that 
prevents the formation of the complete receptor after IL-18 binding to IL-18-Rb (Andre et 
al, 2003; Fiszer et al, 2007; Booker & Grattan, 2014).  
 
4.2. Active IL-1α and HMGB1 alarmin release  
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Alarmins are endogenous molecules that, in normal condition, remain intracellular to 
perform their “daily job”. However, they can also be released outside the cell upon injury 
to alert immune cells. This release can occur passively following cell death or actively, 
generally by using specialized secretion systems. This active secretion is only described 
in immune cells.  
The alarmin family includes a large variety of structurally different endogenous 
molecules. Among them are IL-1α and HMGB1, two molecules linked to inflammasome 
which will be further described below. 
 
4.2.1. IL-1α 
 
IL-1α and IL-1β are encoded by different genes, but share the same receptor (IL-1R) 
and exhibit similar biological effects. In addition, both proteins are synthetized as 
precursors and lack a signal peptide suggesting a non-canonical secretion pathway of 
secretion.  
On the other hand, IL-1α and IL-1β are differently regulated: 1) While IL-1β is always 
induced, IL-1α can be constitutively expressed in some cell types such as keratinocytes or 
epithelial cells (Hachiya et al, 2001; Garlanda et al, 2013). 2) Even if IL-1α is also 
synthetized as a precursor, this latter has been shown to be already active (Mosley et al, 
1987). 3) The cleavage of IL-1α is not mediated by caspase-1 but by calpaïn-like 
proteases (Howard et al. 1991; Gross 2012), which is thought to enhance the IL-1α 
activity (Miller et al, 1994).  
The secretion mechanism of IL-1α is still not well established. Until recently, it was 
broadly admitted that it is only passively released after necrotic cell rupture (Chen et al, 
2007; Eigenbrod et al, 2008). Nevertheless, recent publications have demonstrated that 
IL-1 is also actively secreted by myeloid cells and keratinocytes after exposure to 
NLRP3, NLRP1 and AIM2 inflammasome-activating stimuli (Guarda et al. 2011; Keller et 
al. 2008; Yazdi et al. 2010; Gross et al. 2012; Fettelschoss et al. 2011). Initially, it was 
hypothesised that IL-1β is necessary for the secretion of IL-1α. Accordingly, a model was 
proposed in which IL-1 directly binds to IL-1β using it as a shuttle for co-secretion (Yazdi 
& Drexler, 2013). However, some arguments are not in line with this idea. First, the 
requirement of an inflammasome for IL-1α release seems to be stimuli dependent, at least 
in case of the NLRP3 inflammasome. Indeed, IL-1α secretion triggered by particles occurs 
independently of NLRP3, whereas nigericin or ATP lead to IL-1α release in an NLRP3-, 
ASC- and Caspase-1-dependent manner (Gross et al, 2012). Remarkably, such a stimuli-
dependency has not been described for IL-1β. Secondly, another refuting argument is that 
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inhibiting caspase-1 activity does not affect nigericin-induced release of IL-1α, while totally 
abolishing IL-1β secretion (Gross et al, 2012). Finally, and determinately, the active 
release of IL-1α after inflammasome activation is unchanged in IL-1β knockout mice 
(Yazdi & Drexler, 2013). 
In summary, the inflammasome might participate in the active IL-1α secretion but 
more investigation is needed to understand by which exact mechanism. 
 
4.2.2. HMGB1 
 
HMGB1 is a non-histone chromatin-binding protein that is highly conserved and 
ubiquitously expressed. HMGB1 is located in the nucleus where it stabilizes the chromatin 
structure and controls the expression of genes important for mitochondrial quality control 
and autophagy (Kashayar et al, 1978; Tang et al, 2011). 
In addition, HMGB1 plays a second role once it is translocated out of the cell, for 
example upon cell injury. Once outside of the cell, HMGB1 turns into a powerful 
pro-inflammatory alarmin cytokine (Wang et al, 1999). HMGB1 acts on surrounding cells 
via a different receptors, for example TLRs and RAGE (receptor for advanced glycation 
end-products ; Bianchi & Manfredi, 2009; Yang et al, 2011). According which receptor it 
binds to, HMGB1 will trigger distinct immune responses such as activation of 
pro-inflammatory pathways, migration or proliferation (Venereau et al, 2012; Keyel, 2014).  
In addition to its “alarmin” function, HMGB1 shares other common characteristics 
with IL-1α. First, even if HMGB1 can be released passively – for example during necrosis 
– some cell types, such as macrophages, monocytes, hepatocytes, natural killer cells, and 
dendritic cells, are also able to secrete HMGB1 actively (Tsung et al, 2014). Second, this 
active HMGB1 secretion mainly occurs in an inflammatory context (Lamkanfi et al, 2010; 
Andersson & Tracey, 2011). Finally, HMGB1 also lacks a classical signal peptide required 
for the transport through the classical secretory pathway, indicating that an alternative 
mechanism is responsible for its active release (Gardella et al, 2002).  
Interestingly, several reports suggest a role for the inflammasome in HMGB1 
release. For example, Willingham and colleagues showed that macrophages exposed to 
bacteria release HMGB1 in an NLRP3 and ASC-dependent manner (Willingham et al, 
2009). These results were rapidly supported by another publication demonstrating that 
NLRP3, NLRC4 and ASC are required for HMGB1 release (Lamkanfi et al, 2010). 
However, it is still unclear, how the inflammasome regulates the HMGB1 release. 
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4.3. Pyroptosis 
 
Pyroptosis is a rapid lytic form of cell death, classically defined as the terminal 
response of cells with active pro-inflammatory caspase-1 or -11. Currently, it remains to 
be clarified whether pyroptosis truly constitutes a cell death pathway on its own or whether 
it represents a particular case of caspase-dependent apoptosis (Galluzzi et al, 2012).  
An argument to liken pyroptosis to apoptosis is the proteolytic cleavage of 
caspase-7 by caspase-1, one of the classical apoptotic caspases (Lamkanfi 2008). 
However, caspase-7 activation, as well as caspase-3 activation, are dispensable for 
pyroptosis (Lamkanfi 2008), indicating that death by pyroptosis occurs independently of 
the apoptosis program. Moreover, pyroptosis is characterized by some specific hallmarks 
digressing to classical apoptotic definition (Fig. 15). 
 
 
Fig. 15: Pyroptosis: main features and differences from apoptosis. 
(A) Caspase-1/11 activation is the defining feature of pyroptosis and mediates this form of cell death. Pyroptosis is 
characterized by the formation of membranous pores, water entry, cell swelling and following membrane rupture. The 
secretion of pro-inflammatory factors is also an important pyroptosis feature and contributes to its inflammatory nature.            
(B) Pyroptosis differs in several aspects from apoptosis. Adapted from (Lamkanfi, 2011) 
 
 
A proximal event in pyroptosis is the caspase-1-dependent formation of small 
cationic pores in the plasma membrane. They appear following cell exposure to numerous 
inflammasome activators, such as Salmonella or anthrax lethal toxin (Fink, Bergsbaken, 
and Cookson 2008). The subsequent osmotic variations lead to water entry, cell swelling 
INTRODUCTION 
 
 36 
and finally cell lysis (Fink & Cookson, 2006). Interestingly, the release of pro-inflammatory 
molecules after caspase-1 activation, such as IL-1β, IL-18, IL-1α and HMGB1 does not 
directly lead to cell death but contributes to the inflammatory nature of pyroptosis. 
During this lytic process, caspase-1 also induces nuclear condensation and DNA 
fragmentation (via currently unknown DNAses ; Fink & Cookson, 2006) with maintenance 
of nuclear membrane integrity (Molofsky et al, 2006).  
 
5. Inflammasome and diseases 
 
The importance of inflammasome research was underlined by the discovery of its 
implication in autoinflammatory hereditary syndromes called Cryopyrin-Associated 
Periodic Syndromes (CAPS). In 2001, Hoffman and colleagues have shown that the 
hereditary diseases Muckle-Wells syndrome (MWS) and the Familial Cold 
Autoinflammatory syndrome (FCAS) are both caused by mutations in the Nlrp3 gene 
(Hoffman et al, 2001). In addition to CAPS, a large variety of diseases are linked to 
inflammasome perturbation: gout (Martinon et al, 2006), osteoarthritis (Denoble et al, 
2011), atherosclerosis (Duewell et al, 2010), Alzheimer’s diseases (Heneka et al, 2013; 
Tan et al, 2014), multiple sclerosis (Jha et al. 2010) and Type 2 diabetes (Larsen et al, 
2007; Donath & Shoelson, 2011). Some of these inflammasome-associated diseases are 
treated with endogenous recombinant proteins targeting IL-1. Among them, the most 
widely used is Anakinra, a recombinant IL-1R antagonist. However, some antibody-based 
treatments, such as Canakinumab, a neutralizing IL-1β antibody or the soluble decoy IL-1 
receptor Rilonacept, are also used. These molecules have been tested in the treatment of 
CAPS and other IL-1β-associated diseases, such as type II diabetes (Dinarello et al, 
2012; Dinarello & van der Meer, 2013). 
In the meantime, therapeutic researches were focused on finding a molecule that 
would directly target the inflammasome complex, in order to gain in specificity. Different 
pharmacologic inhibitors of inflammasome function have already been described, such as 
glyburide (Lamkanfi et al, 2009), CRID3 (Coll & O’Neill, 2011), Bay 11–7082 (Juliana et al, 
2010) parthenolide (Juliana et al, 2010), 3,4-Methylenedioxy-β-nitrostyrene (He et al, 
2014) or dimethyl sulfoxide (DMSO, Ahn et al. 2013). However, while all these products 
have been tested in vitro, some in vivo reports are missing. Recently, a new NLRP3 
inhibitor called MCC950 has been described and tested in vivo, in an experimental 
autoimmune encephalomyelitis (EAE) model and in a CAPS model. In EAE, MCC950 
limits the disease severity and in CAPS the treatment protects mice from neonatal lethality 
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(Coll et al, 2015). Further investigations are awaited to confirm this inflammasome 
inhibitor as a treatment for other inflammatory diseases (de Rivero Vaccari et al, 2015). 
 
In conclusion, the inflammasome plays a pivotal role in numerous inflammatory 
diseases and it seems to be a potential therapeutic target to limit the development of 
these pathologies. In regard to these observations, studying the inflammasome represents 
a promising avenue to understand and cure neuroinflammatory diseases. 
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Part IV: The Inflammasome in CNS 
 
1. Inflammasome function in CNS diseases 
 
IL-1β, IL-18, IL1α and HMGB1 are known for the many functions they play in healthy 
or injured brain. In the CNS, IL-1 cytokines induce fever, increase slow wave sleep, 
amplify hypothalamic-pituitary-adrenal activation but also promote the neuroinflammation 
(Rothwell & Luheshi, 2000; Simi et al, 2007). For its part, extracellular HMGB1 is depicted 
as facilitator of neurite outgrowth and cell migration during early brain development and as 
neuroinflammatory compound after injury (Fang et al, 2012).  
All these inflammasome-related factors are also associated to the pathogenesis of 
several neurological diseases including AD, PD, traumatic brain injury, epilepsy and 
stroke (Alboni et al, 2010; Fang et al, 2012; Walsh et al, 2014). Both neuroprotective and 
detrimental effects are described, depending on the timing, the context and the disease.  
As IL-1β, IL-18, IL1α and HMGB1 secretions are all linked to the inflammasome 
activation, one expectation could that, depending on the context, they play similar 
beneficial or deleterious roles on the brain parenchyma. The reality is far more complex. 
For example, Il18 knockout mice are not protected from CNS ischaemic injury (Wheeler et 
al, 2003) while mice lacking IL-1, IL-1β or HMGB1 present a resistance to the pathogenic 
effects of ischemia (Boutin et al, 2001; Kim et al, 2006). Another illustration is the 
divergent effects of IL-1β and IL-18 on remyelination after cuprizone treatment, where IL-
1 is protective (Mason et al, 2001) and IL-18 detrimental (Jha et al, 2010).  
In light of these differences, it seems judicious to investigate how their production is 
regulated and, therefore explore the inflammasome implication in CNS diseases. Indeed, 
this field of research is currently deeply studied (for review see, Singhal et al, 2014; Walsh 
et al, 2014).  
These last years, a lot of publications have depicted the inflammasome as an important 
player in different neurological disorders such as CNS infections, acute sterile injuries or 
chronic neurodegenerative diseases. An overview of these findings is summarised in 
table 3. 
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Table 3:  Inflammasome in neurological diseases. 
 Disease context Inflammasome involvement References 
In
fe
c
ti
o
n
 
Turberculous meningitis M. tuberculosis induces NLRP3- and ASC-dependent IL-1 secretion from microglial cultures. (Lee et al, 2013) 
Pneumococcal meningitis 
ASC- and NLRP3-deficiency decrease the neuroinflammation and the scores of disease severity via reduction 
of IL-1 and IL-18 secretion. 
(Hoegen et al, 2011; Mitchell 
et al, 2012) 
Brain abcesses S. aureus infection activates microglial NLRP3 and IL-1β secretion in vitro. (Hanamsagar et al, 2011) 
Viral encephalitis 
West Nile virus activates NLRP3 inflammasome in vivo. NLRP3- and ASC-deficiency reduce the survival after 
mice were infected with the virus. 
Murine Encephalitis virus activates caspase-1 and subsequent IL-1 and IL-18 secretion, in vitro and in vivo. 
(Kaushik et al, 2012; Ramos 
et al, 2012; Jha et al, 2013) 
A
c
u
te
 a
n
d
 c
h
ro
n
ic
 s
te
ri
le
 i
n
fl
a
m
m
a
ti
o
n
 
Traumatic brain injury (TBI) 
TBI induces NLRP1 inflammasome assembly, caspase-1 activation and IL-1 release in rat neurons. The 
antibodies against ASC or NLRP1 are neuroprotective in this model. 
Patients with cranial trauma exhibit higher CSF levels of NLRP1 and ASC. 
(de Rivero Vaccari et al, 2009; 
Adamczak et al, 2012) 
Spinal cord injury (SCI) 
Processing of IL-1 and IL-18 by active caspase-1 is observed in SCI rat model. Anti-ASC neutralizing 
antibodies promote tissue integrity and functional improvement. 
(de Rivero Vaccari et al, 2008) 
Thromboembolic stroke 
NLRP1 inflammasome, IL-1 and IL-18 are implicated in a mouse model of thromboembolic stroke. 
Neutralising antibodies against NLRP1 act as anti-inflammatory compound after ischemia. 
(Abulafia et al, 2009) 
Ischemic stroke NLRP3 deficiency improves cerebral injury after ischemic stroke. (Yang et al, 2014) 
Demyelinating autoimmune 
inflammatory disease 
The experimental autoimmune encephalomyelitis (EAE) and the cuprizone models, two model of multiple 
sclerosis are linked to inflammasome. 
The ASC- and NLRP3-deficiency reduce the disease progression in both models, at least to a certain extent. 
(Gris et al, 2010; Jha et al, 
2010) 
Prion disease 
 
In vitro exposure of microglia to prion protein peptides induces NLRP3 inflammasome-depend release of IL-1β. 
However, mice lacking NLRP3 or ASC do not survive better in an in vivo prion pathogenesis model. 
(Hafner-Bratkovič et al, 2012; 
Shi et al, 2012; Nuvolone et 
al, 2015) 
Amyotrophic Lateral Sclerosis 
Mutant SOD-1 triggers IL-1β secretion in an ASC-dependent manner. Caspase-1- and IL-1β-deficient mice 
expressing the mutant form of SOD-1 show better survival compared to the wild-type mice. 
(Meissner et al, 2010; Johann 
et al, 2015) 
Alzheimer’s disease 
Different forms of Aβ are implicated in the formation of the NLRP3 and NLRP1 inflammasomes. 
NLRP3- and caspase-1-deficiency are protective in an APP/PS1 transgenic AD model. 
(Halle et al, 2008; Heneka et 
al, 2013; Tan et al, 2014) 
Adapted from Walsh et al, 2014 
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All these studies suggest an important role of inflammasomes in CNS diseases and lead 
to the emergence of new research avenues. However, most of these studies were 
descriptive and based on tissue analysis and did not identify the respective role of each 
cell type in the inflammasome signalling. In the next section, we will review the actual 
knowledge of the expression and regulation of inflammasomes in the different brain cells. 
 
2. Inflammasome expression in the brain 
 
2.1. Inflammasome in neurons  
 
Studies addressing the inflammasome function within neurons have particularly 
focused on the NLRP1 complex. They have been performed in different neuronal cell 
types (cortical and spinal motor neurons), as well as in different models of CNS disorders 
(traumatic brain injury, spinal cord injury, age-related cognitive impairment or stroke), in 
both rat and human (de Rivero Vaccari et al, 2008, 2009; Abulafia et al, 2009; Mawhinney 
et al, 2011; Adamczak et al, 2012). More recently, new in vitro and in vivo reports have 
shown the importance of the neuronal NLRP1 inflammasome in AD, ischemic stroke, 
Rasmussen’s encephalitis and neuropathic pain (Fann et al, 2013; Li et al, 2013; 
Ramaswamy et al, 2013; Tan et al, 2013).  
It has been shown for instance that the activation of neuronal NLRP1 inflammasome 
depends on Pannexin-1 (Silverman et al, 2009). In summary, high extracellular K+ lead to 
the opening of pannexin-1 channels, allowing a strong ATP efflux, which in turn stimulates 
the P2X7 receptor and finally activates the NLRP1 inflammasome (de Rivero Vaccari et 
al, 2015). 
In addition to NLRP1, neurons express AIM2 inflammasome components, which 
could be assembled in presence of aberrant DNA (Adamczak et al, 2012, 2014; Kaushal 
et al, 2015). Similarly for NLRP1, the activation of AIM2 seems to be pannexin-
1-dependent and leads to the secretion of IL-1β as well as to pyroptotic cell death 
(Adamczak et al, 2014).  
The ability of neurons to express other inflammasome components, and in particular 
NLRP3, is less clear. It has been for example reported that mouse cortical neurons, 
placed in ischemia-like conditions, overexpress NLRP1 and NLRP3 and increase their 
secretion of IL-1β and IL-18 (Fann et al, 2013). However, other studies suggest that 
NLRP3 is expressed neither in mice nor in human neurons (Kummer et al, 2007; 
Ramaswamy et al, 2013; Yang et al, 2014; Kaushal et al, 2015). Similarly, the presence of 
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an active NLRC4 inflammasome in neurons is also controversial. One report suggests that 
neurons exposed to flagellin express and form a NLRC4 inflammasome (Kaushal et al, 
2015) whereas another study failed to detect any NLRC4 mRNA in these cells 
(Ramaswamy et al, 2013). 
  
2.2. Inflammasome in astrocytes  
 
The presence of activated caspase-1 in astrocytes growing in K+-enriched medium 
raised the question if an inflammasome complex could be present in these cells 
(Silverman et al, 2009).  
Several reports analysed the expression patterns of NLR and other inflammasome 
components in astrocytes. They commonly showed that human and murine astrocytes 
express NLRP1, NLRC4, AIM2, ASC and caspase-1 proteins, albeit at lower levels than in 
other cell types (Ramaswamy et al, 2013; Alfonso-Loeches et al, 2014; Kaushal et al, 
2015; Zeis et al, 2015).  
Regarding the expression of NLRP3, the reports diverge. On the one hand, some 
authors claim that NLRP3 protein is upregulated in cortical astrocyte cultures after 
exposure to LPS, ethanol or MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine ; Zou & 
Crews, 2012; Alfonso-Loeches et al, 2014; Lu et al, 2014; Zeis et al, 2015). This has been 
strengthened by in vivo observations showing that, in different neuropathological 
conditions, NLRP3 could be upregulated in astrocytes (Tezel et al, 2012; Kawana et al, 
2013). On the other hand, other recent publications fail to detect any NLRP3 mRNA in 
human and murine astrocytes (Ramaswamy et al, 2013; Kaushal et al, 2015; Nuvolone et 
al, 2015). Thus, additional studies are still required to determine if astrocytes express 
NLRP3 and whether they can form a functional NLRP3 inflammasome. 
More interestingly, the existence of a functional inflammasome has only been 
described in human astrocytes. This inflammasome assembles after treatment with ATP 
and is composed of NLRP2, ASC and caspase-1 (Minkiewicz et al, 2013). However, this 
finding needs confirmation and in particular with regard to the existence of such an 
inflammasome in mice. 
 
2.3. Inflammasome in microglia 
 
It is well known that microglia express different inflammasome-related proteins such 
as NLRP1, NLRP3, NLRC4, AIM2, ASC and Caspase-1 (Halle et al, 2008; Hanamsagar 
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et al, 2011; Kaushik et al, 2012; Jamilloux et al, 2013; Cox et al, 2015). At first glance, 
their expression profile seems equivalent to the one of macrophages. However, a recent 
publication shows that there are differences between microglia and macrophages, 
especially in regard to the expression level of inflammasome components in primates 
(Burm et al. 2015).  
To date, the NLRP3 inflammasome remains the most studied inflammasome 
complex in microglia. A great number of reports demonstrate that activated microglia can 
form a functional NLRP3 inflammasome in sterile or infectious conditons. ATP, MSU and 
pathogens, representing different classical NLRP3 inflammasome activators, are able to 
trigger the release of IL-1β and IL-18 in microglia (Halle et al, 2008; Hanamsagar et al, 
2011; Kaushik et al, 2012; Savage et al, 2012; Burm et al, 2015). In addition, the 
microglial NLRP3 inflammasome can be activated after in vitro exposure to different 
neuropathology-related proteins, such as prion protein (Shi et al, 2012) or the AD-related 
proteins Aβ and Chromogranin A (Halle et al. 2008a; Parajuli et al. 2013; Terada et al. 
2010; Wu et al. 2013). The mechanisms leading to NLRP3 inflammasome activation in 
microglia and in macrophages have been described to be very similar (Halle et al. 2008a; 
Wu et al. 2013; Parajuli et al. 2013; Murphy et al. 2014).  
All these studies confirm that microglia express a functional NLRP3 inflammasome. 
However, it has been poorly investigated if other inflammasomes need to be implicated in 
the secretion of IL-1β by microglia. Indeed, a single report described a NLRC4 
inflammasome-dependent caspase-1 activation after brain infiltration by Legionella 
pneumophila (Jamilloux et al, 2013).  
 
In conclusion, microglia, astrocytes and neurons have all been reported to express 
functional inflammasomes. However, some of the cited publications have to be confirmed 
by others. Moreover, little is known about the conditions under which inflammasome 
activation occurs in these cells as well as how these cell-specific inflammasome 
participate to CNS pathologies. 
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Since 2008, several research groups started to investigate whether the 
inflammasome is active in the CNS. The first published results were very encouraging 
since they demonstrated an important implication of the inflammasome signalling in 
diverse neuroinflammatory conditions. For example, recent evidences highlighted a role of 
the inflammasome in the development of two neurodegenerative diseases: Amyotrophic 
Lateral Sclerosis and Alzheimer’s disease (Heneka 2013, Meissner 2010).  
Parkinson’s disease (PD) is another well described neurodegenerative disease, 
which also presents an important inflammatory component but, surprisingly, little is known 
about the implication of the inflammasome in this pathology. However, many PD reports 
suggest such a link: i) the detection of IL-1 in the CSF of patients, ii) ROS production and 
mitochondrial damage implicated in the neuronal death, or iii) the presence of misfolded 
proteins in Lewy bodies and their capacity to activate microglia. According to these 
considerations, we aim to investigate the possible involvement of inflammasome in 
Parkinson’s pathology. 
 
In order to correctly study the link between the inflammasome and PD, we first 
decided to clarify the expression profile and activation of the inflammasome in microglia 
and astrocytes. While different publications already addressed this topic, some critical 
questions remains. For example, it is admitted that microglia express a functional NLRP3 
inflammasome but there is no evidence of such an expression in astrocytes. It is also 
unknown whether microglia and astrocytes are able to actively secrete IL-1α and HMGB1 
or to trigger the pyroptosis after inflammasome activation. In addition, the expression of 
alternative inflammasome complexes by both cell types is, until now, largely under 
investigated. In respect with these observations, the first part of this work will be to 
characterize the detailed in vitro capacities of murine microglia and astrocytes in term of 
inflammasome expression, activation and regulation. 
 
In the second part of the project, we will focus our attention on the implication of the 
inflammasome in Parkinson’s disease. For this purpose, we will first test the reactivity of 
the glial inflammasome to products-related to neurodegenerative diseases in vitro. Then, 
we will study the effect of the NLRP3 deficiency on the neurodegenerative process 
occurring during PD, via an in vivo 6-hydroxydopamine (6-OHDA) PD model. 
 
A summarized view of these objectives  is depicted in the figure 16. 
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Fig. 16: Aims of the work. 
Aim 1: Characterization of inflammasome components expression and regulation in mouse astrocyte and microglia. Aim 2: 
Study of the implication of inflammasome in Parkinson’s disease. 
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1. Mice 
 
1.1 Mice strains 
 
C57BL/6JOlaHsd mice (WT) were from Harlan (The Netherlands). Nlrp3-/- mice were 
provided by the University of Lausanne (Martinon, 2002). Casp1-/-/Casp11-/- (hereafter 
referred to as Casp1-/-) and P2rx7-/- mice were obtained from The Jackson Laboratory (Bar 
Harbor, USA) (see Table 4). All mouse strains were housed and bred in our animal house 
facility approved by the National Veterinary Inspection. The cages were maintained 
around 22°C with a 12:12 hour light:dark cycle and food and water were available ad 
libitum. All animal stabulation/procedures were conducted in accordance with European 
regulations. 
 
Table 4. Knockout mice information. 
Common name Strain name Background Origin 
Nlrp3-/-  / C57BL/6JOla University of Lausanne 
Casp1-/-/11-/-  B6.129S2Casp1tm1Flv/J C57BL/6NJ Jackson Laboratory (# 016621) 
P2rx7-/-  B6.129P2P2rx7tm1Gab/J C57BL/6J Jackson Laboratory (# 005576) 
 
1.2 Genotyping 
 
DNA was extracted from mouse tail biopsies digested with 20 mg/mL proteinase K 
(Invitrogen) in Direct PCR buffer (Viagen Biotech, USA). After a 5 h incubation at 55°C 
under orbital shaking (550 rpm), the proteinase K was inactivated by heating the sample 
at 85°C during 45 min. The presence of each gene of interest was detected by performing 
a polymerase chain reaction (PCR). The primer sequences used for each strain are 
summarized in Table 5.  
 
Table 5. Primer sequences for genotyping. 
Mice Primer sequences 
Nlrp3-/-  Forward: 5’ -TCAAGCTAAGAGAACTTTCTG-3’  
Reverse: 5’-ACACTCGTCATCTTCAGCA-3’ 
Reverse (EGFP cassette): 5’-AAGTCGTGCTGCTTCATGT-3’ 
Casp1-/- /11-/- Reverse: 5‘-GAGACATATAAGGGAGAAGGG–3' 
Forward (WT): 5’-GAGACATATAAGGGAGAAGGG-3' 
Forward (KO): 5’-TGCTAAAGCGCATGCTCCAGACTG-3' 
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P2rx7-/- Reverse (WT): 5’-TGGACTTCTCCGACCTGTCT-3’ 
Forward (WT): 5’-TGGCATAGCACCTGTAAGCA-3’ 
Reverse (KO): 5’-CTTGGGTGGAGAGGCTATTC-3’ 
Forward (KO): 5’-AGGTGAGATGACAGGAGATC-3’ 
 
Subsequently, the PCR samples were migrated on a 1.2% agarose gel (E-gel 
double comb 1.2% agarose, Invitrogen). The presence of amplicon bands were revealed 
on a ChemiDoc MP system and its ImageLab software (BioRad, Belgium), as shown in 
the example presented in figure 17. 
 
 
Fig. 17: Genotyping of Nlrp3 +/+, Nlrp3 -/-, Nlrp3 -/+.mice. 
 
2. Cell cultures 
 
2.1 Mouse primary cultures 
 
2.1.1 Mixed glial cell cultures 
 
Mixed glial cell cultures (MGC P0) were prepared from newborn C57BL/6 mice 
brains (Fig. 18 ; Losciuto et al, 2012). Briefly, after removing meninges, large blood 
vessels and the diencephalon, the brains were pooled and minced in cold phosphate-
buffered saline (PBS, Sigma, Diegem, Belgium) solution by mechanical dissociation. Cell 
suspensions were centrifuged (10 min, 1100 rpm, 4°C), washed and plated in Dulbecco’s 
Modified Eagle Medium (DMEM, Sigma) supplemented with 10% fetal bovine serum 
(FBS, Life Technologies), 100 U/mL penicillin and 100 U/mL streptomycin (Lonza, 
Verviers, Belgium) at 37°C, in a humidified atmosphere containing 5% CO2. The culture 
medium was changed after three days and new fresh medium was added after 10 days. 
Mixed glial cultures had reached confluence after 2 weeks and were ready for passage or 
purification. 
MATERIALS AND METHODS 
 
 49 
 
Fig. 18. Workflow for glial primary cultures achievement. 
 
2.1.2 Microglial cultures 
 
Microglia were positively sorted out from MGC P0 by the MACS (Magnetic Cell 
Sorting) technique (see Fig. 18). Before to start, the supernatant of MGC P0 cultures was 
collected to be further used as “mixed glial cell culture conditioned medium”. Then, cells 
were washed with PBS and subsequently incubated with Trypsin/EDTA 
(Ethylenediaminetetraacetic acid) for 5 min at 37°C. After trypsin inactivation by FBS, cells 
were collected and centrifuged at 1100 rpm during 10 min. Then, the cells were washed 
by adding 10 mL of MACS buffer (PBS, 2 mM EDTA, 0.5% BSA ; all from Sigma) and 
counted. After an additional centrifugation step, the cells were resuspended in 90 μL of 
MACS buffer per 107 cells and complemented with anti-CD11b antibody coated magnetic 
nanoparticules, following the manufacturer’s instructions (10 µl /107 cells, Miltenyi Biotec). 
CD11b is widely used as marker for microglial identification. Following 20 minutes of 
incubation at 4°C, the cells were washed again with 2 mL of buffer by 107 cells. After a 
final centrifugation step, the cells were resuspended in 500 µl of buffer and transferred on 
a LS column (Miltenyi Biotec) placed in a strong magnetic field (MidiMACS magnetic 
separation unit, Miltenyi Biotech). CD11b expressing microglia were trapped in the column 
due to their binding to magnetic nanoparticules. The remaining cells flowed through the 
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column and were harvested to constitute astrocyte-enriched cultures (see section 2.1.3.1). 
Afterwards, microglia were harvested by removing the column from the magnetic field and 
flushing it with 5 mL of MACS buffer. The cell suspension was centrifuged at 1100 rpm 
during 10 min and resuspended in DMEM supplemented with 20% of “mixed glial culture 
conditioned medium” and plated at a density of 2000 cells/mm² in MW96 plates and 
1300 cells/mm² in MW6 plates. Microglia were treated twenty-four hours later. 
 
2.1.3 Astrocyte cultures 
 
2.1.3.1. Primary astrocytes 
 
Astrocytes were negatively sorted during the MACS procedure dedicated to the 
microglia isolation and described above (Losciuto et al, 2012). The obtained 
“astrocyte-enriched cultures” (AEC-M1) were plated in complete medium (DMEM 
containing 10% FBS and 1% antibiotics) in 75 cm2 flasks. After 3 days, medium was 
renewed and after seven days cultures reached confluence. At this time, the MACS 
procedure was repeated in order to reduce the microglial contamination of the astrocyte 
population. Cells were plated at a density of 800 cells/mm² in MW6 plates and were ready 
to use 7 days later. 
 
2.1.3.2. Neurosphere-derived astrocytes 
 
Neurospheres were obtained from embryonic murine NSCs derived from the 
ventricular zone of C57BL/6 mouse embryos at E14, as described previously (Grandbarbe 
et al, 2003; Crocker et al, 2008).  
Neurospheres were cultured in Neurobasal medium supplemented with 2mM glutamine, 
penicillin (100 U/mL), streptomycin (100 U/mL), mouse recombinant Epidermal Growth 
Factor (EGF, 20 ng/mL) and 2% B27 without Vitamin A (All from Invitrogen, Belgium). 
Neurospheres were plated in 75 cm² flasks. After 4-7 days of proliferation, cells were 
dissociated with an enzyme-free cell dissociation buffer (Invitrogen), and reseeded as a 
single cell suspension after a 1:2 dilution. 
Neurospheres were differentiated into astrocytes as previously described (Crocker 
et al, 2008). Briefly, non-dissociated neurospheres were plated on poly-L-ornithine 
(Sigma) coated multiwell plates. The cells were grown in DMEM containing 10% FBS with 
1% Penicillin-Streptomycin (Invitrogen) until they reached confluence. The medium was 
renewed after 1, 2 and 7 days of differentiation and then, once a week. Mature astrocytes 
were submitted to treatment after 8 weeks of differentiation. 
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2.1.5. Bone marrow-derived macrophages (BMDM) 
 
Bone marrow-derived macrophages (BMDM) were generated as previously 
described (Guarda et al, 2009). Bone marrow cells were isolated from tibia and femur of 
mice. To differentiate the cells into macrophages, primary bone marrow cells were 
cultured for 6 days in DMEM supplemented with 100 U/mL penicillin, 100 U/mL 
streptomycin, 10% FBS and 30% of L929 cells conditioned medium providing M-CSF 
(Macrophages colony-stimulating factor) among other factors. Cells were plated at a 
density of 2000 cells/mm² in MW96 plates and 1300 cells/mm² in MW6 plates. 
 
2.2 Cell lines 
   
2.2.1. MMGT12 
 
MMGT12 are a murine cell line and are a subclone of the MMGT1, a murine cell line 
established after transfection of primary microglial cell cultures with a v-myc-containing 
plasmid. MMGT12 were provided by Dr. Vanmechelen (Innogenetics, Belgium; Briers et 
al, 1994). Cells were cultured in DMEM/F12 (Life Technologies) supplemented with 2% 
FBS, 1% Insulin-Transferrin-Selenium (ITS, Life Technologies) and 15% filtered WEHI 
conditioned medium (WEHI 3, WEHI3B and WEHI 3D, producers of interleukin-3 and 
granulocyte-macrophage-colony stimulating factor). Cells were passaged twice a week by 
mechanical dissociation (scrapping). For the experiments, MMGT12 cells were seeded at 
a concentration 1000 cells/mm² in MW6 plates and cultured in DMEM/F12 supplemented 
with 10% FBS and 1% ITS. 
 
2.2.2. BV2 
 
BV-2 cells were derived from raf/myc-immortalised murine neonatal microglia and 
were provided by Prof. Blasi (University Medical School, Perugia, Italy ; Blasi et al, 1990). 
Cells were maintained in DMEM with 10% FBS and passaged twice per week after 
mechanical dissociation (scrapping). For the experiments, cells were plated on 
poly-L-lysine coated-plate, at a density of 1200 cells/mm² in MW96 and grown in DMEM 
with 5% FBS. Any antibiotic was added to the medium. 
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2.3 Reagents 
 
2.3.1 Pro-inflammatory agents 
 
Cells were primed for 6 h or 24 h with ultrapure liposaccharide (LPS, 10 ng/mL), 
Pam3CSK4 (10 ng/mL) (both from Invivogen, Toulouse, France) or cytokines IL-1β 
(10 ng/mL), TNFα (10 ng/mL) or IFNγ (20 ng/mL) (all from R&D, Abingdon, UK), alone or 
in combination in case of the Complete Cytokine Mix (CCM: 10 ng/mL IL-1β, 10 ng/mL 
TNFα and 20 ng/mL IFNγ). 
 
2.3.2 Inflammasome activators  
 
Classical inflammasome activation was performed by Adenosine 5’-triphosphate 
(ATP, 1 mM, 30 min, Sigma). Other inflammasome activators used were Nigericin (1.34 
M, 2 h, Sigma), Aluminium hydroxide (100 μg/mL, 5 h, Pierce) or Ultra-pure flagellin (2.5 
µg/mL, 5 h, Invivogen). Poly(dA:dT) (Invivogen) and highly concentrated ultrapure LPS 
(Invivogen) were delivered to the cytoplasm by transfection with Lipofectamine 2000 (Life 
technologies). Briefly, activators were mixed with lipofectamine in Opti-MEM medium 
during 5 min at room temperature. After the incubation, the mix was added to the wells at 
a final concentration of 2.5 µg/mL for poly(dA:dT), 1 µg/mL for LPS and 10 μg/mL for 
Lipofectamine. The cells were then incubated during 5 h poly(dA:dT) and 16 h for LPS. 
 
2.3.3 Others activators 
 
The amyloid beta peptide 25-35 (Aβ25-35), its reverse form Aβ35-25 and rotenone (all 
from Sigma) were used as indicated in the figure legends. 
Aβ1-42 peptide (from Sigma or Anaspec, Fremont, Canada or Bachem, Weil am Rhein, 
Germany) was resuspended following manufacturer’s instructions, aliquoted and stored at 
-20°C. The fibrillar form was obtained by heating a 1:10 dilution (DMEM) of the peptides at 
37°C during 7 days. 
WT and A53T mutant α-synuclein were purchased from rPeptide (Bogart, USA). Aliquots 
were resuspended in H2O to obtain a 100 µM solution. For an activation by oligomeric 
α-synuclein, the preparation was used directly. To obtain a fibrillar α-synuclein 
preparation, oligomeric form was diluted twice with Tris-HCl buffer and then incubated for 
4 days at 57°C with shaking. 
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The fibrillar Aβ and α-synuclein preparations were characterized by western blotting (see 
section 3.3) using 6E10 anti-Aβ antibody (Eurogentec SIG-39320, Belgium) and 4D6 
anti-α-synuclein antibody (Abcam, ab1903). 
Nucleotides (ATP, ADP and Adenosine) were purchased from Sigma and used at 
1 mM during 30 min to 6 h. The ATP contamination was controlled by the ATP 
Determination Kit (Life Technologies).  
All these products have been tested for endotoxin contamination using the LAL 
PYROGENTTM Plus Single Test Vials (Lonza). 
 
2.3.4. Inhibitors 
 
The following molecules have been tested to inhibit the inflammasome activation: 
Potassium Chloride (KCl; 130, 75 or 25 mM), N-acetyl-L-cysteine (NAC, 5mM, antioxidant) 
and Cytochalasin D (cytoD, 2µM, inhibitor of actin polymerization) (all from Sigma) but 
also (L-3-trans-(Propylcarbamoyl)oxirane-2- Carbonyl)-L-Isoleucyl-L-Proline Methyl Ester 
(CA074-Me, 10 μM, inhibitor of cathepsin B, PeptANOVA). All inhibitors were added 30 
min before the inflammasome activation except KCl which, was added in the same time 
than LPS priming. 
Z-YVAD-FMK, a specific caspase-1 inhibitor (SantaCruz, Heidelberg, Germany) had also 
been used at a concentration of 20 μM and was added 15 min prior priming step. 
3. Analytical techniques 
 
3.1 Cell death/viability measurement 
 
3.1.1 MTT assay 
 
Cell viability was assessed after treatment by the mitochondria-dependent reduction 
of Thiazolyl Blue Tetrazolium Bromide (MTT) assay (Mosmann, 1983). MTT assay is 
based on the MTT (Sigma) reduction into the water-insoluble formazan by mitochondrial 
succinate dehydrogenase. Since the reduction of MTT can only occur in metabolically 
active cells, its measure reflects the viability of the cells. After treatment, cells were 
incubated with a 5 mg/mL MTT solution diluted 1:10 in DMEM during 30 min to 4 h, at 
37°C. Then, medium was removed and the formazan was solubilized by 10 min incubation 
in DMSO at 37°C. The absorbance was read at 540 nm using a microplate reader 
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(TECAN, Austria). The viability was estimated by comparison to untreated cells (100% 
viability). 
3.1.2 Lactate dehydrogenase release assay 
 
Cell death and cell lysis were quantified by the colorimetric assay based on 
measurement of lactate dehydrogenase (LDH) released into the cell supernatant. LDH is 
a stable cytoplasmic enzyme released in case of membrane damage. Quantity of LDH in 
supernatant was determined following the assay protocol of Cytotoxicity Assay kit 
(Roche). Briefly, cells were submitted to treatment of interest or to medium containing 2% 
Triton 100x, which induced 100% of cell lysis. The cell-free culture supernatant were 
collected and incubated with the commercial reaction mixture (freshly prepared; 25 μL of 
solution 1 + 1.125mL of solution 2), during 30 min. The absorbance was read at 490 nm 
with a microplate reader. The determination of the cytotoxicity was calculated by 
comparison to untreated cells (= low control) and lysed cells (high control). 
 
                 
                     
                        
      
 
3.2 Real-Time PCR gene expression analysis 
 
3.2.1 Total RNA extraction and quantification 
 
Total RNA was isolated using the InvisorbTM Spin Cell RNA mini Kit (Invitek) or 
InnuPREP RNA mini Kit (Analytik Jena AG, Jena, Germany) according to the 
manufacturer’s protocol. Briefly, cell lysates were loaded on a first column to remove 
DNA. The filtrate was mixed with a 70% ethanol solution and loaded on a second column. 
After two washing steps with provided buffer, RNA was eluted with H2O. RNA samples 
were then stored at -80°C. 
Total RNA concentration was quantified by reading the absorbance at 260 nm of 
each sample using a Nanodrop 2000 spectrophotometer (Thermo Scientific). The sample 
contamination by protein, phenol or other contaminants was estimated by the absorbance 
ratio 260/280 that should be greater than 2. 
 
3.2.2 Reverse transcription  
 
Complementary DNA (cDNA) was synthetized from RNA samples using the 
ImProm-II Reverse Transcription System (Promega, Leiden, The Netherlands). Two mixes 
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were prepared (see Table 6): the primer-sample mix and the reverse transcription mix. 
The secondary structures of RNAs were denaturated by heating the primer-sample mix at 
70°C for 5 min followed by a flash cooling step on ice. Then, the two mixes were pooled 
together to obtain a final volume of 40 μL. Samples were then incubated for 5 min at 25°C 
(annealing), 1 h at 42°C (extension) and 15 min at 70°C (reverse transcriptase 
inactivation) and subsequently stored at -20°C until use. 
 
Table 6. Reverse transcription mixes. 
Primers sample mix  Reverse transcription mix 
Oligo(dT) 1µl  ImProm-II 5x Reaction buffer 8µl 
Total RNA 0,1µg to 2µg  MgCl2 (25mM) 6µl 
Nuclease free water qs 10µl  dNTP mix (10mM) 2µl 
Final volume 10µl  Recombinant RNAsin Ribonuclease inhibitor 1µl 
   ImProm-II reverse transcriptase 2µl 
   Nuclease free H2O 11µl 
   Final volume 30µl 
 
3.2.3 Real-time polymerase chain reaction 
 
Gene expression was analysed using Bio-Rad Thermal Cyclers (iQ5 and CFX Real-
Time PCR Detection System, Bio-Rad Laboratories) with SYBR Green Supermix 
(Promega). Expression was normalized to the housekeeping genes (Rpl27). Primer 
sequences were designed using the Beacon Designer Software (Bio-Rad) and are listed 
in Table 7. Analysis of gene expression was performed using the comparative 2-dCt 
method:  
 
dCt = (Ct, target – Ct, Rpl27)     2-dCt = Relative expression  
 
Table 7. Mouse primers sequences. 
Gene Accession number Sequences 
Aif1 NM_019467 F: 5’-TTCCCAAGACCCACCTAG-3’ 
R: 5'-TCCTCATACATCAGAATCATTC-3’ 
Aim2 NM_001013779 F: 5’-ATAGGAGGAACAACAACAT-3’ 
R: 5'-GCCATCTTCTGCTACATA-3’ 
Casp1 NM_009807 F: 5’-AGGAATTCTGGAGCTTCAATCAG-3’ 
R: 5'-TGGAAATGTGCCATCTTCTTT-3’ 
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Casp4 NM_007609 F: 5’-GCTCTTACTTCATCACTA-3’ 
R: 5'-AATATCTCGTCAAGGTTG-3’ 
Cxcl10 NM_021274 F: 5’-TTCTGCCTCATCCTGCTG-3’ 
R: 5'-AGACATCTCTGCTCATCATTC-3’ 
Gfap NM_010277 F: 5’-GGTTGAATCGCTGGAGGAG-3’ 
R: 5'-CTGTGAGGTCTGGCTTGG 
Hmgb1  NM_010439 F: 5’-TGGCAAAGGCTGACAAGGCTC-3’ 
R: 5'-GGATGCTCGCCTTTGATTTTGG-3’ 
Il18 NM_008360 F: 5’-ACCAAGTTCTCTTCGTTGAC-3’ 
R: 5'-TCACAGCCAGTCCTCTTAC-3’ 
Il1a NM_10554 F: 5'-GTATCAACTCTAAGAACTACT-3’  
R: 5'-ATATCTGGAAGTCTGTCATA -3’ 
Il6 NM_031168 F: 5'-ACCGCTATGAAGTTCCTCTC-3’ 
R: 5'-CTCTGTGAAGTCTCCTCTCC-3’ 
Itgam NM_008401 F: 5’-TGGACGCTGATGGCAATACC-3’ 
R: 5'-GGCAAGGGACACACTGACAC-3’ 
Nlrc4 NM_001033367 F: 5'-GTCAAGTGTTATCCAAGTTA-3’ 
R: 5'-CGCTAATATCATAGTCATCAA-3’ 
Nlrp1 NM_001004142 F: 5'-GGTGTGCTGGTTGGTCTGC-3’ 
R: 5'-GTGCTGTGGTGGTCTGTGAG-3’ 
Nlrp12 NM_001033431 F: 5'-AAGAGATGAGATGCTACCTTGAGAG-3’ 
R: 5'-ATGCCAACACTTCCTCCTTCAC-3’ 
Nlrp2 NM_177690 F: 5'-AAGCCTGTAGAGGTCTTACTG-3’ 
R: 5'-ACTGTGTCCGTGTGGTTAC-3’ 
Nlrp3 NM_145827 F: 5'-GCTCCAACCATTCTCTGACC-3’ 
R: 5'-AAGTAAGGCCGGAATTCACC-3’ 
Nlrp6 NM_001081389 F: 5'-GGACGAGAGGAAGGCAGAG-3’ 
R: 5'-GCACACGAAGGGCACAAAG-3’ 
Nos2 NM_010927 F: 5'-AGCCCTCACCTACTTCCTG-3’ 
R: 5'CAATCTCTGCCTATCCGTCTC-3’ 
Ptgs2 NM_011198 F: 5’-GCCTGGTCTGATGATGTATGC-3’ 
R: 5'-GAGTATGAGTCTGCTGGTTTGG-3’ 
Pycard NM_023258 F: 5’-AGGAGTGGAGGGGAAAGC-3’ 
R: 5'-AGAAGACGCAGGAAGATGG-3’ 
Rpl27 NM_011289 F: 5'-ACATTGACGATGGCACCTC-3’ 
R: 5'-GCTTGGCGATCTTCTTCTTG-3’ 
Tlr4 NM_021297 F: 5'-TTCACCTCTGCCTTCACTAC-3’ 
R: 5'-CACTACCACAATAACCTTCCG-3’ 
Tnf NM_013693 F: 5'-GGTTCTGTCCCTTTCACTCAC-3’ 
R: 5'-TGCCTCTTCTGCCAGTTCC-3’ 
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3.3 Immunoblotting 
 
3.3.1 Protein extraction 
 
Cell extracts were harvested after direct cell lysis by 100μL of SB3x buffer 
(187.5 mM Tris-HCl, 6% w/v SDS, 0,012% w/v bromophenol blue, 30% w/v glycerol and 
50 mM DTT (dithiothreitol, added freshly), pH 6.8). 
Proteins from supernatant were precipitated following a Chloroform-Methanol 
precipitation protocol (Wessel, 1984). Briefly, supernatants were collected, centrifuged 
and mixed with 1:1 methanol and 1:5 chloroform. After centrifugation (13 000 rpm, 5 min), 
the upper aqueous phase was removed and 1:1 methanol was added. Samples were 
newly centrifuged (13 000 rpm, 5 min), and the liquid phase discarded. The pellets were 
resuspended in 60 μL of SB3x buffer.  
All protein samples were denaturated by a heating step (95°C for 5 min) and then 
stored at -20°C. 
 
3.3.2 Western Blot 
 
Cell lysates were separated by a denaturing SDS-PAGE (Sodium Dodecyl Sulfate 
Polyacrylamide Gel Electrophoresis). The samples were migrated at 100 V during 120 min 
(47 mA). The proteins were transferred onto a nitrocellulose membrane at 400 mA during 
50 min (5-7 V). To avoid aspecific protein interactions, the membranes were blocked with 
a 3% milk PBS-0.1% Tween solution during 1 hour, at room temperature. The blots were 
then incubated overnight (4°C) with a specific primary antibody diluted in blocking buffer 
(see Table 8). The next day, the membranes were washed with PBS-0.1% Tween solution 
and subsequently incubated with Horseradish Peroxidase (HRP)-linked secondary 
antibody for 2 hours at room temperature. After washing, the presence of labelled protein 
bands was revealed with the SuperSignal West Femto Chemiluminescence Substrate 
(Life Technologies) and the pictures were acquired on the Bio-Rad ChemiDoc XRS 
Imager and its Image Lab Software (Bio-Rad Laboratories). 
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Table 8. Immunoblotting antibodies. 
Primary antibody Host Dilution  Origin 
Anti-ASC Rabbit 1:1000 AdipoGen (AG_25B-0006) 
Anti-Caspase-1 Mouse 1:1000 AdipoGen (AG-20B-0042) 
Anti-HMGB1 Rabbit 1:1000 Abcam (Ab18256) 
Anti-IL-1α Goat 1:500 R&D systems (AF-400-NA) 
Anti-IL-1β Goat 1:500 R&D systems (AF-401-NA) 
Anti-NLRP3 Mouse 1:1000 AdipoGen (AG-20B-0014) 
Anti-α-tubulin Mouse 1:1000 Abcam (Ab7291) 
 
Secondary antibody Host Dilution  Origin 
HRP-conjugated anti-rabbit Donkey 1:5000 Amersham (NA934) 
HRP-conjugated anti-mouse Sheep 1:2000 Amersham (NA931) 
HRP-conjugated anti-goat Bovine 1:1000 Jackson ImmunoResearch (205-035-108) 
 
 
3.4 Immunocytochemistry 
 
Cells dedicated to an immunocytochemistry analysis were cultured on poly-L-lysine 
coated coverslips, stimulated and then fixed with paraformaldehyde (4% in PBS) for 20 
min. After 3 washing steps with PBS (5 min), the cells were permeabilized during 5 min in 
PBS containing 0.3% Triton X-100 (Sigma). The blocking step was done during 30 min 
using a PBS solution containing 3% BSA (Bovine Serum Albumin, buffer is named BSA 
buffer) (Sigma). A double immunostaining was performed by simultaneously incubating 
the coverslips with primary antibodies of interest overnight at 4°C. The used primary 
antibodies are listed in Table 9. After 3 additional washing steps in PBS (5 min each), the 
cells were incubated with the secondary antibodies during 2 h at room temperature (for 
dilutions in BSA buffer, see Table 9). Cells were then washed and mounted with DAPI-
Fluoromount G (SouthernBiotech, USA). The picture acquisition was performed with a 
LSM 510 META inverted confocal microscope (Carl Zeiss Micro Imaging, Göttingen, 
Germany). 
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Table 9. Immunocytochemistry antibodies. 
Primary antibody Host Dilution  Origin 
Anti-Iba1 Rabbit 1:200 Biocare medical (CP290) 
Cy3-labelled anti-GFAP Mouse 1:800 Sigma (C9205) 
 
Secondary antibody Host Dilution  Origin 
Alexa-Fluor 555 anti-rabbit Donkey 1:1000 Life Technologies (A-31572) 
 
3.5 Protein release quantification 
 
 
3.5.1 IL-1α, IL-1β, IL-18, TNFα, HMGB1 and CXCL10 quantification. 
 
After treatment, cell culture supernatants were harvested and assayed for the 
presence of IL-1α, IL-1β, TNFα and CXCL10 by Enzyme Immunoassay’s according to the 
manufacturer’s instructions. Briefly, 96-well microplates (NUNC immuno plate Maxisorb, 
Thermo Scientific) were coated overnight with the appropriate “Capture antibody”. On the 
next day, the plates were washed and incubated with a blocking buffer (specific to each 
ELISA). After 1 h and additional washing steps, the samples and standards were 
incubated in the capture antibody-coated plates for 2 h. Then, after additional washing 
steps, a biotinylated “Detection antibody” recognizing the protein of interest was incubated 
for 2 h. Exceeding antibodies were removed by several washing steps and 
peroxidase˗conjugated streptavidin was added in each wells for 20 min. The incubation of 
the peroxidase with its substrate produced a colorimetric reaction. After 20 min of 
incubation, the reaction was stopped by adding sulfuric acid. The absorbance was 
measured at 450 nm with a reference wavelength of 540 nm using an absorbance 
microplate reader. A standard curve was generated by plotting the optical density of 
standards. On this base, the sample optical density values were converted into 
concentrations.  
The IL-18 and HMGB1 ELISA kits used the same principle than exposed before. 
However, IL-18 ELISA kit contains a 96-wells microplate already coated with two 
monoclonal antibodies against two different epitopes of IL-18. In the case of HMGB1 
quantification, the wells of the provided microtiter strips were already coated with purified 
anti-HMGB1 antibody and the detection antibody was directly bind to peroxidase, 
suppressing one step of the previous protocol. 
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Table 10. Enzyme linked Immunobsorbent assay’s list. 
Target Kit name Reference Origin 
IL-1β Mouse IL-1 beta/IL-1F2 DuoSet DY401 R&D systems 
IL-1α Mouse IL-1 alpha/IL-1F1 DuoSet DY400 R&D systems 
IL-18 Mouse IL-18 ELISA Kit 7625 MBL 
CXCL10 Mouse CXCL10/IP-10/CRG-2 DuoSet DY466 R&D systems 
TNFα Mouse TNF-alpha DuoSet DY410 R&D systems 
HMGB1 Mouse HMGB1 ELISA ST51011 IBL international 
 
3.5.2 PGE2 quantification 
 
The PGE2 EIA kit (ADI-900-001, Enzo Life Sciences) is a competitive 
immunoassay.  
In a MW96 plate, 50 μL of cell supernatant were added to 50 μL of “PGE enzyme 
conjugate”. The plate was then shaking at 500 rpm during 2 h. After washing, 150 μL of 
substrate solution were added for 30 min. Then, the reaction was stopped by adding of 
50 L of trisodium phosphate solution to each well. The absorbance was immediately 
measured at 405 nm using a microplate reader (TECAN). Sample concentrations were 
determined with a PGE2 standard curve. 
 
4. 6-OHDA Parkinson’s disease mouse model 
 
The 6-hydroxydopamine (6-OHDA) is an organic compound derived from dopamine 
by addition of a 6-hydroxyl group (Fig. 19). It is known to be neurotoxic as it selectively 
causes the death of the dopaminergic and noradrenergic neurons. 6-OHDA enters into 
neurons via the dopamine reuptake transporter. Once in the cytosol, 6-OHDA (or its 
metabolite) induces an oxidative stress resulting in dopaminergic neuron cell death. The 
administration of 6-OHDA into the striatum cause a retrograde degeneration of 
dopaminergic neurons within the substantia nigra (Schober, 2004; Dooley et al, 2012).  
 
                 
Fig. 19. Dopamine and 6-hydroxydopamine structures. 
Dopamine (DA) 6-OHDA 
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4.1 Reagents and Solutions 
 
The 6-OHDA solution was prepared under sterile conditions at a final concentration 
of 2 μg/μL. To this end, an ascorbic acid solution was prepared by dissolving 2 mg of 
ascorbic acid (Sigma) in 10 mL of 0.9% saline solution. 10 mg of 6-OHDA hydrochloride 
(Sigma) was dissolved in 4 mL of the ascorbic acid solution to obtain a 2 μg/μL solution. 
The 6-OHDA and vehicle (ascorbic acid) solutions were sterilized through a 0.22 μm filter. 
As 6-OHDA oxidized rapidly, the solutions were aliquoted into 100 µl tubes, stored on ice, 
protected from light and were always freshly prepared. 
 
4.2 Surgery 
 
12 weeks (for transcripts analysis) or 18 weeks old (for immunohistochemistry) 
wild-type and Nlrp3-/- mice were used. Mouse anaesthesia was induced under 3% 
isoflurane. Mice were then transferred into the stereotaxic frame (Kopf) and the skin was 
incised with a scalpel. After revelation of sutures by a 3% H2O2 solution, the skull was 
pierced with a 0.7 mm drill at following coordinates: ML: +2.3 mm; AP: +0.5 mm. The 
needle of the Hamilton syringe, previously loaded with either the vehicle or the 6-OHDA 
solution, was introduced down into the striatum, to the +3.3 mm dorso-ventral (DV) 
coordinates for 10 seconds and then withdrawn back to +3.2 mm DV (Fig. 20).  
 
 
Fig. 20. Theoretical coordinates for the injection site. From Franklin and Paxinos, 2007. 
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After 2 min, 6-OHDA or vehicle was injected at a rate of 2 μL/5 min. After 2 additional 
minutes, the needle was withdrawn, the skull hole sealed with bone wax and the wound 
clipped. In order to avoid any post-operative pain we locally administered 2% lidocaine gel 
onto the wound (Astra Zeneca 2% Xylocaine gel). After the surgical procedure, the mice 
were housed at 2 animals per cage and monitored during the following days. 
 
4.3 Sacrifice and brain sampling 
 
Prior perfusion, the anesthetic solution was prepared by mixing 550 μL of ketamine 
solution (Nimatek 100 mg/mL) together with 323.4 μL of Dorbene Vet (1mg/mL) and 2.2 
mL of PBS. The mice were anesthetized with a 200 µL intra-peritoneal injection. Once 
sedated, the skin was incised below the sternum and after cutting, the heart and liver were 
exposed. A 25 gauge needle was introduced into the left ventricle and after the PBS flow 
was turned on, the right atrium was incised. After 7 minutes, the brain was extracted and 
processed according to the following analyses.  
 
4.4 Immunohistochemistry 
 
4.4.1 Brain fixation 
 
After extraction, the brain was placed into a 50 mL falcon tube containing 7.5 mL of 
a 4% formaldehyde solution and cooled at +4°C. After 2 days of fixation, the brains were 
washed 3 times in PBS and stored in a 0.02% PBS–azide solution at +4°C. 
 
4.4.2 Brain sections 
 
Thick sections (40μm) were realized on a Leica VT1000S vibratome. The brain was cut 
into two hemispheres, which were glued onto the object holder with cyanoacrylate 
adhesive. The dorsal parts of both hemispheres (cortices) were oriented toward the razor 
blade. The buffer tray was filled with PBS and the cutting speed as well as the frequency 
set to 5. The first 1 mm of the brain were cut into 100 μm thick slices and discarded. After 
discarding two additional 40 μm thick sections, the further sections (40 μm) were serially 
collected into eight 2 mL tubes containing 1.8 mL of cryoprotective medium (PBS – 
Ethylene glycol V/V supplemented with 1% PVP40). The tubes were stored at -20°C until 
use for immunohistochemical analysis. 
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4.4.3 Floating sections immunohistochemistry 
 
The free-floating sections were first removed from the cryoprotective medium and washed 
twice with PBS containing 0.1% Triton X-100. Next, the permeabilization was performed 
by a 20 min incubation in PBS with 3% H202 and 1% Triton X-100. Once again, sections 
were washed twice and incubated during 1 h in PBS with 0.1% triton X-100 and 5% BSA. 
After new washing steps, slices were incubated overnight with primary antibodies (see 
Table 11) diluted in PBS with 0.1% triton X-100 and 0.5% BSA. On the next day, slices 
were newly washed and then incubated for 90 min, at room temperature and under 
shaking, with the secondary antibodies (see Table 11) diluted in PBS containing 0.1% 
Triton X-100 and 0.5% BSA. Then, sections were washed 10 min and stained with DAPI 
(Molecular probes, The Netherlands) diluted 1:5000 in PBS containing 0.1% Triton X-100 
to label the nuclear DNA. Finally, after twice washing steps, slices were transferred into 
TBS (pH 7.4) before being mounted onto slides with fluoromount-G (Southern Biotech). 
 
Table 11. Immunohistochemistry antibodies. 
Primary antibody Host Dilution  Origin 
Anti-Iba1 Rabbit 1:2000 Wako (019-19741) 
Anti-CD68 Rat 1:2500 AbDserotec (MCA1957) 
Anti-GFAP Mouse 1:2000 Cell Signalling (3670S) 
Anti-TH Rabbit 1:2000 Millipore (AB152) 
    
Secondary antibody Host Dilution  Origin 
Alexa-Fluor 488 anti-rat Goat 1:1000 Life Technologies (A11006) 
Alexa-Fluor 647 anti-rabbit Donkey 1:1000 Life Technologies (A31573) 
Cy3 anti-rat Donkey 1:2000 Jackson ImmunoResearch (712-165-153) 
Cy3 anti-mouse Donkey 1:2000 Jackson ImmunoResearch (715-165-151) 
 
4.4.4 Picture acquisition and analysis 
 
Pictures were acquired by using a LSM 510 META inverted confocal microscope 
(Carl Zeiss Micro Imaging, Göttingen, Germany). Striatum and midbrain pictures were 
acquired with 20x and 10x objectives respectively. For each animal, the striatum was 
analysed at 4 different medio-lateral levels (3, 2.7, 2.4 and 2.1 mm from midline) and the 
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midbrain at 5 different medio-lateral levels (1.8, 1.64, 1.48, 1.32, and 1.16). After 
acquisition, the pictures were imported in the ImageJ software and binarized. The regions 
of interest were delimited and the stained surface measured. For each hemisphere the 
integrated value were used for the subsequent analysis (sum of 4 values for the striatum 
or 5 values for the midbrain). 
 
4.5 Transcript analysis 
 
4.5.1 Sampling 
 
Once removed, the brain was dissected in order to recover the midbrain and 
striatum regions. These biopsies were immediately dry frozen at -80°C until the RNA 
extraction. 
 
4.5.2 RNA extraction 
 
Total RNA were extracted following a phenol-chloroform protocol using RNA NOW 
reagent (Biogentex, Seabrook, USA), according to the manufacturer’s protocol. Briefly, 
tissues were mechanically lysed and homogenized in the RNA NOW solution. After 
addition of chloroform, samples were frozen overnight at -80°C. Following defrosting and 
centrifugation, the homogenate layers were into two phases. The upper phase, containing 
RNA, was carefully collected and transferred to a new tube. Then, isopropanol was added 
to the samples, which were subsequently placed overnight at -80°C. The next step 
consisted in a centrifugation in order to obtain RNA precipitated pellets. After 2 ethanol 
washing steps, pellets were air dried and finally dissolved in water. 
 
4.5.3 Quantification, Reverse Transcription and RT-PCR 
 
Please refer to the section 3.2. 
 
5. Statistical analysis 
 
The significance of multiple treatments was analysed by a non-parametric analysis 
of variance Kruskal–Wallis test followed by Dunn’s multiple comparisons test or by a 
parametric One-way analysis of variance (ANOVA) followed by Dunnett’s multiple 
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comparisons tests.  
ANOVA on gene expression was performed on the delta-Ct values (Ctgene of interest -  
Cthousekeeping gene) and the analysis of protein quantification (ELISA) was performed on 
log-transformed concentrations (if present, zero values were removed by adding an offset 
to the dataset equal to half the smallest non-zero concentration).  
All statistical analyses were performed using GraphPad Prism 6 software and 
differences with p-values less than 0.05 were considered significant. All experiments have 
been performed at least three times.  
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Part I: Characterization of inflammasome expression in glial cells . 
 
Until now, the inflammasome signalling in glial cells has only been partially 
addressed. This is why the main focus of this thesis was to characterize the expression 
and regulation of inflammasome components in glial cells. We turned our attention to all 
inflammasome complexes expressed in both microglia and astrocytes but with a special 
regard to the NLRP3 inflammasome.  
 
1. Inflammasome expression and regulation in microglia. 
 
1.1 The NLRP3 inflammasome in microglia. 
 
1.1.1 Primary culture is the best model to study NLRP3 inflammasome in microglial 
cells. 
 
In order to investigate the expression and regulation of the NLRP3 inflammasome in 
microglia, we first tried to identify the best-suited model. We tested three different 
microglial models: the MMGT12 and BV2 cell lines as well as the mouse primary microglia 
(hereafter simply referred as microglia). In addition, we used bone marrow-derived 
macrophages (BMDM) as a positive control for NLRP3 inflammasome expression and 
activation. All cells were submitted to the classical protocol of NLRP3 inflammasome 
activation, consisting in a priming step of 6 h with LPS (signal 1) followed by a 30 min ATP 
stimulation (signal 2 ; Fig. 21A).  
First, we analysed, in all cell types and by RT-PCR, the gene expression of the 
NLRP3 inflammasome components NLRP3, ASC and Caspase-1. We observed that the 
constitutive expression levels (Ctrl) of all these genes were, on average, 30-fold lower in 
both microglial cell lines compared to primary microglia and BMDM (Fig. 21B). However, 
an exposure to LPS could upregulated the Nlrp3 and Casp1 genes in all cells (Fig. 21B). 
In addition to the inflammasome components, we also studied the expression level of the 
Il1b gene. Its expression was upregulated in all cell types (161-fold for MMGT12, 70-fold 
for BV2, 49-fold for microglia and 43-fold for BMDM ; Fig. 21C). This result was confirmed 
at the protein level by Western blot (WB) analysis. All studied microglial cells were able to 
upregulate the expression of the pro-IL-1 protein after LPS priming (Fig. 21D).  
As IL-1 secretion is commonly used as a read out for inflammasome activation, we 
analysed the ability of the different microglial cells to release IL-1 upon inflammasome 
RESULTS 
 
 68 
stimulation. To this end, we performed WB assays (Fig. 21D) and ELISAs (Fig. 21E). The 
WB analysis showed that, while all microglia models produced pro-IL-1 after LPS priming 
(Fig. 21D), the primary microglia were the sole to secrete detectable mature IL-1 into the 
supernatant (Fig. 21D). Moreover, this microglial IL-1 secretion, which we quantified by 
ELISA (2172±359 pg/mL), was in the same order of magnitude as for BMDM                      
(4636±1163 pg/mL, Fig. 21E). In line with these observations, we selected primary 
microglia to further investigate NLRP3 activation and regulation in microglial cells. 
 
 
 
 
 
 
and bone marrow-derived macrophages (BMDM). Data are normalized to Rpl27. (D, E) Cells were activated following the 
classical activation protocol by LPS and/or ATP. (D) Cell-free culture supernatant (Sup) and cell lysates (Xt) were 
analysed by WB for the expression of IL-1β after activation with LPS and/or ATP. (E) IL-1β released in culture 
supernatant was quantified by ELISA. Data are mean ± SEM of at least three independent experiments, *=p<0.05 
compared to Ctrl. Kruskal-Wallis test followed by Dunn’s multiple comparisons test 
Fig. 21: NLRP3 inflammasome expression and activation in 
different models of microglial cells. 
 (A) The classical activation protocol of the NLRP3 
inflammasome activation is composed of two steps. Cells were 
first primed with LPS (10 ng/mL) during 6 h and subsequently 
treated with ATP (1 mM) for 30 min. mRNA expression levels of 
inflammasome components (Nlrp3, Pycard and Casp1) (B) and 
inflammasome substrate Il1b (C) were analysed by RT-PCR, in 
untreated (Ctrl) or LPS-primed MMGT12, BV2, primary 
micr gli   
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1.1.2 Microglia secrete IL-1 in an NLRP3 inflammasome-dependent way. 
 
In macrophages, NLRP3 inflammasome is known to be activated by a large variety 
of factors including PAMPs and DAMPs (see Introduction, Part II. 2.1). Here, we wanted 
to investigate if the microglial NLRP3 inflammasome also responds to ATP, Nigericin and 
Alum. To this end, we treated LPS-primed microglia with these NLRP3 activators. WB 
assays and ELISA analysis revealed that these treatments induced caspase-1 cleavage 
as well as IL-1 secretion in microglia (Fig. 22A and Fig. 22B). It is noteworthy that the 
priming step is prerequisite for these events, as we were not able to observe any IL-1 
secretion without LPS treatment (Fig. 22B). Moreover, we noted that ATP and Nigericin 
treatments induced a stronger IL-1 release (respectively 2945±638 pg/mL and 4260±994 
pg/mL) than particulate stimuli (Alum, 457±112 pg/mL ; Fig. 22B). In addition to IL-1 
production, a trend in an increase of LDH release was observed in the supernatant after 
inflammasome activation (Fig. 22C).  
 
 
 
 
Fig. 22: ATP, Nigericin and Alum induce caspase-1 cleavage and IL-1 release by LPS-primed microglia. 
Untreated or LPS-primed microglia were stimulated with ATP (1 mM, 30 min), Nigericin (Nig, 1.34 µM, 2 h), or Aluminium 
hydroxide (Alum, 300 µg/ml, 5 h). (A) Cell-free culture supernatants (Sup) and cell lysates (Xt) were analysed by WB for 
IL-1 and caspase-1 expressions. (B). IL-1 secretion in the supernatant was analysed by ELISA. (C) LDH release in the 
supernatant was analysed by LDH cytotoxicity test. LDH results are shown as percentage of LDH release by cells treated 
with Triton-X100 (100%). Data are mean ± SEM of at least three independent experiments, except for WB (one 
representative experiment of at least 3 independent experiments). *=p<0.05 compared to Ctrl. Kruskal-Wallis test followed 
by Dunn’s multiple comparisons test.  
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In order to analyse whether this IL-1 production depends on the NLRP3 
inflammasome, we submitted Nlrp3-/- and Casp1-/- microglia to the same activation 
protocol. We observed a dramatic decrease of IL-1 secretion in both deficient cell types 
and in response to all tested stimuli (ATP, Nigericin or Alum ; Fig. 23A). Similarly, the 
treatment with z-YVAD, a caspase-1 inhibitor, reduced the release of IL-1β subsequent to 
the inflammasome activation (Fig. 23B). In contrast, the NLRP3- or Caspase1-deficiency 
did not affect LPS-mediated TNFα secretion (Fig. 23C).  
 
 
Fig. 23: Microglia secrete IL-1 in an NLRP3 inflammasome-dependent way. 
LPS-primed microglia were stimulated with ATP (1 mM, 30 min), Nigericin (Nig, 1.34 µM, 2 h), or Aluminium hydroxide 
(Alum, 300 µg/ml, 5 h). (A) Secretion of IL-1β in the supernatant of wild-type (WT), Nlrp3-/- and Casp1-/- microglia was 
quantified by ELISA. (B) IL-1β secretion in the supernatant of microglia exposed to z-YVAD-FMK, a specific caspase-1 
inhibitor, was quantified by ELISA. The inhibitor was added 15 min before the LPS-priming. (C) Secretion of TNFα into the 
supernatant of microglia was quantified by ELISA. The bars represent the mean ± SEM of at least three independent 
experiments, *=p<0.05 KO compared to WT, #=p<0.05 compared to ø, ns= not significant. Kruskal-Wallis test followed by 
Dunn’s multiple comparisons test.  
 
To determine if Nigericin and Alum directly trigger the inflammasome assembly or if 
they act indirectly by inducing the intermediate release of ATP, we quantified the ATP 
concentration in the supernatant following Nigericin or Alum treatment. In these 
conditions, no intermediate ATP release was detected (0.08 mM ATP for Nigericin 
treatment ; Fig. 24A), suggesting that Nigericin and Alum directly activate IL-1 
production. Accordingly, we observed no statistical difference in IL-1 secretion upon 
Nigericin or Alum treatment between wild-type and P2xr7-/- cells (Fig. 24B). The P2X7 
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receptor was only required for IL-1 release in response to the stimulation with ATP 
(1969±502 pg/mL in wild-type vs        39±22 pg/mL in P2rx7-/-, Fig. 24B). 
 
 
 
Fig. 24: Microglia secrete IL-1 in a P2X7R-independent-way. 
LPS-primed microglia were stimulated with ATP (1 mM, 30 min), Nigericin (Nig, 1.34 µM, 2 h), or Aluminium hydroxide 
(Alum, 300 µg/ml, 5 h). (A) ATP release was quantified in cell supernatant upon treatment using a luminescent assay (B) 
IL-1β secretion was assessed by ELISA in wild-type (WT) and P2rx7-/- microglia. Data are mean ± SEM of at least three 
independent experiments, *=p<0.05 compared to Ctrl, #=p<0.05 KO compared to WT. One-way ANOVA followed by 
Dunnet’s multiple comparisons test. 
 
1.1.3 Microglia secrete IL-18, IL-1α and HMGB1 after NLRP3 inflammasome activation. 
 
IL-1 is not the sole molecule to be released after inflammasome activation. IL-18 or 
alarmins, such as IL-1α and HMGB1, are also secreted following inflammasome assembly 
in macrophages. We investigated the expression and secretion profile of these factors in 
microglia. 
First, primary microglia constitutively expressed the Il18 gene (CtIl18=25.1, 
CtL27=22.3). However, LPS priming significantly increased by 10.4-fold its expression      
(Fig. 25A). In order to investigate the release of IL-18 in microglia, we activated LPS-
primed cells with either ATP, Nigericin or Alum. We quantified the IL-18 released in the 
culture supernatant by ELISA. Similar to IL-1, the priming of cells by LPS was required to 
detect any release of IL-18 after ATP, Nigericin or Alum exposure (187±71 pg/mL, 
297±87 pg/mL and 47±18 pg/mL respectively, Fig. 25B). In addition, the production of IL-
18 occurred in an NLRP3 inflammasome-dependent manner, as its secretion was 
significantly decreased in supernatants of NLRP3- and Caspase-1-deficient microglia (Fig. 
25C). Similarly, the caspase inhibitor z-YVAD-FMK almost completely abrogated the IL-18 
secretion (Fig. 25D).  
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We further investigated the expression and secretion of both alarmins IL-1α and 
HMGB1. We analysed whether IL-1α was constitutively expressed by RT-PCR and WB. 
Since the basal Il1a mRNA level was low (CtIl1a=30.7, CtL27=22.1) and that we were not 
able to detect the protein, we considered that IL-1α was not constitutively expressed in our 
microglia (Fig. 26A and Fig. 26B). However, stimulating the cells with LPS induced 
1744-fold the Il1a gene expression (Fig. 26A) and upregulated the IL-1α translation          
(Fig. 26B). While the treatment with LPS alone was not sufficient to trigger the release of 
IL-1α into the supernatant, subsequent stimulation with either ATP, Nigericin or Alum led 
to the release of IL-1α (at respectively 435±259 pg/mL, 622±314 pg/mL and 121±64 
pg/mL ; Fig. 26C).  
In order to investigate whether the release of IL-1 was dependent on the NLRP3 
inflammasome, we compared the IL-1α protein levels in the supernatant of wild-type, 
Nlrp3-/- and Casp1-/- stimulated microglia. The results showed that ATP or Nigericin 
treatment required the presence of the NLRP3 inflammasome to induce IL-1α release, 
whereas Alum did not (Fig. 26D). Moreover, while the ATP- and Nigericin-mediated IL-1 
release required the presence of caspase-1, its activity was dispensable, since the 
Fig. 25: IL-18 is expressed in microglia and released 
after NLRP3 inflammasome activation. 
(A) Expression level of Il18 was analysed by RT-PCR 
in untreated or LPS-primed microglia. Data are 
normalized to Rpl27. *=p<0.05 compared to Ctrl. Mann 
and Whitney test (B, C, D) Untreated or LPS-primed 
microglia were stimulated with ATP (1 mM, 30 min), 
Nigericin (Nig, 1.34 µM, 2 h), or Aluminium hydroxide 
(Alum, 300 µg/ml, 5 h). IL-18 secretion was assayed by 
ELISA in supernatant of wild-type (WT) (B), Nlrp3-/- and 
Casp1-/- microglia (C) and in supernatant of WT 
microglia exposed to z-YVAD-FMK, a specific 
caspase-1 inhibitor. The inhibitor was added 15 min 
before the LPS-priming (D). Data are mean ± SEM of 
at least three independent experiments, *=p<0.05 
compared to Ctrl, #=p<0.05 KO compared to WT, 
$=p<0.05 compared to ø. One-way ANOVA followed 
by Dunnet’s multiple comparisons test. 
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treatment with the caspase-1 inhibitor z-YVAD-FMK did not significantly alter the levels of 
IL-1α release (292 vs 198 pg/mL for ATP, 582 vs 601 pg/mL for Nigericin and 126 vs 
69 pg/mL for Alum; Fig. 26E). 
 
 
Fig. 26: NLRP3 activators induce IL-1α secretion in LPS-primed microglia, but display differential requirement for the 
inflammasome components.  
(A, B) Microglia were stimulated with 10 ng/mL LPS during 6 h. (A) Expression level of Il1a was analysed by RT-PCR. Data 
are normalized to Rpl27. *=p<0.05 compared to Ctrl. Mann and Whitney test. (B) Cell lysates (Xt) were analysed by WB for 
the expression of IL-1α in untreated or primed condition. α-Tubulin was used as a loading control. (C, D, E) Untreated or 
LPS-primed microglia were stimulated with ATP (1 mM, 30 min), Nigericin (Nig, 1.34 µM, 2 h), or Aluminium hydroxide 
(Alum, 300 µg/ml, 5 h). IL-1α secretion was assayed by ELISA in the supernatant of wild-type (WT) (C), Nlrp3-/- and Casp1-/- 
microglia (D) and in the supernatant of WT microglia exposed to z-YVAD-FMK, a specific caspase-1 inhibitor. The inhibitor 
was added 15 min before LPS-priming (E). Data are mean ± SEM of at least three independent experiments, except for WB 
(one representative experiment of at least 3 independent experiments). *=p<0.05 compared to Ctrl and #=p<0.05 KO 
compared to WT. Kruskal-Wallis test followed by Dunn’s multiple comparisons test. 
 
A recent report showed that microglia actively secrete HMGB1 in response to acute 
stress (Weber 2015). However, the authors did not study whether the inflammasome was 
implicated in this process. Thus, we wanted to study if microglia could be able to secrete 
HMGB1 following NLRP3 inflammasome activation. As expected, HMGB1 was 
constitutively expressed in microglia (CtHmgb1=22.1, CtL27=22.3 ; Fig. 27A and Fig. 27B). 
However, we could not detect its secretion, neither in the control condition nor after 
stimulation with LPS. In fact, we were only able to detect HMGB1 in the supernatant of 
LPS primed cells once the cells were treated with either ATP (6.4 ng/mL) or Nigericin 
(18.8 ng/mL; Fig. 27C). Interestingly, Alum treatment was not able to trigger the release of 
HMGB1 by LPS-primed microglia (Fig. 27C). Consistently with a role for the NLRP3 
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inflammasome, ATP- and Nigericin- mediated HMGB1 release were abrogated in 
NLRP3-deficient (2.4±0.7 ng/mL with ATP and 4.3±1.6 ng/mL with Nigericin) or 
Caspase-1-deficient microglia (3.7±1.2 ng/mL with ATP and 5.6±1.9 ng/mL with Nigericin) 
compared to wild-type microglia (13.8±4.9 ng/mL with ATP and 32±9 ng/mL with 
Nigericin, Fig. 27D). Similar to our observation with IL-1α, we were still able to detect 
HMGB1 in the supernatant of the cells treated with the caspase-1 inhibitor z-YVAD (Fig. 
27E). Yet, in both cases, we were able to confirm the efficacy of the caspase-1 inhibitor by 
quantifying IL-1 on the same supernatants. 
 
 
Fig. 27: LPS-primed microglia actively released HMGB1 after inflammasome activation by ATP and Nigericin. 
(A, B) Microglia were stimulated with 10 ng/mL LPS during 6 h. (A) Expression level of Hmgb1 was analysed by RT-PCR. 
Data are normalized to Rpl27.*=p<0.05 compared to Ctrl. Mann and Whitney test. (B) Cell lysates (Xt) were analysed by WB 
for the expression of HMGB1 in untreated or primed condition. α-Tubulin was used as a loading control. (C, D, E) Untreated 
or LPS-primed microglia were stimulated with ATP (1 mM, 30 min), Nigericin (Nig, 1.34 µM, 2 h), or Aluminium hydroxide 
(Alum, 300 µg/ml, 5 h). HMGB1 secretion was assayed by ELISA in supernatant of wild-type (WT) (C), Nlrp3-/- and Casp1-/- 
microglia (D) and in supernatant of WT microglia exposed to z-YVAD-FMK, a specific caspase-1 inhibitor. The inhibitor was 
added 15 min before the LPS-priming (E). Data are mean ± SEM of at least three independent experiments, except for WB 
(one representative experiment of at least 3 independent experiments). *=p<0.05 compared to Ctrl and #=p<0.05 KO 
compared to WT. Kruskal-Wallis test followed by Dunn’s multiple comparisons test. 
 
1.1.4 Inflammasome-dependent IL-1β production in microglia occurred through similar 
mechanisms than described in macrophages. 
 
We wanted to investigate whether the mechanisms underlying inflammasome 
activation in microglia are similar to those described in macrophages. To this purpose, we 
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studied the implication of potassium efflux, ROS and lysosomal damage in microglial 
NLRP3 inflammasome activation. 
First, we stimulated the cells in a potassium-enriched medium (25 to 130 mM KCl) in 
order to investigate the importance of potassium efflux for inflammasome activation. We 
tested whether the potassium-enriched conditions affect the viability of microglia by using 
a MTT assay. We found that KCl seemed not toxic despite a slight decrease in viability 
when its concentration reached 130 mM (86.4% of viability, Fig. 28A). When we treated 
microglia with increasing concentrations of KCl (25 mM, 75 mM and 130 mM), we 
observed a dose-dependent reduction in ATP-mediated IL-1 release (Fig. 28A). The 
concentration decreased from 1362 pg/mL in the control condition to 114 pg/mL with 25 
mM KCl, 12 pg/mL with 75 mM KCl and 1.7 pg/mL with 130 mM KCl (Fig. 28B). Similarly, 
we observed that the presence of 25 mM KCl also inhibited the release of IL-1 following 
Nigericin (3674 pg/mL to 1207 pg/mL) or Alum treatment (571 pg/mL to 118 pg/mL, Fig. 
28C).  
 
 
Fig. 28: High extracellular concentration of KCl inhibits Il1b and Nlrp3 expression as well as IL-1 release. 
(A) Microglia were cultured in classical medium or in 25 mM, 75 mM, or 130 mM KCl-enriched medium. Cell viability was 
tested by MTT assay. Data are shown in percentage of the non-treated cells viability (Ctrl). (B, C) LPS-primed microglia 
were stimulated with ATP (1 mM, 30 min), Nigericin (Nig, 1.34 µM, 2 h), or Aluminium hydroxide (Alum, 300 µg/ml, 5 h) in 
presence of KCl-enriched medium. IL-1 secretion in supernatant was quantified by ELISA after exposure to ATP (B) and 
Nigericin or Aluminium hydroxide (C). (D, E). LPS-primed microglia were cultured in classical medium or in 25 mM, 75 mM, 
or 130 mM KCl-enriched medium. (D) Expression levels of Il1b and Nlrp3 were analysed by RT-PCR and normalized to 
Rpl27. The expression ratio of these genes was calculated for “LPS+KCl” vs “LPS” conditions. (E) Cell lysates (Xt) were 
analysed by WB for the expression of IL-1β and NLRP3. α-Tubulin was used as a loading control. Data are mean ± SEM of 
at least three independent experiments, except for WB (one representative experiment of at least 3 independent 
experiments) *=p<0.05 compared to Ctrl. One-way ANOVA followed by Dunnet’s multiple comparisons test. 
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Surprisingly, we noted that adding KCl not only affected the activation of NLRP3 but also 
the priming step (Fig. 28D and Fig. 28E). Indeed, when we analysed the transcripts by 
RT-PCR, we observed that KCl was able to downregulate the LPS-induced Il1b 
expression in a dose-dependent manner (Fig. 28D). Il1b expression decreased of 53.2% 
with 25 mM KCl, 67.6% with 75 mM KCl and 97.9% with 130 mM of KCl. Interestingly, the 
expression of Nlrp3 was only affected in presence of the highest concentration of KCl 
(130 mM) and dropped down by 96.3% in this condition (Fig. 28D). Our WB analysis 
confirmed these observations at the protein level (Fig. 28E). 
 
ROS have previously been proposed as being crucial for NLRP3 activation. Thus, 
we analysed their implication in microglial inflammasome activation by testing the effect of 
the antioxidant molecule N-Acetyl-L-Cystein (NAC) on IL-1β secretion. As a prerequisite, 
we performed an MTT assay which showed that NAC did not exhibit any adverse effect on 
the cell viability (Fig. 29A). Our experiments indicated that the exposure to NAC impaired 
the IL-1 secretion induced by either ATP (from 3933±952 pg/mL to 2091±89 pg/mL) or 
Alum (from 283±42 pg/mL to 71±7 pg/mL ; respectively Fig. 29B and Fig. 29C). In 
addition, the effect of NAC on the release of IL-1β was priming-independent, as the RT-
PCR analysis showed no variation in the expression of either Il1b or Nlrp3 gene in 
presence of NAC      (Fig. 29D). 
 
 
 
Fig. 29: IL-1 release is decreased in presence of NAC antioxidant. 
(A) Microglia were treated for 330 min with the antioxidant N-Acetyl Cysteine (NAC, 5 mM). Cell viability was tested by MTT 
assay. Data are shown in percentage of non-treated cells viability (Ctrl). (B and C). IL-1 secretion was quantified by ELISA 
performed on supernatant of LPS-primed microglia stimulated with ATP (1 mM, 30 min) (B), or Aluminium hydroxide (Alum, 
300 µg/ml, 5 h) (C) and exposed to NAC (added 30 min prior to the inflammasome activator). (D) LPS-primed microglia 
treated for 330 min with NAC were submitted to transcripts analysis. Expression levels of Il1b and Nlrp3 were analysed by 
RT-PCR and normalized to Rpl27. The expression ratio of these genes was calculated for “LPS+NAC” vs “LPS” conditions 
(D). Data are mean ± SEM of at least three independent experiments, *=p<0.05 compared to Ctrl. One-way ANOVA 
followed by Dunnet’s multiple comparisons test. 
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It has also been reported that, in macrophages, particulates could induce lysosomal 
damage and subsequent release of cathepsin B, which are responsible for the activation 
of the NLRP3 inflammasome. To study whether particulates act in the same way on 
microglia, we first inhibited their phagocytosis capacity by using Cytochalasin D (Cytod), 
an inhibitor of actin polymerization. Then, we also blocked cathepsin B activity by using 
the inhibitor CA074-Me. These compounds did not give rise to significant cell death (Fig. 
30A). As expected, both inhibitors did not affect the IL-1β secretion observed in response 
to ATP (Fig. 30B), whereas Cytod and CA074-Me induced a decrease of Alum-triggered 
IL-1 secretion of respectively 98.6% and 86.3% (Fig. 30C). Moreover, this effect was 
priming-independent, as RT-PCR analysis showed no difference in the expression of 
either Il1b or Nlrp3 gene in presence of CA074-Me or Cytod (Fig. 30D). 
 
 
 
Fig. 30: Phagocytosis and cathepsin B activity are required for IL-1 release following Alum exposure. 
(A) Microglia were treated for 330 min with Cytochalasin D (Cytod, 2 μM) or CA074-Me (10 μM). Cell viability was tested by 
MTT assay after inhibitor exposure. Data are shown in percentage of non-treated cells viability (Ctrl). (B and C) The IL-1 
secretion in supernatant of LPS-primed microglia stimulated with ATP (1 mM, 30 min) (B), or Aluminium hydroxide (Alum, 
300 µg/ml, 5 h) was quantified by ELISA (C) in presence of Cytod or CA-074Me. (D) LPS-primed microglia treated for 
330 min with Cytod or Ca-074Me were submitted to transcripts analysis. Expression levels of Il1b and Nlrp3 were analysed 
by RT-PCR and normalized to Rpl27. The expression ratio of these genes was calculated for “LPS+inhibitor” vs “LPS” 
conditions (D). Data are mean ± SEM of at least three independent experiments, *=p<0.05 compared to Ctrl. One-way 
ANOVA followed by Dunnet’s multiple comparisons test. 
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1.2 Preliminary results: Other functional inflammasomes in microglia.  
 
Even if NLRP3 inflammasome is the best characterized, other inflammasome 
complexes have been described (see Introduction, Part II, section 3). As some of them 
have been linked to neuroinflammation, we further investigated the expression of the 
inflammasome-related proteins in microglia. To this purpose, we performed RT-PCR on 
cDNA derived from untreated or LPS-primed microglia. The different expression levels are 
reported in figure 31 as a heat map representing the -dCt (-Ctgene of interest – CtRpl27) values. 
The expression data of all genes are provided in supplemental table 1. We detected the 
constitutive expression of Nlrp1 (Ct = 30.2±1.9), Nlrp6 (Ct = 26.9±1.5), Aim2                            
(Ct = 20.5±0.6) and Nlrc4 (Ct = 27.5±1.5) genes in microglia (Fig. 31). In addition, we 
observed that Casp4 (caspase-11) mRNA could be upregulated 240-fold when microglia 
were primed with LPS (Fig. 31).  
 
 
 
Fig. 31: Expression profile of inflammasome-related genes in microglia. 
Microglia were primed with LPS (10 ng/mL) during 6 h. RNA were extracted and analysed for gene expression of Nlrp1, 
Nlrp2, Nlrp3, Nlrp6, Nlrp12, Aim2, Nlrc4, Pycard, Casp1 and Casp4 by RT-PCR. Results were normalized to Rpl27. The 
Heat map represents the normalized expression values (-dCt). Blue represents low level of expression (-dCt = -12) and red 
represents high level of expression (-dCt = -2). Data are the mean of at least three independent experiments. 
 
Based on these results, we started a functional analysis of AIM2 and NLRC4 
inflammasome complexes in microglia, since this question has, until now, been poorly 
addressed.  
As AIM2 is able to sense cytosolic double stranded DNA, we transfected LPS-
primed cells with the synthetic double-stranded DNA poly(dA:dT). After the transfection, 
we were able to observe that microglia released a highly variable but significant amount of 
IL-1  (729±423 pg/mL ; Fig. 32A). As expected, this release was NLRP3-independent 
since the level of IL-1β was not significantly altered in NLRP3-deficient microglia (Fig. 
32B).  
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Fig. 32: The AIM2 inflammasome ligand, poly(dA:dT), induces IL-1 release by LPS-primed microglia. 
Microglia were primed for with LPS (10 ng/mL, 6 h) and transfected with Poly(dA:dT) (2.5 μg/mL, 5 h) by using 
Lipofectamine (10 μg/mL). IL-1 production in culture supernatant was assessed by ELISA in wild-type (WT) (A) or Nlrp3-/- 
microglia (B). Data are mean ± SEM of at least three independent experiments, *=p<0.05 compared to Ctrl, ns= not 
significant. Kruskal-Wallis test followed by Dunn’s multiple comparisons test. 
Next, we investigated the functionality of the NLRC4 inflammasome, which is 
classically assembled after detection of bacterial flagellin. Thus, we stimulated LPS-
primed microglia with flagellin during 5 h. We could indeed observe a significant release of 
IL-1β (244±161 pg/mL), but only after 24 h of LPS priming (Fig. 33A). Here again, we 
further used NLRP3-deficient microglia to show that this flagellin-mediated IL-1 release 
was NLRP3-independent (Fig. 33B).  
 
 
 
 
Fig. 33: LPS-primed microglia release IL-1 following flagellin exposure. 
Microglia were primed with LPS (10 ng/mL, 24 h) and stimulated with ultra-pure flagellin (2.5 μg/mL, 5 h). IL-1 production in 
culture supernatant was assessed by ELISA in wild-type (WT) (A) or Nlrp3-/- microglia (B). Data are mean ± SEM of at least 
three independent experiments, *=p<0.05 compared to Ctrl, ns= not significant. Kruskal-Wallis test followed by Dunn’s 
multiple comparisons test. 
 
We have previously mentioned that LPS was able to induce the upregulation of 
Casp4 (Fig. 31). In fact, this gene encodes mouse caspase-11, which is implicated in the 
“non-canonical inflammasome” pathway after binding to intracellular LPS (see the section 
3.4 in Part II of the introduction). This observation led us to study the microglial capacity to 
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trigger this non-canonical inflammasome pathway. To this purpose, we used lipofectamine 
to transfect a high dose of LPS (1 µg/ml) into microglial cells. This transfection induced the 
release of IL-1 (461±254 pg/mL), as revealed by ELISA (Fig. 34A), but also led to an 
increase in LDH release (13.5-fold compared to Ctrl, Fig. 34B). Surprisingly, when we 
treated the cells with high LPS concentration (1 µg/ml), without transfection agent, we 
were nevertheless able to detect a significant release of IL-1β into the supernatant                        
(239±82 pg/mL, Fig. 34A) as well as a release of LDH (16%, Fig. 34B). We further noted 
that the release of IL-1β tended to decrease in Nlrp3-/- mice (467±359 pg/mL vs                     
228±183 pg/mL, Fig. 34C) whereas the LDH release remained similar in wild-type and 
NLRP3-deficient cells (respectively 23% and 28%, Fig. 34D). 
 
 
 
Fig. 34: High dose of LPS triggered IL-1β release by microglia.  
Microglia were stimulated for 16 h with a high dose of LPS (1 μg/mL), transfected by using Lipofectamine (10 μg/mL). IL-1β 
production and LDH release in culture supernatant were assessed respectively by ELISA and LDH cytotoxicity test in 
wild-type (WT) (A, B) or Nlrp3-/- microglia (C, D). LDH results are shown as percentage of LDH release by Triton-X100 
treated cells. Data are mean ± SEM of at least three independent experiments, *=p<0.05 compared to Ctrl, ns= not 
significant. Kruskal-Wallis test followed by Dunn’s multiple comparisons test. 
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2. Inflammasome expression in astrocytes. 
  
Even if astrocytes physiology is currently an important field of research, their direct 
contributions under inflammatory conditions is still controversial. For example, it is still 
debated if astrocytes are able to produce IL-1. Moreover, only few studies tried to 
characterize inflammasomes in astrocytes. Therefore, we aimed to investigate 
inflammasome expression and activation in astrocytes. 
 
2.1 Astrocyte culture purity is crucial. 
 
First, we wanted to emphasize the importance to work with astrocyte cultures devoid 
of microglia in inflammatory studies. Primary mixed glial cultures (MGC P0) contain at 
least both glial cell types (astrocytes and microglia). As microglia are extremely reactive 
immune cells, it is important to deplete them as much as possible from astrocyte 
cultures-derived from MGC P0.  
In order to obtain highly astrocyte-enriched cultures in vitro, we performed a MACS 
isolation where microglia were positively selected during the sorting. The resulting 
astrocyte-enriched cultures were named AEC-M1. To characterize the purity of this type of 
culture, we realized an immunocytochemistry staining using antibodies against GFAP and 
Iba1 in order to label astrocytes or microglia respectively (Fig. 35A). Cell counting 
revealed that AEC-M1 contained less than 2% of Iba1 positive microglial cells. While this 
level of purity is often described as being acceptable in the literature, our preliminary 
experiments have demonstrated that the remaining microglial cells were still introducing a 
bias during inflammatory studies. Indeed, experimental results were not reproducible as 
the pro-inflammatory gene expression was highly variable, probably due to different 
amounts of microglial contamination. For example, the Ct value obtained by RT-PCR for 
Il1b varied from 32 to 38. In order to fix this issue, we decided to perform a second MACS 
sorting to reduce even more the remaining microglial cells. The thereby obtained cultures 
were called AEC-M2. In these cultures, we were not able to detect Iba1-positive cells 
anymore             (Fig. 35A), indicating a purity close to 100%. To confirm these results by 
an alternative method, we characterized the gene expression levels of relevant cell type 
specific markers, i.e. Aif1 (Allograft inflammatory factor 1), Itgam (Integrin alpha M) and 
Gfap in AEC-M1, AEC-M2, microglial cultures and MGC P0. Itgam and Aif1 are the genes 
respectively coding for CD11b and Iba1 proteins and expressed in microglia. Figure 35B 
shows that Aif1 and Itgam were expressed at higher levels in microglia cultures than in 
MGC P0 (respectively 14-fold and 4-fold) and in AEC-M1 (respectively 14-fold and 6-fold). 
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Moreover, these genes were less expressed in AEC-M2 than in AEC-M1 cultures (3-fold 
for Aif1 and 2-fold for Itgam).  
Based on these observations, we decided to use AEC-M2 to investigate 
inflammasome expression and regulation in astrocytes in vitro. 
  
 
Fig. 35: AEC-M2 contain less contaminant microglia than AEC-M1 or MGC P0. 
(A) Immunocytochemistry was performed on non-treated mixed glial cultures (MGC P0) and on astrocyte-enriched cultures 
(AEC) sorting once (AEC-M1) or twice (AEC-M2) by MACS technique. Astrocytes are detected using anti-GFAP antibody 
(red). Microglia were detected using anti-Iba1 antibody (green). DAPI staining identifies nucleus (blue). Pictures are one 
representative experiment of at least three independent experiments. (B) Gene expressions of Aif1, Itgam (microglia 
markers) and Gfap (astrocyte marker) were analysed in untreated MGC P0, AEC-M1, AEC-M2 and microglial cultures by 
RT-PCR. Results were normalized to Rpl27. Data are mean ± SEM of at least three independent experiments, *=p<0.05 
compared to MGC P0. Kruskal-Wallis test followed by Dunn’s multiple comparisons test.  
 
2.2 Astrocytes do not express all NLRP3 inflammasome components. 
 
As astrocytes do not strongly respond to LPS stimulation (Henn 2011), probably due 
to their weak Tlr4 expression (Suppl. Fig. 1), we tried to setup an alternative priming 
method. To this aim, we tested the TLR2 ligand Pam3CSK4 (P3C, 10 ng/mL) or the 
cytokines IL-1 (10 ng/mL), TNFα (10 ng/mL) and IFNγ (20 ng/mL) separately or in 
combination (CCM: IL-1β + TNFα + IFNγ). Untreated and LPS-primed microglia were 
used as positive controls even if P3C and CCM were also able to efficiently prime NLRP3 
in these cells (Suppl. Fig. 2).  
After 6 h of astrocytes priming by the cited activators, we performed a RT-PCR to 
monitor the expression levels of selected pro-inflammatory genes (i.e. Il6, Nos2, Ptgs2 
Cxcl10 and Tnf) but also of NLRP3 inflammasome-related genes (i.e. Il1b, Il1a, Il18, 
Hmgb1, Nlrp3, Pycard and Asc ; Fig. 36A). The obtained data are represented as a heat 
map representing the -dCt values for each genes. The exhaustive expression values are 
provided in supplemental Table 2. 
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Fig. 36: Astrocytes weakly expressed Il1b, Il1a, Nlrp3 and Pycard genes and do not respond to inflammasome activation, 
even after an efficient priming.  
(A) Primary astrocytes (AECM2) were primed for 6 h with LPS (10 ng/mL), P3C (10 ng/mL), IL-1β (10 ng/mL), TNF-
(10 ng/mL), IFNγ (10 ng/mL) or CCM (10 ng/mL IL-1β + 10 ng/mL TNFα + 20 ng/mL IFNγ). Primary microglia were primed 
with LPS (10 ng/mL, 6 h) and served as control. RNA were extracted and analysed by RT-PCR for expression of the pro-
inflammatory genes Il6, Nos2, Ptgs2, Cxcl10 and Tnf) and expression of NLRP3 inflammasome-related genes (i.e. Il1b, Il1a, 
Il18, Hmgb1, Nlrp3, Pycard and Asc). Results were normalized to Rpl27. The Heat map represents these normalized 
expression values (-dCt). Blue represents low level of expression (-dCt = -12) and red represents high level of expression 
(-dCt = -2). Data are mean of at least three independent experiments. CXCL10 (B) and PGE2 (C) secretions were assessed 
after 6 h of CCM exposure. (D) Primary astrocytes (AEC M2) were primed for 6 h with LPS (10 ng/mL) or CCM. LPS-primed 
microglia served as control. IL-1β, HMGB1, NLRP3, ASC and Caspase-1 protein levels were analysed by WB. α-Tubulin 
was used as a loading control. IL-18 (E) and HMGB1 (F) secretions were assayed by ELISA on supernatant of primed 
astrocytes and microglia treated with ATP (1 mM, 30 min) or Nigericin (Nig, 1.34 µM, 2 h). Data are mean ± SEM of at least 
three independent experiments, except for WB (one representative experiment of at least 3 independent experiments). 
*=p<0.05 compared to Ctrl. Kruskal-Wallis test followed by Dunn’s multiple comparisons test. 
 
By looking at the expression levels of Il6, Nos2, Ptgs2, Cxcl10 and Tnf in astrocytes, 
we observed that, among the tested activators, CCM was the most potent one (108-, 675-, 
38.5-, 3777- and 25-fold inductions respectively for Il6, Nos2, Ptgs2, Cxcl10 and Tnf ;        
Fig. 36A). We further confirmed the capacity of CCM to activate astrocytes by measuring 
the secretion of CXCL10 or PGE2 by ELISA. We were able to detect a 78-fold increase of 
CXCL10 in the supernatant after CCM stimulation (0.12±0.01 ng/ml in Ctrl and                       
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9.4±6.7 ng/ml with CCM, Fig. 36B), as well as an upregulation of 2.3-fold of the PGE2 
release (0.85±0.19 ng/ml in Ctrl and 1.96±0.45 ng/ml with CCM, Fig. 36C).  
We also analysed the expression levels of inflammasome-related genes in untreated 
or inflammatory conditions. Surprisingly, we failed to detect any Il1a and Il1b transcripts in 
astrocytes, in both unprimed and primed conditions. In addition, the Nlrp3 and Pycard 
genes were poorly expressed in untreated astrocytes, compared to microglia (Fig. 36A). 
Nevertheless, Nlrp3 was significantly upregulated after CCM exposure (332-fold, Fig. 
36A). The heat map also illustrates that astrocytes constitutively expressed Il18 
(Ct = 24.7±2.3), Hmgb1 (Ct = 20.5±1.8) or Casp1 (Ct = 29.3±1.7) and that treating the 
cells with CCM was able to upregulate Casp1 expression by 12.8-fold (Fig. 36A). We 
attempted to confirm these observations at the protein level by WB assays. Interestingly, 
we failed to detect pro-IL-1β, NLRP3 and ASC proteins in primed or unprimed astrocytes 
(Fig. 36D). However, we noted that these cells expressed HMGB1 and caspase-1 in both 
conditions, with an upregulation of caspase-1 expression after priming, consistently with 
our transcripts results (Fig. 36D). 
Although we failed to detect the expression of all NLRP3 inflammasome 
components in astrocytes, we have tested the effects of the inflammasome activators ATP 
and Nigericin on CCM-primed astrocytes. As expected, we did not detect any IL-18 (Fig. 
36E) or HMGB1 (Fig. 36F) release after treatment, even if they are expressed by 
astrocytes. IL-1β release was also undetectable in the supernatant (Suppl. Fig. 3). 
In order to confirm our results, these experiments have been repeated on another 
model of astrocytes devoid of microglia: neurosphere-derived astrocyte cultures (Crocker 
et al, 2008). Similar to primary astrocytes, these cells exhibited a very low expression of 
Asc and Nlrp3 but expressed Casp1 which was upregulated after CCM-priming 
(Suppl. Fig. 4). On another hand, Il1b and Il18 genes were not expressed by the 
neurosphere-derived astrocytes, either in unstimulated or in CCM-primed conditions 
(Suppl. Fig. 4). 
 
2.3 Astrocytes do not express other functional inflammasomes.  
 
As we failed to detect a functional NLRP3 inflammasome in astrocytes, we further 
investigated the expression of other inflammasome-related proteins in these cells. To this 
purpose, we performed RT-PCR on RNA extracted from untreated or primed astrocytes. 
Figure 37 shows a heat map representation of the normalized expression levels. The 
expression data of all genes are provided in supplemental table 3. We found that 
astrocytes and microglia contained similar transcript levels of the intracellular sensors 
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Nlrp6 (respectively Ct = 29.9±1.9 and 29.6±1.5) and Aim2 (respectively Ct = 22±0.7 and             
20.5±0.6 ; Fig. 37 and Suppl. Table 3). On the contrary, Nlrp1, Nlrp2, Nlrp12 and Nlrc4 
genes were poorly expressed in astrocytes (Fig. 37) as demonstrated by their respective 
Ct values: 32.6, 34.2, 33.2 and 35.3 (Suppl. Table 3). Interestingly, we were able to 
observe a 27-fold upregulation of Casp4 (Caspase-11) gene expression after CCM-
priming in astrocytes, although the expression levels remain much lower than in LPS-
primed microglia (Ct=30.2±3.1 in primed astrocytes vs 21.1±0.2 Ct in primed-microglia; 
Fig. 37 and Suppl. Table 3).  
 
 
 
Fig. 37: Expression profile of other inflammasome-related genes in astrocytes. 
Primary astrocytes were untreated or primed with CCM (10 ng/mL IL-1β + 10 ng/mL TNFα + 20 ng/mL IFNγ, 6 h). Primary 
microglia were untreated or primed with LPS (10ng/mL, 6 h) and served as comparison. RNA were extracted and analysed 
for gene expression of Nlrp1, Nlrp2, Nlrp6, Nlrp12, Aim2, Nlrc4 and Casp4 by RT-PCR. Results were normalized to Rpl27. 
The Heat map represents these normalized expression values (-dCt). Blue represents low level of expression (-dCt = -12) 
and red represents high level of expression (-dCt = -2). Data are the mean of at least three independent experiments.  
 
In view of these results we tried to activate the AIM2 inflammasome complex as well 
as the non-canonical inflammasome pathway in astrocytes. As for LPS-primed microglia 
(Results section 1.2), we transfected CCM-primed astrocytes with the AIM2 
inflammasome activator poly (dA:dT) or with LPS. Both stimulations failed to induce the 
release of IL-1β, IL-18 and HMGB1 (data not shown). 
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Part II: The inflammasome in neurodegenerative diseases. 
 
The development of Parkinson’s disease (PD) is accompanied by chronic 
inflammation in which IL-1β plays an important role. However, a possible implication of the 
inflammasome in the pathogenesis of PD remains poorly addressed. In order to 
investigate this relation, we developed in vitro assays to study inflammasome activation in 
microglia, in response to neurodegenerative diseases-associated stimuli. In a second 
time, the in vivo significance of NLRP3 deficiency in Parkinson’s disease physiopathology 
was addressed. 
 
1. In vitro NLRP3 inflammasome activation in response to 
neurodegenerative diseases-related signals.  
 
As our previous results demonstrated the capacity of microglia to form a functional 
NLRP3 inflammasome, we aimed to explore the reactivity of this complex to three different 
types of factors that have been associated with the neurodegenerescence: the 
neurodegenerative diseases-related proteins, the purine metabolites and the pesticide 
rotenone. 
 
1.1 Differential microglial inflammasome activation in response to the 
neurodegenerative disease-related peptides A and -synuclein. 
 
Before the onset of this project, in 2011, a single report suggested that the 
stimulation of microglia with Amyloid-β (A) was able to induce an NLRP3-dependent 
release of IL-1 (Halle et al, 2008). Thus, we wanted to confirm these observations but 
also to investigate the inflammasome activation capacity of -synuclein, the principal 
constituent of the Lewy bodies. To this end, we exposed microglia to these both peptides 
and analyzed their potential to prime (signal 1) or activate NLRP3 (signal 2). 
We tested two different fragments of the amyloid-β protein: Aβ25–35 and Aβ1-42 (see 
Introduction, Part I, section 3).  
First, we study the effect of the A25-35, as it is endogenously found in elderly people 
and has been described to be a more toxic form (Millucci et al, 2009). To explore the 
priming capacity of this Aβ25–35 peptide, we activated microglia for 6 h with 50 μM of the 
peptide as well as with its reverse form (Aβ35–25, negative control) and LPS (positive 
RESULTS 
 
 87 
control). The gene expression analysis performed by RT-PCR indicated that the Aβ25–35 
was unable to prime microglia, as Nlrp3 and Il1b were not upregulated after treatment 
(Fig. 38A).  
 
 
Fig. 38: Aβ25-35 induces caspase-1 cleavage and IL-1β release in an NLRP3-dependent and P2X7R-independent way. 
(A) Microglia were stimulated with Aβ25-35 (20 or 50 μM, 5 h), Aβ35-25 (50 μM, 5 h) or LPS (10 ng/mL, 6 h). Transcripts were 
analysed for expression of Nlrp3 and Il1b by RT-PCR. Data were normalized to Rpl27. (B, C, D) Untreated or LPS-primed 
microglia were stimulated with Aβ25-35 (20 or 50 μM) or Aβ35-25 (50 μM) for 5 h. (B) Cell free culture supernatants (SN) and 
cell lysates (XT) were analysed by WB for the expression of caspase-1 and IL-1. α-Tubulin was used as a loading control. 
IL-1β production in culture supernatant was assessed by ELISA in wild-type (C), Nlrp3-/- and Casp1-/- (D), or P2rx7-/- 
microglia (E). (F) ATP release was quantified in microglial supernatant upon treatment with Aβ25-35 (50 μM, 5 h) or Aβ35-25 
(50 M, 5 h) or LPS (10 ng/mL, 6 h) performed using a luminescent assay. Data are mean  SEM of at least three 
independent experiments, except for WB (one representative experiment of at least 3 independent experiments). *p<0.05 
compared to Ctrl, p<0.05, KO compared to WT, ns= not significant. One-way ANOVA followed by Dunnet’s multiple 
comparisons test. 
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Even if the Aβ25–35 peptide was unable to act as a signal 1, it seemed to be able to act as a 
signal 2. Indeed, WB analysis revealed that, in LPS-primed microglia, Aβ25–35 was able to 
induce caspase-1 cleavage and IL-1β secretion, whereas the control peptide Aβ35–25 was 
not (Fig. 38B). The additional IL-1 quantification performed by ELISA demonstrated that 
this IL-1β release was dose-dependent since the levels increased from 132±30.5 pg/mL 
with 20 μM of Aβ25–35 to 272±85 pg/mL with 50 μM (Fig. 38C). To confirm the involvement 
of the NLRP3 inflammasome, we used this peptide and its negative reverse control on 
Nlrp3-/- and Casp1-/- microglia. We observed a strong reduction of IL-1β release in the 
supernatant of the knockout cells compared to the wild-type (95% and 77% of decrease 
respectively in Nlrp3-/- and Casp1-/-, Fig. 38D). To determine if this activation could be due 
to an indirect release of ATP, we also treated P2X7 receptor-deficient microglia. Both 
wild-type and P2rx7-/- cells secreted similar amounts of IL-1β, respectively 152±65 pg/mL 
and 214±71 pg/mL in response to 50 μM of Aβ25–35 (Fig. 38E). This latter result was 
strengthened by the absence of ATP in the supernatant of microglia treated with Aβ25–35 
(Fig. 38F). 
 
In addition to the peptide fragment A25-35, we wanted to test the capacity of the full 
length peptide Aβ1-42 to induce NLRP3 activation. This peptide is supposed to be 
physiologically more relevant as it is found in amyloid plaques of AD patients (Shahdat & 
Hashimoto, 2012). The Aβ1-42 peptide was used in its oligomeric and fibrillar forms. The 
fibrillation protocol (see Materials and Methods, section 2.3.3.) led to the formation of 
larger oligomers even if monomers were still present (Fig. 39A). Microglia exposed to 10 
μM of both oligomeric and fibrillar forms, for 6 h or 24 h, failed to significantly modulate 
Il1b and Nlrp3 gene expressions, as shown by RT-PCR analysis (Fig. 39B). This 
observation was confirmed by WB analysis, where we failed to detect pro-IL-1β after Aβ1-
42 treatment         (Fig. 39C). These experiments also demonstrated that, even after LPS-
priming step, Aβ1-42 was still failing to induce a significant IL-1β release, independently 
from its conformation or incubation times (Fig. 39C and Fig. 39D). To exclude the 
possibility that the lack of activity could be linked to the peptide manufacturer (Bachem), 
we also tested Aβ1-42 from other providers (Anaspec and Sigma) and observed similar 
results (data not shown). 
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Fig. 39: Oligomeric and fibrillar Aβ1-42 fail to activate the inflammasome in microglia. 
(A) Aβ1-42 (10 μM) was used under oligomeric form (Olig. = directly resuspended following manufacturer’s instructions) or 
under fibrillar form (Fib. = obtained by heating at 37°C during 7 days). These different Aβ1-42 conformations were analysed 
by WB. (B) Microglia were stimulated for 6 h or 24 h with both forms of Aβ1-42 (10 μM) or for 6 h with LPS (10 ng/mL). 
Transcripts were analysed for the expression of Nlrp3 and Il1b by RT-PCR. Data were normalized to Rpl27. (C, D) 
Untreated or LPS-primed microglia were stimulated for 6 h, 24 h or 48 h with both forms of Aβ1-42 (10 μM) or with ATP (1 
mM, 30 min). (C) Cell free culture supernatants (SN) and cell lysates (XT) were analysed by WB for expression IL-1. -
Tubulin was used as a loading control. (D) IL-1 production in culture supernatant was assessed by ELISA. Data are mean 
 SEM of at least three independent experiments, except for WB (one representative experiment of at least independent 
experiments). *p<0.05 compared to Ctrl. Kruskal-Wallis test followed by Dunn’s multiple comparisons test. 
 
In addition to A peptide, related to AD, we had tested the ability of α-synuclein 
(α-syn), linked to PD, to trigger inflammasome activation. Some mutations in the Snca 
gene have been associated to familial forms of PD. Among them, the substitution of 
alanine to threonine at position 53 of the α-syn protein (A53T) was identified as causing a 
higher propensity to form -syn fibrils. Therefore, we tested the human native and A53T 
mutant -syn, in both oligomeric and fibrillar forms, for their ability to activate mouse 
microglial inflammasome. To obtain the fibrillar form, the peptides were incubated during 4 
days at 57°C, under shaking conditions (see Materials and Methods, section 2.3.3.). WB 
analysis revealed the monomeric and dimeric forms, represented respectively by the 
17 kDa and 37 kDa bands. Once heated, we observed additional bands at 50 kDa and 
around 150 kDa (Fig. 40A).  
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We investigated, by RT-PCR, whether α-syn could prime microglia. Indeed, the 
native human α-syn (WT α-syn) tended to increase the transcription of Nlrp3 (4-fold for 
oligomeric preparation and 2-fold for fibrillar preparation, Fig. 40B). Interestingly, the 
mutant A53T α-syn seemed to be more potent than the WT α-syn, especially in its 
oligomeric form, since we were able to observe a stronger trend toward Nlrp3 upregulation 
after the treatment (7.5-fold, Fig. 40B).  
 
 
 
Fig. 40: WT and mutant (A53T) α-synuclein fail to activate the inflammasome. 
(A) Wild-type (WT) or mutant (A53T) α-synuclein (α-syn) were used under oligomeric form (Olig. = directly resuspended in 
water) or under fibrillar form (Fib. = obtained by heating at 57°C during 4 days under shaking). These different 
conformations of α-syn were analysed by WB. (B, C) Microglia were stimulated for 6 h, 24 h or 48 h with both forms of WT 
and A53T α-syn (5 μM) or for 6 h with LPS (10 ng/mL). (B) Transcripts were analysed for the expression of Nlrp3 and Il1b by 
RT-PCR. Data were normalized to Rpl27. (C) Cell lysates (XT) were analysed by WB for pro-IL-1 and NLRP3 expression. 
-Tubulin was used as a loading control. (D) LPS-primed microglia were stimulated with both forms of WT or A53T α-syn (5 
μM, 6 h) or with ATP (1 mM, 30 min). IL-1 production in culture supernatant was assessed by ELISA. Data are mean  
SEM of at least three independent experiments, except for WB (one representative experiment of at least 3 independent 
experiments). *p<0.05 compared to Ctrl. Kruskal-Wallis test followed by Dunn’s multiple comparisons test. 
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Even if these effects on transcripts were non-significant and remained largely below the 
effect of LPS, we were able to confirm such an upregulation by a WB analysis. Figure 40C 
shows that pro-IL-1β and NLRP3 protein were overexpressed after treatment with either 
human WT or A53T oligomeric α-syn (Fig. 40C). To study if both form could be able to 
activate the inflammasome, we used them on LPS-primed microglia. While ATP induced a 
strong release of IL-1β detected by ELISA, we could not observe IL-1β in the supernatant 
of cells treated with the different α-syn forms (Fig. 40D). 
 
1.2 ADP and adenosine are able to prime the NLRP3 inflammasome in 
microglia. 
 
During neurodegenerative diseases, dying neurons are thought to release ATP 
which might locally reach high concentrations in the brain parenchyma. It is already known 
that ATP is an efficient NLRP3 inflammasome activator, but much less is known about the 
potential of its metabolites, ADP and adenosine. Therefore, we decided to analyse their 
capacity to prime or activate the microglial NLRP3 inflammasome.  
First, we activated microglia with 1 mM of adenosine, ADP or ATP for 3 h and 
analysed changes in gene expression by RT-PCR. Surprisingly, ADP, and to a lower 
extent adenosine, significantly upregulated Nlrp3 and Il1b gene expressions, while ATP 
did not (Fig. 41A). The priming effect of ADP and adenosine also influenced other pro-
inflammatory factors, such as Cxcl10, Il6 or Tnf (Suppl. Fig. 5). 
To investigate whether ADP or adenosine would be able to activate NLRP3, we 
stimulated LPS-primed microglia with both compounds and quantified the IL-1β levels 
secreted in the supernatant. Interestingly, our ELISA analysis revealed that adenosine did 
not trigger any IL-1β release (Fig. 41B), whereas ADP led to a dose-dependent IL-1β 
secretion (Fig. 41C). Moreover, the quantified levels were similar to those observed after 
ATP exposure (Fig. 41C). To confirm that the ADP-induced IL-1β release did not rely on 
the ATP receptor P2X7, we performed the activation on P2rx7-/- cells. Surprisingly, we 
failed to detect IL-1β release in P2X7R-deficient cells (Fig. 41D). As ADP is not supposed 
to bind to this receptor, we decided to test whether ATP could be present in commercial 
ADP batches. These quantifications, based on a luminescent assay, revealed that they 
were indeed contaminated by 20% of ATP (Fig. 41E). 
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Fig. 41: ADP upregulates Il1b and Nlrp3 genes and triggers IL-1β release via the P2X7R in microglia. 
(A) Microglia were stimulated for 3 h with adenosine (Ad., 1 mM), ADP (1 mM), ATP (1 mM) or LPS (10 ng/mL). Transcripts 
were analysed for expression of Nlrp3 and Il1b by RT-PCR. Data were normalized to Rpl27. (B, C, D) LPS-primed microglia 
were stimulated for 30 min with adenosine (1mM), ADP (0.5 mM, 1 mM, or 5 mM) or ADP (1mM). IL-1 production was 
assessed by ELISA in culture supernatant of wild-type (WT) (B and C) or P2rx7-/- (D) microglia. (E) ATP concentration in 
ADP and ATP samples was quantified using a luminescent assay. Data are mean  SEM of at least three independent 
experiments. *p<0.05 compared to Ctrl, p<0.05, KO compared to WT. Kruskal-Wallis test followed by Dunn’s multiple 
comparisons test. 
 
1.3 IL-1β release triggered by rotenone is NLRP3 
inflammasome-dependent but ROS- and ATP-independent. 
 
Inflammasome and neurodegenerative diseases are both related to mitochondrial 
dysfunction. To study the implication of mitochondrial dysfunction in microglial 
inflammasome activity, we used rotenone, a specific mitochondrial complex I inhibitor. 
This product is also described as a causative agent of Parkinson’s disease. 
LPS-primed microglia were stimulated with different concentrations of rotenone 
(from 10 nM to 5 μM) for different incubation times (from 15 to 90 min). As shown in figure 
42A, rotenone exposure induced a significant release of IL-1 after 90 min (100±46, 
150±72 and 157±66 pg/mL after respectively 0.1, 1 and 5 μM of rotenone). This IL-1 
secretion occurred in an NLRP3 inflammasome-dependent way, as its secretion was 
strongly decreased in supernatants of NLRP3-deficient microglia as compared to wild-type 
(respectively               4.3±1.3 pg/mL vs 161±57 pg/mL, Fig. 42B). In addition, we 
observed an impressive disruption of the IL-1 release from 466±144 pg/mL to 34±9 
pg/mL when the cells were activated in presence of the caspase-1 inhibitor z-YVAD-FMK 
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(Fig. 42C). Then, we analysed the implication of ROS in the rotenone-triggered 
inflammasome activation. For this purpose, the antioxidant molecule NAC was used. 
Surprisingly, the secretion of IL-1 was not affected by this compound (Fig. 42D). In 
addition, we observed that rotenone did not induce ATP release in microglia, indicating 
that it acted in an ATP-independent way (Fig. 42E). 
 
 
 
Fig. 42: IL-1 secretion is triggered by rotenone via the NLRP3 inflammasome activation. 
(A) LPS-primed microglia were stimulated with rotenone (Rot) at different concentrations (from 10 nM to 5 μM) and different 
time points (between 15 to 90 min). Supernatants were analysed for IL-1β secretion by ELISA. (B, C, D) LPS-primed 
microglia were stimulated for 90 min with rotenone (1 mM). Secretion of IL-1β was quantified by ELISA in supernatant of 
wild-type (WT) and Nlrp3-/- microglia (B) or in presence of inhibitors, i.e. z-YVAD-FMK (20 nM, added 15 min before LPS) 
(C), N-Acetyl Cysteine (NAC, 5 mM, 2 h) (D). (F) ATP release was quantified in cell supernatant using a luminescent assay 
and upon treatment with LPS (10 ng/mL, 6 h), rotenone (1 mM, 90 min), or ATP (1 mM, 30 min). Data are mean ± SEM of at 
least three independent experiments, *=p<0.05 compared to Ctrl, #=p<0.05 KO compared to WT. Kruskal-Wallis test 
followed by Dunn’s multiple comparisons test. 
 
2. Preliminary results: Effect of NLRP3 deficiency in an in vivo model of 
Parkinson’s disease. 
 
In addition to in vitro studies, we decided to investigate the role of the NLRP3 
inflammasome in an in vivo model of Parkinson’s disease. For this purpose, we chose to 
study the effect of the NLRP3 deficiency on the neurodegenerative processes occurring in 
a mouse intra-striatal 6-OHDA injection model. 
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Most of this in vivo project was performed by Dr. Eric Koncina. I expanded the 
NLRP3 knockout mice colony, performed the genotyping and generated the first cohort of 
NLRP3-deficient KO mice.  
The striata of the Nlrp3-/- mice and age-matched wild-type mice, were injected with 
4 µg 6-OHDA or with the vehicle. Fourteen days after the injection, the mice were 
euthanized and the neurodegeneration, as well as the extent of microgliosis, were 
evaluated by immunostaining. To detect the presence of dopaminergic neurons, we used 
an antibody against Tyrosine hydroxylase (TH) whereas microgliosis was highlighted by 
the expression of CD68. We analysed these markers in two related anatomical structures: 
the substantia nigra pars compacta (SNpc, in midbrain), containing the dopaminergic 
neuron cell bodies, and the striatum, which is the target of their axonal projections. The 
summary of the results obtained are reported in the figure 43.  
 
 
 
Fig. 43: 6-OHDA triggers similar neurodegenerescence and microgliosis in wild-type and in Nlrp3-/- mice. 
Results obtained by Dr. Eric Koncina. 4 μg of 6-OHDA or vehicle was injected into the mouse striatum (at stereotaxic 
coordinates: AP: +0.5 mm, ML: +2.3 mm, DV: +3.2mm) of wild-type (+/+) and Nlrp3-/- (-/-) mice. Fourteen days after the 
injection, mice were sacrificed and brain collected. TH (Tyrosine hydroxylase) and CD68 staining were performed (A)  on 
sagittal striatum sections, at 4 medio-lateral levels (3, 2.7, 2.4 and 2.1 mm from midline) and (B) on sagittal midbrain 
sections, at 5 medio-lateral levels (1.8, 1.64, 1.48, 1.32, 1.16 mm from midline) for both uninjected or injected hemispheres. 
The quantification of the TH and CD68 stained surface is represented by the sum of the 4 values for the striatum or the 5 
values for the midbrain. n = 13 per group (WT and KO) *** = p<0.001 compared to left. Two-way ANOVA. 
As expected, we can observe that in wild-type mice the TH staining was strongly reduced 
in the striatum of the injected hemisphere compared to the contralateral one (Fig. 43A). 
However, there was no significant difference in the degeneration between wild-type and 
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Nlrp3-/- mice (Fig. 43A). Similarly, we observed a significant TH+ neuron degeneration in 
the substantia nigra (Fig. 43B), but this neuronal cell loss was equivalent in wild-type and 
NLRP3-deficient mice (Fig. 43B). Microgliosis, which was characterized by the expression 
of CD68, appeared significantly upregulated in the injured substantia nigra but again 
regardless of the genotype of the mice (Fig. 43B). 
The precise kinetic of the ongoing neuroinflammation in the 6-OHDA model is not 
very well defined. This is why we decided to characterize the time window in which 
selected pro-inflammatory markers, including IL-1β, are expressed in this model. To this 
purpose, we performed a kinetic transcript analysis of the pro-inflammatory factors 
expressed in response to 6-OHDA. 
First, we have validated our dissection protocol of collecting samples from the 
mouse striatum and the substantia nigra. Figure 44 shows the expression profile of genes 
relevant to dopamine neurons: Slc6a3 (DAT, (Dopamine Active Transporter), Th and 
Slc18a2 (VMAT2, Vesicular Monoamine Transporter 2) in three collected structures: the 
cortex (Cx), the striatum (St) and the midbrain (Mb). As expected, we observed that these 
genes linked to dopamine neurons were mostly expressed in the midbrain (Fig. 44).  
 
 
 
Fig. 44: Validation of the striatum and midbrain dissection protocol. 
RNA were extracted from biopsies of the cortex (Cx), the striatum (St) and the midbrain (Mb) collected from wild-type mice. 
RT-PCR was performed to analyse the gene expression of Slc6a3, Th and Slc18a2 respectively coding for DAT, TH and 
VMAT2. The expression ratio of these genes was calculated on the Cx. Data are mean  SEM of six independent 
experiments. *p<0.05 compared to the Cx. Kruskal-Wallis test followed by Dunn’s multiple comparisons test. 
 
Once our dissection protocol was validated, we administered the vehicle or 6-OHDA 
into wild-type mice by stereotaxic injection (Fig. 45A). The mice were euthanized after 3, 7 
or 14 days. The striatum and midbrain from both hemispheres (ipsi- and contralateral) 
were collected for RNA extraction. In addition, after 14 days, we isolated the brain from a 
mouse of each group (Vehicle or 6-OHDA) in order to check, by immunohistochemistry, 
whether the neurodegeneration was effective in this experiment. 
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The transcripts collected from the striatum were analysed by RT-PCR to investigate 
the expression of pro-inflammatory genes. For each animal, we calculated the ratio of the 
gene expression in the ipsilateral sample compared to the gene expression in the 
contralateral sample of the same animal. The results showed a modest, non-significant, 
trend in upregulation (around 2-fold) of the pro-inflammatory genes Cxcl10, Tnf and Il1b in 
the injected hemispheres, 3 or 7 days after the injection. (Fig. 45B). However, we were not 
able to detect a difference between the vehicle and 6-OHDA injected animals. The Aif1 
and Gfap genes also showed a weak and non-significant increase (around 1.8-fold) in 
expression after 3 days, which might indicate, respectively, the microgliosis and 
astrogliosis (Fig. 45B). As we were unable to observe a significant change in expression, 
we performed an immunohistochemistry staining on the dedicated brains (Fig. 45A). We 
were able to observe an intense upregulation of the GFAP, Iba1 and CD68 staining in the 
ipsilateral side of injected brains compared to the contralateral one (Fig. 45C). In addition, 
the TH staining in the striatum and substantia nigra were decreased in the 6-OHDA 
injected slices, confirming the efficacy of our injection (Fig. 45D). 
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Fig. 45: Pro-inflammatory genes are modestly upregulated in the striatum of mice injected with vehicle or 6-OHDA. 
(A) Plan of the kinetic transcript analysis performed (B, C, D) Striatum of wild-type mice were injected with 4 µg 6-OHDA or 
with vehicle. Mice were euthanized after 3, 7 or 14 days. (B) RT-PCR analysis of mRNA levels for Cxcl10, Tnf, Il1b, Aif1, 
Gfap and Th in striatum samples was performed. Three to five mice were analysed for each time point and for each 
experimental group. Data are expressed as ratio of the relative expression to Rpl27 in ipsilateral site versus contralateral 
site from individual animal. Data are mean ± SEM. (C) Representative immunofluorescent histochemical staining for CD68 
(white), Iba1 (yellow) and GFAP (green) in ipsilateral and contralateral striatum. (D) Representative immunofluorescent 
histochemical staining for TH (Tyrosine hydroxylase, green) in the striatum and midbrain of 6-OHDA injected mice.  
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1. Characterization of inflammasome expression and activation in brain 
cells. 
 
The inflammasome is a multiprotein complex which, once activated, results in the 
activation of caspase-1 and in the subsequent maturation and secretion of active IL-1. 
IL-1 release has been linked to neuroinflammatory conditions and neurodegenerative 
diseases for a long time with both beneficial and detrimental effects described (Allan et al, 
2005). However the potential role of the inflammasome in the local production of IL-1β in 
the brain is not very well understood. Recently, several reports started to investigate 
inflammasome activation in neuroinflammatory and neurodegenerative conditions but 
many fundamental questions remain. We therefore wanted to characterize in more detail 
the in vitro capacities of microglia and astrocytes to express and activate the 
inflammasome.  
 
Inflammasome in microglia 
 
Although microglia resemble hematopoietic macrophages both in phenotype and 
function, it has recently been discovered that they originate from a different progenitor 
(Ginhoux et al, 2010; Schulz et al, 2012; Lourbopoulos et al, 2015). Furthermore, 
microglia, which are isolated from the periphery by the BBB, exhibit differences with 
circulating immune cells (Schulz et al, 2012; Ginhoux et al, 2013). Thus, the investigations 
of inflammasome expression and activation in microglia have to be directly addressed in 
these cells rather than being extrapolated from the existing inflammasome knowledge in 
macrophages. 
For this purpose, we have decided to perform our in vitro experiments on primary 
microglial cells, since our preliminary data showed that these cells exhibit a better 
response to the inflammasome activation compared to microglial cells lines. It is also well 
admitted and described that primary cells better reflect the physiology of in situ microglia.  
Our results showed that primary microglia express the NLRP3 inflammasome core 
components (NLRP3, ASC and Caspase-1) as well as other inflammasome genes, such 
as Nlrp1, Nlrp6, Aim2, Nlrc4 or Casp4 (Casp11). These findings are in accordance with 
other reports suggesting that microglia could form NLRC4 and NLRP3 inflammasome 
complexes (Walsh et al, 2014). In this work, we have mainly focused our attention on the 
NLRP3 inflammasome, since this specific complex assembles in response to DAMPs, 
such as ATP or misfolded proteins, which are strongly linked to neurodegenerative 
diseases. 
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First, we aimed to study if microglia respond to NLRP3 inflammasome activation in 
the same manner than macrophages, in terms of caspase-1 activation and cytokines 
secretion. Our findings indicated that the stimulation of LPS-primed microglia with the 
classical NLRP3 activators ATP, Nigericin and Alum led to the inflammasome complex 
assembly and to subsequent cleavage of caspase-1. We also showed that this caspase-1 
activation triggered the maturation and release of IL-1, IL-18, IL-1 and HMGB1 by 
microglia. Moreover, our observations of the activation of caspase-1, associated with an 
important release of LDH, might indicate that microglia undergo pyroptotic cell death 
following inflammasome activation (Rayamajhi et al, 2013). 
In this work, we have used NLRP3- and Caspase-1 knockout mice to show the 
requirement of the NLRP3 inflammasome in these processes. Our results are in line with 
different reports showing that microglia possess the capacity to release IL-1 in an 
NLRP3- and Caspase-1-dependent way (Halle et al, 2008; Hafner-Bratkovič et al, 2012; 
Kaushik et al, 2012). However, the release of IL-18, IL-1α and HMGB1 by microglia after 
inflammasome activation is less described.  
A previous publication showed that the microglial secretion of IL-18 in response to 
stimulation with S.aureus was NLRP3- and ASC-independent (Hanamsagar et al, 2011). 
Interestingly, we were able to show that in response to ATP, Nigericin or Alum treatment, 
the microglial secretion of IL-18 is, on the contrary, NLRP3 inflammasome-dependent. 
These divergent findings clearly open interesting questions concerning a possible 
differential production of IL-18 by microglia depending on the activation stimuli.  
Our experiments also demonstrated that microglial inflammasome activation by ATP 
and Nigericin led to the release of IL-1 and HMGB1 and that this event was abrogated in 
NLRP3 and Caspase-1 knockout cells. It has been already demonstrated that 
macrophages can release IL-1α and HMGB1 after LPS+ATP or LPS+Nigericin treatment 
(Lamkanfi et al, 2010; Gross et al, 2012). However, our study is, to our knowledge, the 
first one which is addressing the involvement of NLRP3 inflammasome in the release of 
these alarmins in microglia. Furthermore, we showed that the caspase-1 protease activity 
was not required for the ATP- and Nigericin-mediated release of HMGB1 and IL-1α in 
microglia. These findings are also in line with previous results obtained from cultured 
macrophages (Gross et al, 2012).  
 
Little is known about the signalling pathways required to trigger the inflammasome 
activation in the CNS (de Rivero Vaccari et al, 2014). First, it is unclear whether the 
two-step model of NLRP3 activation described in macrophages is operational in glial cells. 
Our results showed that microglia required a priming signal (LPS in our experiments) 
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before the exposure to an NLRP3 activator (here, ATP, Nigericin or Alum) in order to 
secrete IL-1. Human monocytes for instance behave differently, as IL-1 can be released 
after a single stimulation with bacterial products alone (Rubartelli et al, 2011). Intriguingly, 
Burguillos and colleagues have shown in 2011 that, unlike in macrophages, the LPS 
priming of mouse microglia might require caspase 8 activation (Burguillos et al, 2011). 
Remarkably, despite several attempts, we were unable to detect the caspase-8 activity in 
microglia after LPS stimulation alone (data not shown). 
After considering the requirement of such a signal 1 to prime the microglial 
inflammasome, we focused our study on the cellular cascades responsible for the specific 
activation of NLRP3. Our investigations showed that the main mechanisms described in 
macrophages — including ROS production, K+ efflux and endosomal rupture — also 
applied to NLRP3 activation within microglia, as supported by previous reports (Halle et al, 
2008; Hoegen et al, 2011; Kaushik et al, 2012).  
First, we were able to highlight the implication of the potassium efflux in the 
activation of NLRP3. Indeed, we observed that blocking this efflux, by adding KCl to the 
extracellular medium, strongly reduced IL-1 secretion by microglia. These results are in 
line with two reports showing a decrease of bacteria- and virus-triggered IL-1 secretion 
when microglia are cultured in high potassium conditions (Hoegen et al, 2011; Kaushik et 
al, 2012). However, these studies did not investigate the effect of KCl on the priming step 
of the inflammasome activation. Interestingly, we observed that blocking potassium efflux 
was linked to a strong decrease in NLRP3 and pro-IL-1 expression. Therefore, we 
suggest that K+ efflux is well implicated in the NLRP3-dependent IL-1β secretion in 
microglia by playing, at least, upstream of the NLRP3 activation. Our observation is in 
opposition with a previous study using macrophages as the authors did not observe a 
modification of pro-IL-1 in KCl-enriched conditions (Pétrilli et al, 2007). These discrepant 
results between microglia and macrophages suggest a possible differential regulation 
level of potassium efflux in inflammasome activation in both cell types.  
In addition, we showed that, with all the NLRP3 activators we tested, the presence 
of an antioxidant reduced the IL-1β secretion, suggesting a role for ROS in microglial 
inflammasome activation. It has been hypothesized that ROS inhibition does not directly 
affect the activation of the NLRP3 inflammasome. Instead, it might negatively regulate the 
priming step of NLRP3 inflammasome activation (Bauernfeind et al, 2011). However, in 
our experiments, the modulatory effect of the antioxidant NAC was independent of the 
priming as the exposure to it did not influence the expression of Nlrp3 and Il1b genes. 
While we cannot exclude that this difference might be linked to the use of different 
antioxidants i.e. DPI in the study of Bauernfeind and colleagues vs NAC in ours, we 
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strongly believe that the redox state of microglia could affect the NLRP3 activity in 
microglia, independently of the priming. Indeed, it is noteworthy that these authors applied 
the antioxidant before the LPS treatment while we used NAC after the priming step.  
Finally, we demonstrated that the Alum-induced IL-1β release relied on cathepsin B 
and phagocytosis. A similar mechanism has been demonstrated for Aβ (Halle et al, 2008). 
However, blocking phagocytosis and cathepsin B activity failed to abrogate the release of 
IL-1 triggered by ATP or Nigericin. Thus, our observations suggest that lysosomal 
damage might only be implicated in the particle-mediated NLRP3 activation in microglia, 
as described in peripheral myeloid cells (Hornung et al, 2008). 
Taken together, our results on primary microglia indicate that they are able to form a 
functional NLRP3 inflammasome, through mechanisms close to those described in 
macrophages. In addition, we demonstrate that this inflammasome is responsible for the 
secretion of IL-1β, IL-1α, IL-18 and HMGB1.  
 
 
In addition to the most studied NLRP3 inflammasome, other inflammasome 
complexes have been characterized. However, their contribution to the cerebral 
production of IL-1 has not been extensively addressed. Our transcript analysis showed 
that microglia express all core components of the AIM2 and NLRC4 inflammasome. 
Therefore, we started to investigate the microglial capacity to form these two complexes. 
In line with the hypothesis that these inflammasomes might be active in microglia, we 
showed that microglia release IL-1 following poly(dA:dT) or Flagellin that respectively 
activate the AIM2 and NLRC4 inflammasome in macrophages. As expected, this IL-1 
secretion occurred independently of NLRP3. While a single publication already 
demonstrated that microglia could assemble the NLRC4 inflammasome (Jamilloux et al, 
2013), the formation of the AIM2 inflammasome in CNS cells has until now only been 
described in neurons (Adamczak et al, 2014). Our findings also suggest that, in addition to 
the AIM2 and NLRC4 complexes, the non-canonical inflammasome pathway could be 
effective in microglia. Indeed, our results showed that LPS transfection triggered the 
secretion of IL-1 and initiated the release of LDH, a possible sign of pyroptosis. However, 
we need to clarify different points by additional experiments, and in particular: (i) confirm 
that our transfection protocol is efficient (ii) determine if the transfection is required (as the 
high LPS concentration was, in our conditions, sufficient to induce IL-1) (iii) decipher the 
precise implication and interaction of caspase-1 and caspase-11 in microglia. 
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We are aware that our actual results on the functionality of AIM2, NLRC4 or the non-
canonical inflammasome in microglia require further evidences and verifications to clarify 
if murine microglia could form other inflammasome complexes than NLRP3. 
 
In summary, our results showed that the inflammasome is an important player of the 
inflammation triggered by primary murine microglia. However, we have to keep in mind 
that cultured microglia do not faithfully reflect the in situ properties of microglia in a 
normal, nonpathological brain (Kettenmann et al, 2011). Moreover, a recent study also 
underlines the fact that adult microglia significantly differ from neonatal microglia, that we 
used (Butovsky et al, 2014). 
 
Inflammasome in astrocytes  
 
Current evidence has shown astrocytes as important actors in neuroinflammation. 
During CNS injury, astrocytes become reactive, migrate to the damaged site, release 
numerous pro-inflammatory factors and form the glial scar (Pekny & Pekna, 2014). 
Despite their implication in immune response, only few studies have tried to characterize 
the inflammasomes in astrocytes.  
Before analysing the inflammasome expression in astrocytes, we emphasized the 
importance of the purity of astrocyte cultures. Indeed, studying the pro-inflammatory role 
of astrocytes required some precautions. In the last few years, we and others have 
noticed that, even small amounts of highly reactive microglia could interfere with the 
astrocytic response and mitigate the experimental readout (Saura, 2007; Losciuto et al, 
2012). This could even result in an erroneous attribution of inflammatory capacities to 
astrocytes in place of microglia. To avoid such misleading conclusions, we purified our 
astrocyte cultures by two successive passages on MACS columns, in order to deplete as 
many microglia as possible. This protocol of purification has been validated and published 
by our group (Losciuto et al, 2012, included in Appendixes). 
 
In the literature, numerous publications described the expression and release of 
IL-1 by astrocytes following diverse stimuli and in particular the exposure to LPS (e.g. 
Fontana et al. 1983; Lau and Yu 2001; Ma et al. 2013). We failed, however, to detect any 
Il1b mRNA or pro-IL-1 in astrocyte-enriched cultures, although we tested several 
potential inducers, such as LPS, P3C or CCM, as well as longer exposure times. The lack 
of Il1b expression was also supported by our experiments on neurosphere-derived 
astrocytes, a model of astrocyte culture devoid of microglia. Moreover, our results are in 
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line with the recent findings of Facci and colleagues using the lysosomotropic agent L-
leucyl-L-leucine methyl ester (Leu-Leu-OMe) to eradicate residual microglia from 
astrocyte cultures (Facci et al, 2014). In this study, classical astrocyte cultures released 
IL-1 into the medium while microglia-depleted cultures did not. By taking all these 
considerations together, we believe that many reports of IL-1 production by astrocytes 
could be due to microglial contaminations and that there is still no convincing evidence for 
IL-1 expression in astrocytes.  
Even if pure astrocytes might not be able to express IL-1, they nevertheless 
constitutively expressed IL-18 and HMGB1. As both need a functional inflammasome to 
be matured and/or released, we investigated the expression of NLRP3 inflammasome 
components by astrocytes. Despite the constitutive presence of caspase-1, we observed 
very weak levels of NLRP3 and ASC transcripts and almost no NLRP3 and ASC proteins, 
with or without priming. On the contrary, we were able to detect Aim2 and Nlrp6 
expression in astrocytes. However, the stimulation of astrocytes with poly(dA:dT), an 
efficient AIM2 activator did not result in detectable IL-18 production by astrocytes. As the 
AIM2 inflammasome is dependent on ASC, the lack of ASC expression in murine 
astrocytes could explain this observation. 
Together, these considerations suggest that the capacity of mouse astrocytes to 
form a functional inflammasome might be compromised. However, some hints suggest 
that, in opposition to the mouse cells, human astrocytes could present a different profile of 
inflammasome components expression. Indeed, some reports described the expression of 
NLRP3, ASC or IL-1 in human astrocytes (Zou & Crews, 2012; Kawana et al, 2013; 
Kaushal et al, 2015). Moreover, a publication described a functional NLRP2 
inflammasome in human astrocytes (Minkiewicz et al, 2013). In mice, NLRP2 expression 
seems to be restricted to ovaries playing a role in early embryonic development as a 
maternal effect gene (Peng et al, 2012). Accordingly, we did not detect NLRP2 expression 
in our mouse astrocytes. Together, these observations suggest species-specific 
differences in inflammasome components expression in astrocytes. 
 
Astrocytes and microglia represent key actors of the neuroinflammatory response. In 
case of brain injury, microglia are able to trigger an appropriate response involving 
secretion of cytokines and chemokines, resulting in the activation of astrocytes. Our 
results suggest that mouse microglia express a functional inflammasome contrarily to 
astrocytes and are thus the main glial cell type in the brain responsible for IL-1 and IL-18 
secretion. However, we have to keep in mind that, even if astrocytes might not be able to 
express or release IL-1 and IL-18, they are a target of both cytokines. As such, they 
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certainly are an important element in the study of neuroinflammation triggered by the 
inflammasome. Therefore, it is crucial to analyse the crosstalk between microglia and 
astrocytes to fully appreciate the importance of the inflammasome function in the brain 
and the potential therapeutic applications in neurodegenerative diseases.  
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2. NLRP3 inflammasome in neurodegenerative diseases. 
 
Activators of microglial NLRP3 inflammasome in neurodegenerative context 
 
The relationship between the NLRP3 inflammasome and CNS diseases has 
emerged only recently. Several studies suggested that the NLRP3 inflammasome might 
be involved in acute brain infections, multiple sclerosis or in neurodegenerative diseases 
(Walsh et al, 2014). So far, the molecular and cellular events responsible for the activation 
of NLRP3 in these pathological conditions have been poorly investigated. Our purpose is 
to investigate and discuss the events that might facilitate an effective inflammasome 
activation during neurodegenerative pathologies, with a special regard to Parkinson’s 
disease. To this aim, we have explored the role of neurological disease-relevant 
molecules in the NLRP3 inflammasome activation, such as neurodegenerative disease-
associated misfolded proteins, ATP and its metabolites or mitochondrial inhibitors. 
 
Inflammasome function has been linked to a number of diseases that are 
characterized by peptide aggregates or particulate structures, such as uric acid crystals in 
gout or islet amyloid polypeptide in type 2 diabetes (Masters et al, 2010; Robbins et al, 
2014). The accumulation of protein aggregates is a hallmark of many neurodegenerative 
diseases such as -synuclein in PD, A in AD or prion proteins in prion disease. Recent 
studies showed that prion protein fibrils are able to induce inflammasome-dependent IL-1 
secretion in microglia (Hafner-Bratkovič et al, 2012; Shi et al, 2012). Besides, several 
other reports demonstrated the capacity of different conformations of the A peptide to 
trigger an inflammasome-dependent IL-1 secretion in macrophages and microglia (Halle 
et al, 2008; Parajuli et al, 2013; Wu et al, 2013b). In addition to these in vitro experiments, 
the in vivo relevance of the NLRP3 inflammasome in Alzheimer's disease has recently 
been demonstrated in the APP/PS1 mouse model where NLRP3-deficient mice show less 
severe symptoms (Heneka et al, 2013). 
 
At the beginning of our project, in 2011, only one report addressed the possibility 
that A could induce IL-1 secretion. Therefore, we aimed to confirm the activation of 
microglial NLRP3 by A. To this purpose, we have used two different A peptides: the 
shorter peptide A25-35 and the full-length A1-42. A25-35 is endogenously found in elderly 
people and has been described to be a more toxic form (Millucci et al, 2009). Moreover, 
the neurodegenerative properties of this peptide have been demonstrated in vitro (Pike et 
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al, 1993) and are supported by in vivo experiments demonstrating that the direct cerebral 
infusion of A25-35 impairs memory (Tohda et al, 2003; Yamada et al, 2005).  
We were able to show that A25-35 could indeed activate the NLRP3 inflammasome 
in microglia, consistently to a previous report (Sanz et al, 2009). However, we observed 
that, in our conditions, IL-1 secretion occurred in a P2X7R-independent way, while Sanz 
and colleagues showed that the expression of P2X7 receptor seemed required for the 
release of IL-1. 
While the A25-35 peptide has been extensively used in previous in-vitro studies, we 
wanted to test the physiologically more relevant full length peptide A1-42 for its capacity to 
induce NLRP3 activation. Surprisingly, we were unsuccessful in triggering inflammasome 
activation by A1-42, contrarily to published studies (Halle et al, 2008; Parajuli et al, 2013; 
Wu et al, 2013b). We tested the oligomeric and fibrillar forms from different providers and 
tried multiple protocols but remained unable to detect IL-1 production in primary 
microglia. We believe it is likely that the preparation of A may be a crucial step and 
explain these discrepancies. It is well admitted that the conformation of A1-42 peptide 
might be of great importance for immune activation, at least in vitro. For example, it has 
been described that A1-42 oligomers induce much greater microglial activation than 
insoluble fibrils (Sondag et al, 2009; Heurtaux et al, 2010; Paranjape et al, 2012). The 
importance of the conformation is sustained by the divergent results that we obtained with 
the A1-42 and A25-35 as the latter peptide is described as being more toxic and less prone 
to aggregation. Moreover, we have to consider that the A peptide changes easily its 
conformation depending on various factors including the concentration, pH or solvent 
(Shahdat & Hashimoto, 2012). In line with these concerns, it is possible that our A 
preparations contain less pro-inflammatory species than A preparations used in 
published reports. This underlines the importance for us and the other authors to clearly 
characterize the different conformations of A that they used. 
 
-synuclein (-syn), the main component of Lewy Bodies in PD, can form fibrils with 
a cross–β-sheet structure. Therefore, we tested the capacity of oligomeric and fibrillar 
-syn to activate the NLRP3 inflammasome in microglia. For this purpose, we used 
human native -syn but also the human A53T mutant form, which occurs in familial forms 
of PD. -syn treatment did not result in mature IL-1 secretion in our hands, although we 
tested different kinetics and concentrations of both forms. Recently, other reports 
described the ability of -syn to trigger the inflammasome in human monocytes and THP1 
cells (Codolo et al, 2013; Freeman et al, 2013). Again, as for A, these discrepancies 
might be explained by a difference in aggregation forms. In addition, these studies were 
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based on human monocyte cell models and it has precisely been described that the 
NLRP3 inflammasome activation occurs through different mechanisms in mouse 
macrophages and human monocytes (Netea et al, 2014; Rubartelli, 2014). Even though 
we failed to characterize -syn as a direct NLRP3 activator, it might still indirectly 
contribute to the activation of the inflammasome. Indeed, in the literature, numerous 
publications described -syn as an important pro-inflammatory agent responsible for 
microglial activation (Béraud et al, 2013). This is also in accordance with our own 
observations where the human WT and A53T forms, in particular the oligomeric ones, 
upregulate the expression of IL-1 and NLRP3 at both transcript and protein levels. Thus, 
our results suggest that α-synuclein could at least participate in the priming step required 
for the NLRP3 inflammasome activation. 
 
In view to the above discussed results, we hypothesized that microglial 
inflammasome might be preferentially activated in response to neuronal death and 
associated ATP release rather than by the presence of peptide aggregates during the 
course of neurodegenerative diseases. It has been reported that the intracellular ATP 
concentration varies between 1 and 10 mM depending on the cell type (Orriss et al, 2009), 
whereas the extracellular concentration is in the nanomolar range. However, after CNS 
injury the extracellular ATP concentration may reach 1 mM at the injury site (Pellegatti et 
al, 2005; Yin et al, 2007; Orriss et al, 2009). We and others have described that such an 
ATP concentrations are able to activate NLRP3 in cultured microglia (Halle et al, 2008; 
Hanamsagar et al, 2011; Hoegen et al, 2011; Facci et al, 2014). In this work, we wanted 
to perform a more extensive study and investigate the role of ATP metabolites during 
microglial activation. Indeed, in the brain, the released ATP can be rapidly hydrolysed 
(within 200 milliseconds) in a stepwise manner to ADP, AMP (Adenosine monophosphate) 
and adenosine by ecto-enzymes (Antonioli et al, 2013). Therefore, ADP and adenosine 
might be transiently present at high concentrations during neurodegeneration and could 
specifically interact with cells via their respective receptors, notably the P2 receptors, 
which are massively expressed by microglia (Koizumi et al, 2013). 
Our results suggest that ADP and adenosine could participate in the establishment 
of neuroinflammation. Indeed, they induced the overexpression and secretion of different 
pro-inflammatory factors (i.e. CXCL10, TNF, IL-6). Most interestingly, adenosine and 
ADP were able to prime microglia for a subsequent NLRP3 activation. Indeed, our 
experiments showed that microglia upregulate the expression of Nlrp3 and Il1b genes 
following the exposure to adenosine or ADP. If the priming ability of adenosine has been 
recently published using THP1 cells (Baron et al. 2015), the pro-inflammatory effect of 
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ADP has, to our knowledge, not been described. 
In 2013, a paper written by Gombault et al. proposed that multiple purinergic 
signalling pathways triggered by ATP, ADP and adenosine could be involved in the 
regulation of the NLRP3 inflammasome (Gombault 2013). Therefore, we wanted to test 
whether ADP or adenosine could activate the NLRP3 inflammasome in LPS-primed 
microglia. We failed to observe any IL-1 secretion even after stimulation with 1mM 
adenosine. These results confirmed a recent publication demonstrating that only 
millimolar concentrations of adenosine (> 3 mM) activate the NLRP3 inflammasome 
(Baron et al, 2015). On another hand, we were surprised to detect a strong ADP-induced 
IL-1 release, similar to the one observed after ATP treatment in LPS-primed microglia. 
Moreover, this ADP-triggered IL-1β release was abrogated in P2X7 receptor-deficient 
microglia. As ADP is not described as a ligand of P2X7 receptor, we suspected our 
commercial ADP sources of being contaminated by ATP. Indeed, the quantification of 
ATP levels in the ADP commercial batch (Sigma) clearly indicated the presence of 20% 
ATP. We ordered and tested ADP batches from alternative providers (Enzo Life Sciences 
and Jena Bioscience) which were contaminated too. Therefore, we cannot confirm or 
deny that ADP could be an NLRP3 activator, although this could provide new molecular 
insights on the mechanisms of inflammasome regulation during neurodegenerative 
processes. 
 
The pesticide rotenone is known to be a causative agent of Parkinson’s disease 
(Tanner et al, 2011). This compound act as a specific mitochondrial complex I inhibitor 
which enhances mitochondrial ROS production. Interestingly, mitochondrial defects and 
ROS generation have both been linked to neurodegenerative diseases (Hussain Bhat et 
al, 2015) but also to inflammasome signalling (Harijith et al, 2014). Therefore, we decided 
to study if rotenone could be a possible microglial NLRP3 activator. In the literature, 
rotenone has been described as a putative inducer of NLRP3 activation and IL-1β release 
in macrophages (Nakahira et al, 2011; Zhou et al, 2011). Accordingly, microglia exposed 
to rotenone released IL-1 in an NLRP3 inflammasome-dependent manner. Our 
observation confirmed a recent report demonstrating that BV2 cells respond to rotenone 
by activating caspase-1 and releasing IL-1β (Liang et al, 2015). However, the same 
authors also report that the antioxidant NAC could modulate this response, an observation 
that we were unable to reproduce. The causes of these discrepancies could be diverse: 
the different treatment durations, the dissimilar concentrations used for both rotenone and 
NAC, and also the different cell models. Indeed, they used a rat cell line instead of mouse 
primary cultures and the redox status of cell lines and primary cells could differ (Rubartelli 
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et al, 2011). Thus, our findings suggest that rotenone could activate the inflammasome in 
a ROS-independent way in primary microglia. As this result was rather unexpected, 
additional investigations are required to determine whether rotenone could activate the 
NLRP3 trough such an alternative activation mechanism.  
 
Taken together, our in vitro results suggest that different hallmarks of 
neurodegenerative diseases could indeed participate in the activation of the NLRP3 
inflammasome and lead to the subsequent secretion of IL-1β, a cytokine which can be 
observed in the brain of PD patients. We hypothesize that the abnormal deposition of 
misfolded proteins in the brain parenchyma could act as the signal 1 by activating and 
priming surrounding microglia. At the same time, mitochondrial dysfunction and ATP 
released by injured cells might play the role of the signal 2 and thus, could induce the 
inflammasome assembly and downstream release of cytokines and alarmins observed in 
neurodegenerative processes. 
 
Parkinson’s disease: a role for NLRP3 inflammasome? 
 
Increasing evidence implies that immune dysregulation and neuroinflammation 
might sustain and exacerbate the loss of the dopaminergic neurons in PD (Brochard et al, 
2009; Perry, 2012; Rodrigues et al, 2014). Among the factors driving neuroinflammation, 
IL-1 has been highlighted for its link to PD: (i) IL-1 is elevated in the CSF (Blum-Degen 
et al, 1995; Mogi et al, 1996) and in the serum of PD patients (Koziorowski et al, 2012; 
Dursun et al, 2015). (ii) Il1b gene polymorphisms have been associated with age-at-onset 
of sporadic PD (Nishimura et al, 2000; McGeer et al, 2002; Wahner et al, 2007). (iii) In 
vivo, the chronic expression of IL-1 by the introduction of adenoviral vectors into the 
substantia nigra of rats elicited diverse characteristics of PD, including dopaminergic cell 
death, akinesia and glial activation (Ferrari et al, 2006). (iv) Blocking IL-1 signalling by 
administration of IL-1Ra reduces the cell loss observed in the 6-OHDA PD model (Koprich 
et al, 2008; Pott Godoy et al, 2008). Taken together, these findings support our hypothesis 
that the release of IL-1 and thus the inflammasome could be involved in dopaminergic 
neuronal degeneration observed in PD. 
Our in vitro results suggest that the NLRP3 inflammasome could be activated during 
the pathogenesis of PD. Thus, we decided to investigate the relevance of NLRP3 
signalling in an in vivo PD mouse model. Among the different animal models of PD, we 
chose the broadly used 6-OHDA injection into the mouse striatum which presents several 
advantages, including a robust degeneration of TH neurons within 15 days. Moreover, the 
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presence of IL-1 in both striatum and substantia nigra have been observed in this model 
(Villar-Cheda et al, 2012; Machado-Filho et al, 2014; Munoz et al, 2014; Nadella et al, 
2014).  
Therefore, we analysed the PD-related features induced by the administration of 
6-OHDA in wild-type compared to NLRP3 knockout mice. Our preliminary results suggest 
that the genetic ablation of NLRP3 did not exert any significant impact on the 
dopaminergic neuron degenerescence after the intra-striatal injection of 6-OHDA. Indeed, 
the absence of NLRP3 did not protect TH neurons from cell death. Moreover, the 
expression of CD68 was similar in wild-type and in NLRP3 KO mice, suggesting no 
modification in terms of microgliosis. Interestingly, a recent report shows that NLRP3 
knockout mice appear less susceptible to MPTP-induced dopaminergic neuronal death 
than wild-type mice (Yan et al, 2015). This dissimilar result could be explained by two 
factors: the different PD model used (6-OHDA vs MPTP) as well as the time points at 
which the degeneration was evaluated. In fact, Yan et al quantified the TH neuron loss 
only 24 h after MPTP injection while we decided to perform our analysis 14 days after the 
injection, which could be considered as an endpoint measurement. Thus, we cannot 
exclude that the loss of NLRP3 might transiently delay the degeneration of dopamine 
neurons. 
In order to explore this hypothesis, we aimed to determine the time frame during 
which IL-1 is present in the intra-striatal 6-OHDA model. For this purpose, we carried out 
a kinetic transcriptional analysis of the pro-inflammatory factors expressed after the 
6-OHDA injection.  
Our results showed that the expression of Il1b and other neuroinflammation-related 
genes were not significantly upregulated in the ipsilateral hemisphere compared to the 
contralateral control, at any tested time point (3, 7 or 14 days). While it might be possible 
than the pro-inflammatory gene expression was really not altered after the injection, we 
believe it is unlikely. Indeed, our immunohistochemistry analyses clearly showed a strong 
inflammation, at least due to the stab wound injury. This last observation supported by the 
bibliographic context argues that a technical failure prevented us from detecting the 
transcriptional overexpression of the pro-inflammatory genes. Thus, additional 
experiments are still required to determine the time frame of IL-1 expression and 
determine whether NLRP3 deficiency could delay the dopaminergic neuron 
degenerescence. 
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In the present study, we outlined the expression and regulation of the inflammasome 
in glial cells, emphasizing its role in neurodegenerative diseases. 
The following points summarise our results: 
 Astrocytes constitutively expressed IL-18 and HMGB1. However, we were unable to 
observe any constitutive or induced expression of IL-1 or IL-1. 
 Astrocytes appeared unable to form a functional NLRP3 inflammasome, as they did 
not express NLRP3 and ASC proteins, at least in our conditions. 
 On the contrary, microglia expressed a functional NLRP3 inflammasome whose 
activation occurred through similar mechanisms than described in macrophages. 
 The exposure of microglia to ATP, Nigericin or Alum triggered IL-1, IL-1, IL-18 
and HMGB1 release in an NLRP3 inflammasome-dependent way.  
 The PD relevant -synuclein did not activate the microglial NLRP3 inflammasome 
but was able to prime it. 
 We confirmed A25-35 ,but not A1-42, as a microglial inflammasome activator 
 Rotenone and ATP induced microglial inflammasome activation. 
 Genetic ablation of NLRP3 did not exert any impact on late stages of 
neurodegenerescence induced by intra-striatal injection of 6-OHDA. 
A summarized view of these findings is depicted in Figure 46.  
 
In conclusion, the experiments presented in this doctoral thesis expand our current 
knowledge of the expression and regulation of inflammasome components in the mouse 
CNS. This project also contributes to the current effort to determine whether NLRP3 is 
involved in neurodegenerative diseases and in particular in Parkinson’s disease. 
However, further experiments are required to complete this work. These include the 
characterization of AIM2, NLRC4 and non-canonical inflammasomes in microglia but also 
the clarification of how the purinergic signalling could activate the inflammasome in 
microglia.  
In addition, our results suggest that microglia is the main glial cell type in the brain 
responsible for IL-1 and IL-18 secretion. However, it is essential to confirm that our 
observation remains true in situ with regard to the intercellular network and specific 
pathologic conditions.  
 
Furthermore, we also have to pursue studies in view to better respond to the 
question: Is the NLRP3 inflammasome implicated in Parkinson’s disease? 
Our in vivo study showed that the deficiency of NLRP3 appeared not able to protect, 
at least permanently, dopamine neurons from the 6-OHDA-induced cell death. However, 
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in light to the recent report of Yan and colleagues showing that the loss of NLRP3 is 
neuroprotective at early time points in the MPTP model, we are now planning to 
investigate whether such an early difference might occur in the 6-OHDA model and thus, 
whether the loss of NLRP3 might provide a transient neuroprotection. 
In addition, we showed in this study that -synuclein, another major hallmark of PD, 
was at least able to prime the inflammasome in microglial cultures. It would be interesting 
to strengthen this observation using an in vivo mouse model and in particular to test 
whether the loss of NLRP3 is beneficial in a transgenic mice model overexpressing -
synuclein. 
 All these investigations could enlighten a potential therapeutic interest of the 
NLRP3 inflammasome for Parkinson’s disease. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
GENERAL CONCLUSION & PERSPECTIVES 
 
 115 
 
 
 
Fig. 46: Summary of our findings.  
The capacity to form a functional NLRP3 inflammasome and secretion of IL-1 is limited to the microglial compartment in 
the mouse brain. Indeed, we were not able to detect the expression neither of IL-1 nor of all NLRP3 inflammasome 
components. In addition to IL-1, microglia were able to secrete IL-18, IL-1 and HMGB1 in an NLRP3 inflammasome-
dependent way and through mechanisms similar to those observed in macrophages. Moreover, our results suggest that 
microglial inflammasome can play a role in the neuroinflammation observed during Parkinson’s disease. Indeed, microglia 
can be primed by -synuclein exposure and microglial stimulation with Parkinson’s disease-related products, such as 
rotenone or ATP, which results in the activation of the NLRP3 inflammasome and IL-1 release. However, our preliminary in 
vivo results tend to indicate that genetic ablation of NLRP3 did not exert any significant impact on neurodegenerative 
processes occurring in an in vivo model of Parkinson’s disease s. 
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Appendix I: Supplemental figures 
 
 
 
Suppl. Table 1. Expression levels of inflammasome-related genes in untreated or LPS-primed microglia.  
Nlrp1, Nlrp2, Nlrp3, Nlrp6, Nlrp12, Aim2, Nlrc4, Pycard, Casp1 and Casp4 gene expressions were analysed by RT-PCR. 
Data are given as means of Ct ± SD and are representative of at least three independent experiments. 
 
 
 
 
 
 
 
 
 
Suppl. Fig. 1: Tlr4 is lower expressed in AEC-M2 than in microglial cultures. 
Gene expression of Tlr4 was analysed in untreated AEC-M2 and microglial cultures by RT-PCR. Results were normalized to 
Rpl27. Data are mean ± SEM of at least three independent experiments 
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Suppl. Fig. 2: P3C and CCM efficiently primed microglia for subsequent NLRP3 inflammasome activation. 
(A, B) Microglia were treated for 6 h with LPS (10 ng/mL), P3C (10 ng/mL), IL-1β (10 ng/mL), TNF-α (10 ng/mL), IFNγ 
(10 ng/mL) or CCM (10 ng/mL IL-1β + 10 ng/mL TNFα + 20 ng/mL IFNγ). (A) The gene expression level of Il1b and Nlrp3 
were analysed by RT-PCR and normalized to Rpl27. Data are shown as a percentage of the LPS-induced gene expression 
(100%). (B) Cell lysates (Xt) were analysed by WB for the expression of IL-1β and NLRP3 proteins. α-Tubulin was used as 
a loading control. (C) Microglia were treated for 6 h with LPS (10 ng/mL), P3C (10 ng/mL), IL-1β (10 ng/mL), TNF-α (10 
ng/mL), IFNγ (10 ng/mL) or CCM (10 ng/mL IL-1β + 10 ng/mL TNFα + 20 ng/mL IFNγ) and then stimulated with ATP (1mM, 
30 min). IL-1β secretion in supernatant were analysed by ELISA. Data are mean ± SEM of at least three independent 
experiments, except for WB (one representative experiment of at least 3 independent experiments). *=p<0.05 compared to 
Ctrl. Kruskal-Wallis test followed by Dunn’s multiple comparisons test. 
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Suppl. Table 2. Expression levels of pro-inflammatory genes and inflammasome-related genes in primed astrocytes. 
Primary astrocytes (AEC M2) were primed for 6 h with LPS (10 ng/mL), P3C (10 ng/mL), IL-1β (10 ng/mL), TNF-α (10 
ng/mL), IFNγ (10 ng/mL) or CCM (10 ng/mL IL-1β + 10 ng/mL TNFα + 20 ng/mL IFNγ). Primary microglia were untreated or 
primed with LPS (10ng/mL, 6 h) and served as control. RNA were extracted and analysed by RT-PCR for expression of the 
pro-inflammatory genes Il6, Nos2, Ptgs2, Cxcl10 and Tnf but also the expression of NLRP3 inflammasome-related genes 
(i.e. Il1b, Il1a, Il18, Hmgb1, Nlrp3, Pycard and Asc). Data are given as means of Ct ± SD and are representative of at least 
three independent experiments. 
 
 
 
 
 
Suppl. Fig. 3: Astrocytes do not release IL-1β following NLRP3 inflammasome activation. 
IL-1β secretion was assayed by ELISA on supernatant of CCM-primed astrocytes and LPS-microglia treated with ATP (1 
mM, 30 min) or Nigericin (Nig, 1.34 µM, 2 h). Data are mean ± SEM of at least three independent experiments. *=p<0.05 
compared to Ctrl. Kruskal-Wallis test followed by Dunn’s multiple comparisons test. 
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Suppl. Fig. 4: Neurosphere-derived astrocytes poorly express Il1b, Pycard and Nlrp3 genes. 
Gene expressions of Nlrp3, Pycard, Casp1, Il1b and Il18 were analysed in neurosphere-derived astrocyte cultures 
stimulated for 6 h with CCM by RT-PCR. Data are normalized to Rpl27 and are mean ± SEM values of at least three 
independent experiments. 
 
Suppl. Table 3. Expression levels of other inflammasome-related genes in untreated or primed astrocytes.  
Primary astrocytes were untreated or primed with CCM (10ng/mL, 6 h). Primary microglia were untreated or primed with 
LPS (10ng/mL, 6 h) and served as comparison. RNA were extracted and analysed for gene expression of Nlrp1, Nlrp2, 
Nlrp6, Nlrp12, Aim2, Nlrc4 and Casp4 by RT-PCR. Data are Ct mean ± SEM and are representative of at least three 
independent experiments. 
 
 
 
Suppl. Fig. 5: ADP and adenosine seems to be pro-inflammatory factors. 
(A) Microglia were stimulated for 3 h with adenosine (Ad., 1mM), ADP (1mM) or ATP (1mM). Transcripts were analysed for 
expression of Cxcl10, Tnf and Il6 by RT-PCR. Data were normalized to Rpl27. (B) Microglia were stimulated for 3 h with 
ADP at 0.5 mM, 1 mM, or 5 mM. CXCL10 and TNFα secretions were assessed by ELISA in culture supernatant of wild-type 
(WT) (B) or P2rx7-/- (D) microglia. Data are mean  SEM of at least three independent experiments. *p<0.05 compared to 
Ctrl, p<0.05, KO compared to WT. Kruskal-Wallis test followed by Dunn’s multiple comparisons test.  
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